Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives

ABSTRACT

A compound of Formula I 
     
       
         
         
             
             
         
       
     
     in free or salt or solvate form, where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10  and R 11  have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

This application is a Continuation application of U.S. patentapplication Ser. No. 14/186,904 filed Feb. 21, 2014, which is aContinuation application of U.S. patent application Ser. No. 13/613,495filed 13 Sep. 2012, which is a Continuation application of U.S. patentapplication Ser. No. 13/157,893, filed 10 Jun. 2011, which isContinuation of U.S. patent application Ser. No. 12/332,086, filed 10Dec. 2008, now U.S. Pat. No. 8,039,472, which claims benefit of priorityto European Priority Application No. 07122739.1, filed 10 Dec. 2007; thecontents of these applications are incorporated herein by reference.

This invention relates to organic compounds, their preparation and useas pharmaceuticals.

In one aspect, the invention provides compounds according to Formula I:

or solvates, hydrates or pharmaceutically acceptable salts thereof,wherein

R¹ is H, halogen, C₁-C₈-alkyl, C₁-C₈-haloalkyl, C₁-C₈-haloalkoxy,C₃-C₁₅-carbocyclic group, nitro, cyano, a C₆-C₁₅-membered aromaticcarbocyclic group, or a C₁-C₈-alkyl substituted by a C₆-C₁₅-memberedaromatic carbocyclic group;

R², R³, R⁴ and R⁵ are each independently selected from H and C₁-C₆alkyl;

R⁶, R⁷, R⁸, R⁹, R¹⁰ and R¹¹ are each independently selected from H;SO₂R¹⁶; aryl optionally substituted by one or more Z groups; a C₃-C₁₀carbocyclic group optionally substituted by one or more Z groups; C₃-C₁₄heterocyclic group optionally substituted by one or more Z groups; C₁-C₈alkyl optionally substituted by an aryl group which is optionallysubstituted by one or more Z groups, a C₃-C₁₀ carbocyclic groupoptionally substituted by one or more Z groups or a C₃-C₁₄ heterocyclicgroup optionally substituted by one or more Z groups; or is representedby the formula 2:

—(C₀-C₆ alkylene)-A-(C₀-C₆ alkylene)-B—(X—R¹²)_(q)—R²², wherein thealkylene groups are optionally substituted by one or more Z groups;

or R⁶ and R⁷ together with the atoms to which they are attached form a3- to 10-membered heterocyclic group, the heterocyclic group includingone or more further heteroatoms selected from N, O and S, and theheterocyclic group being optionally substituted by one or more Z groups;SO₂R¹⁶; C₆-C₁₅-aromatic carbocyclic group optionally substituted by oneor more Z groups; a C₃-C₁₀ carbocyclic group; a C₃-C₁₄ heterocyclicgroup optionally substituted by one or more Z groups; or a grouprepresented by the formula 2;

or R⁷ and R⁸ together with the carbon atom to which they are attachedform a 3- to 10-membered carbocyclic or a 3- to 10-membered heterocyclicgroup, the heterocyclic group including one or more heteroatoms selectedfrom N, O and S, and the carbocyclic and heterocyclic groups beingoptionally substituted by one or more Z groups; SO₂R¹⁶; C₆-C₁₅-aromaticcarbocyclic group optionally substituted by one or more Z groups; aC₃-C₁₀ carbocyclic group; a C₃-C₁₄ heterocyclic group optionallysubstituted by one or more Z groups; or a group represented by theformula 2;

or R⁹ and R¹⁰ together with the carbon atom to which they are attachedform a 3- to 10-membered carbocyclic or a 3- to 10-membered heterocyclicgroup, the heterocyclic group including one or more heteroatoms selectedfrom N, O and S, and the carbocyclic and heterocyclic groups beingoptionally substituted by one or more Z groups; SO₂R¹⁶; C₆-C₁₅-aromaticcarbocyclic group optionally substituted by one or more Z groups; aC₃-C₁₀ carbocyclic group; a C₃-C₁₄ heterocyclic group optionallysubstituted by one or more Z groups; or a group represented by theformula 2;

or R⁸ and R⁹ together with the carbon atoms to which they are attachedform a 3- to 10-membered cycloalkyl or a 3- to 10-membered heterocyclicgroup, the heterocyclic group including one or more heteroatoms selectedfrom N, O and S, and the carbocyclic and heterocyclic groups beingoptionally substituted by one or more Z groups; SO₂R¹⁶; C₆-C₁₅-aromaticcarbocyclic group optionally substituted by one or more Z groups; aC₃-C₁₀ carbocyclic group; a C₃-C₁₄ heterocyclic group optionallysubstituted by one or more Z groups; or a group represented by theformula 2;

or R¹⁰ and R¹¹ together with the atoms to which they are attached form a3- to 10-membered heterocyclic group, the heterocyclic group includingone or more further heteroatoms selected from N, O and S, and theheterocyclic group being optionally substituted by one or more Z groups;SO₂R¹⁶; C₆-C₁₅-aromatic carbocyclic group optionally substituted by oneor more Z groups; a C₃-C₁₀ carbocyclic group; a C₃-C₁₄ heterocyclicgroup optionally substituted by one or more Z groups; or a grouprepresented by the formula 2;

A is selected from a bond, —NR¹³(SO₂)—, —(SO₂)NR¹³—, —(SO₂)—,—NR¹³C(O)—, —C(O)NR¹³—, —NR¹³C(O)NR¹⁴—, —NR¹³C(O)O—, —NR¹³—, C(O)O,OC(O), C(O), O and S;

B is selected from a bond, —(C₂-C₄ alkenyl group)-, —(C₂-C₄ alkynylgroup)-, —NH—, aryl, O-aryl, NH-aryl, a C₃-C₁₄ carbocyclic group and a3- to 14-membered heterocyclic group, the heterocyclic group includingone or more heteroatoms selected from N, O and S, wherein the aryl,carbocyclic and heterocyclic groups are each optionally substituted byone or more Z groups;

X is selected from a bond, —NR¹⁵(SO₂)—, —(SO₂)NR¹⁵—, —(SO₂)—,—NR¹⁵C(O)—, —C(O)NR¹⁵—, —NR¹⁵C(O)NR¹⁷—, —NR¹⁵C(O)O—, —NR¹⁵—, C(O)O,OC(O), C(O), O and S;

R¹² is selected from C₁-C₈ alkylene, C₁-C₈ alkenylene, —C₃-C₈cycloalkyl-, —C₁-C₈ alkylene-C₃-C₈ cycloalkyl-, and -aryl-, wherein thealkylene, cycloalkyl and aryl groups are optionally substituted by oneor more Z groups;

R¹³, R¹⁴, R¹⁵ and R¹⁷ are each independently selected from H and C₁-C₆alkyl;

R¹⁶ is selected from C₁-C₈ alkyl, aryl and a 3- to 14-memberedheterocyclic group, the heterocyclic group including one or moreheteroatoms selected from N, O and S;

Z is independently selected from OH, aryl, O-aryl, C₇-C₁₄ aralkyl,0-C₇-C₁₄ aralkyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, NR¹⁹(SO₂)R²¹, (SO₂)NR¹⁹R²¹,(SO₂)R²⁰, NR¹⁹C(O)NR²⁰, C(O)NR¹⁹R²⁰, NR¹⁹C(O)NR²⁰R¹⁸, NR¹⁹C(O)OR²⁰,NR¹⁹R²¹, C(O)OR¹⁹, C(O)R¹⁹, SR¹⁹, OR¹⁹, oxo, CN, NO₂, and halogen,wherein the alkyl, alkoxy, aralkyl and aryl groups are each optionallysubstituted by one or more substituents selected from OH, halogen, C₁-C₄haloalkyl and C₁-C₄ alkoxy;

R¹⁸ and R²⁰ are each independently selected from H and C₁-C₆ alkyl;

R¹⁹ and R²¹ are each independently selected from H; C₁-C₈ alkyl; C₃-C₈cycloalkyl; C₁-C₄ alkoxy-C₁-C₄ alkyl; (C₀-C₄ alkyl)-aryl optionallysubstituted by one or more groups selected from C₁-C₆ alkyl, C₁-C₆alkoxy and halogen; (C₀-C₄ alkyl)-3- to 14-membered heterocyclic group,the heterocyclic group including one or more heteroatoms selected fromN, O and S, optionally substituted by one or more groups selected fromhalogen, oxo, C₁-C₆ alkyl and C(O)C₁-C₆ alkyl; (C₀-C₄ alkyl)-O-aryloptionally substituted by one or more groups selected from C₁-C₆ alkyl,C₁-C₆ alkoxy and halogen; and (C₀-C₄ alkyl)-O-3- to 14-memberedheterocyclic group, the heterocyclic group including one or moreheteroatoms selected from N, O and S, optionally substituted by one ormore groups selected from halogen, C₁-C₆ alkyl and C(O)C₁-C₆ alkyl;wherein the alkyl groups are optionally substituted by one or morehalogen atoms, C₁-C₄ alkoxy, C(O)NH₂, C(O)NHC₁-C₆ alkyl or C(O)N(C₁-C₆alkyl)₂; or

R¹⁹ and R²⁰ together with the nitrogen atom to which they attached forma 5- to 10-membered heterocyclic group, the heterocyclic group includingone or more further heteroatoms selected from N, O and S, theheterocyclic group being optionally substituted by one or moresubstituents selected from OH; halogen; aryl; 5- to 10-memberedheterocyclic group including one or more heteroatoms selected from N, Oand S; S(O)₂-aryl; S(O)₂—C₁-C₆ alkyl; C₁-C₆ alkyl optionally substitutedby one or more halogen atoms; C₁-C₆ alkoxy optionally substituted by oneor more OH groups or C₁-C₄ alkoxy; and C(O)OC₁-C₆ alkyl, wherein thearyl and heterocyclic substituent groups are themselves optionallysubstituted by C₁-C₆ alkyl, C₁-C₆ haloalkyl or C₁-C₆ alkoxy;

R²² is selected from H, halogen, C₁-C₈ alkyl, C₁-C₈ alkoxy, aryl,O-aryl, S(O)₂-aryl, S(O)₂—C₁-C₆ alkyl, S(O)₂NR²³R²⁴, NHS(O)₂NR²³R²⁴, aC₃-C₁₄ carbocyclic group, a 3- to 14-membered heterocyclic group, theheterocyclic group including one or more heteroatoms selected from N, Oand S, and O-(3- to 14-membered heterocyclic group, the heterocyclicgroup including one or more heteroatoms selected from N, O and S),wherein the alkyl, aryl, carbocyclic and heterocyclic groups are eachoptionally substituted by one or more Z groups;

R²³ and R²⁴ are each independently selected from H, C₁-C₈ alkyl andC₃-C₈ cycloalkyl; or

R²³ and R²⁴ together with the nitrogen atom to which they are attachedform a 5- to 10-membered heterocyclic group, optionally including one ormore further heteroatoms selected from N, O and S, wherein theheterocyclic group is optionally substituted by one or more Z groups;

n is 0, 1 or 2;

o and p are each independently an integer from 0 to 6; and

q is 0, 1, 2 or 3;

with the proviso that when n is 0, at least one of R⁶, R⁷, R⁸, R⁹, R¹⁰and R¹¹ is other than H.

In an embodiment of the invention, there is provided a compoundaccording to the Formula Ia:

wherein

R⁶, R⁷, R⁸, R⁹, R¹⁰ and R¹¹ are each independently selected from H;SO₂R¹⁶; aryl optionally substituted by one or more Z groups; a C₃-C₁₀carbocyclic group optionally substituted by one or more Z groups; C₃-C₁₄heterocyclic group optionally substituted by one or more Z groups; C₁-C₈alkyl optionally substituted by an aryl group, a C₃-C₁₀ carbocyclicgroup optionally substituted by one or more Z groups or a C₃-C₁₄heterocyclic group optionally substituted by one or more Z groups; or isrepresented by the formula 2a:

—(CH₂)_(o)-A-(CH₂)_(p)—B—(X—R¹²)_(q)—R²²;

or R⁷ and R⁸ together with the carbon atom to which they are attachedform a 3- to 7-membered carbocyclic or a 3- to 7-membered heterocyclicgroup, the heterocyclic group including one or more heteroatoms selectedfrom N, O and S, and the carbocyclic and heterocyclic groups beingoptionally substituted by one or more Z groups; SO₂R¹⁶; C₆-C₁₅-aromaticcarbocyclic group optionally substituted by one or more Z groups; aC₃-C₁₀ carbocyclic group; a C₃-C₁₄ heterocyclic group optionallysubstituted by one or more Z groups; or a group represented by theformula 2a;

or R⁹ and R¹⁰ together with the carbon atom to which they are attachedform a 3- to 7-membered carbocyclic or a 3- to 7-membered heterocyclicgroup, the heterocyclic group including one or more heteroatoms selectedfrom N, O and S, and the carbocyclic and heterocyclic groups beingoptionally substituted by one or more Z groups; SO₂R¹⁶; C₆-C₁₅-aromaticcarbocyclic group optionally substituted by one or more Z groups; aC₃-C₁₀ carbocyclic group; a C₃-C₁₄ heterocyclic group optionallysubstituted by one or more Z groups; or a group represented by theformula 2a;

or R⁸ and R⁹ together with the carbon atoms to which they are attachedform a 3- to 7-membered cycloalkyl or a 3- to 7-membered heterocyclicgroup, the heterocyclic group including one or more heteroatoms selectedfrom N, O and S, and the carbocyclic and heterocyclic groups beingoptionally substituted by one or more Z groups; SO₂R¹⁶; C₆-C₁₅-aromaticcarbocyclic group optionally substituted by one or more Z groups; aC₃-C₁₀ carbocyclic group; a C₃-C₁₄ heterocyclic group optionallysubstituted by one or more Z groups; or a group represented by theformula 2a;

A is selected from a bond, —NR¹³(SO₂)—, —(SO₂)NR¹³—, —(SO₂)—,—NR¹³C(O)—, —C(O)NR¹³—, —NR¹³C(O)NR¹⁴—, —NR¹³C(O)O—, —NR¹³—, C(O)O,OC(O), C(O), O and S;

B is selected from a bond, aryl, a C₃-C₁₄ carbocyclic group and a C₃-C₁₄heterocyclic group, wherein the ring systems are optionally substitutedby one or more Z groups;

X is selected from a bond, —NR¹⁵(SO₂)—, —(SO₂)NR¹⁵—, —(SO₂)—,—NR¹⁵C(O)—, —C(O)NR¹⁵—, —NR¹⁵C(O)NR¹⁷—, —NR¹⁵C(O)O—, —NR¹⁵—, C(O)O,OC(O), C(O), O and S;

R¹² is selected from H, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, C₁-C₈ alkyl-C₃-C₈cycloalkyl, C₁-C₈ alkyl-aryl and aryl, wherein the alkyl, cycloalkyl andaryl groups are optionally substituted by one or more Z groups;

R¹³, R¹⁴, R¹⁵ and R¹⁷ are each independently selected from H and C₁-C₆alkyl;

R¹⁶ is selected from C₁-C₈ alkyl, aryl and a 3- to 14-memberedheterocyclic group;

Z is independently selected from OH, aryl, O-aryl, C₇-C₁₄ aralkyl,0-C₇-C₁₄ aralkyl, C₁-C₆ alkyl, C₁-C₆ alkoxy, NR¹⁹(SO₂)R²¹, (SO₂)NR¹⁹R²¹,(SO₂)R²⁰, NR¹⁹C(O)R²⁰, C(O)NR¹⁹R²⁰, NR¹⁹C(O)NR²⁰R¹⁸, NR¹⁹C(O)OR²⁰,NR¹⁹R²¹, C(O)OR¹⁹, C(O)R¹⁹, SR¹⁹, OR¹⁹, oxo, CN, NO₂, and halogen,wherein the alkyl, alkoxy, aralkyl and aryl groups are each optionallysubstituted by one or more substituents selected from OH, halogen, C₁-C₄haloalkyl and C₁-C₄ alkoxy;

R¹⁸, R¹⁹ and R²⁰ are each independently selected from H and C₁-C₆ alkyl;

R²¹ is selected from C₁-C₈ alkyl, aryl and a 3- to 14-memberedheterocyclic group; R²² is selected from H and C₁-C₈ alkyl;

n is 0, 1 or 2;

o and p are each independently an integer from 0 to 6; and

q is 0, 1, 2 or 3;

with the proviso that when n is 0, at least one of R⁶, R⁷, R⁸, R⁹, R¹⁰and R¹¹ is other than H.

In a further embodiment of the invention as defined anywhere above, R⁶is selected from H, C₁-C₃ alkyl and (CH₂)_(d)-phenyl, where the phenylgroup is optionally substituted by OR²³;

R²³ is H or C₁-C₆ alkyl; and

d is an integer from 1 to 5 (optionally 2 to 4).

In a still further embodiment of the invention as defined anywhereabove, R⁷ is H or C₁-C₆; and

R⁸ is selected from H, C₁-C₆ alkyl; (CH₂)_(e)phenyl, where the phenylgroup is optionally substituted by one or more groups selected from haloand OR²⁴; (CH₂)_(t)COOR²⁵; (CH₂)_(g)OC₁-C₆ alkyl, where the alkyl groupis optionally substituted by 1 to 3 groups selected from OH, C₁-C₃ alkyland phenyl; and (CH₂)_(h)NHCO₂(CH₂)_(i)phenyl;

R²⁴ is H or C₁-C₆ alkyl, where the alkyl group is optionally substitutedby 1 to 3 groups selected from OH and OC₁-C₃ alkyl;

R²⁵ is H or C₁-C₃ alkyl;

e is 0, 1, 2, 3, 4 or 5 (optionally 0, 1, 2, 3 or 4);

f, g and h are each independently an integer from 1 to 4; and

i is 1 or 2;

or R⁷ and R⁸ together with the carbon atom to which they attached form a5- or 6-membered non-aromatic carbocyclic ring system or a 5- or6-membered non-aromatic heterocyclic ring system containing one or moreheteroatoms selected from N, O and S, the ring systems being optionallysubstituted by one or more Z groups; SO₂R¹⁶; C₆-C₁₅-aromatic carbocyclicgroup optionally substituted by one or more Z groups; a C₃-C₁₀carbocyclic group; a C₃-C₁₄ heterocyclic group optionally substituted byone or more Z groups; or a group represented by the formula 2 or 2a.Suitably, the ring system defined by R⁷, R⁸ and the carbon to which theyare attached is optionally substituted by C₁-C₃ alkyl, halo or benzyl.

Optionally, f is 2 or 3. Additionally or alternatively, g may be 2 or 3.Additionally or alternatively, h may be 2, 3 or 4. Additionally oralternatively, i may be 1. In the immediately preceding sub-definitionsoff, g, h and i, each sub-definition may be combined with more othersub-definitions or they may be combined with the definitions for therelevant variables given above.

In a yet further embodiment of the invention as defined anywhere above,R⁹ is H, C₁-C₆ alkyl or phenyl;

or R⁸ and R⁹ together with the carbon atoms to which they attached forma 5-, 6- or 7-membered non-aromatic carbocyclic ring system or a 5-, 6-or 7-membered non-aromatic heterocyclic ring system containing one ormore heteroatoms selected from N, O and S, the ring systems beingoptionally substituted by C₁-C₃ alkyl, halo or benzyl.

In a further embodiment of the invention as defined anywhere above, R¹¹is H, SO₂C₁-C₆ alkyl or SO₂phenyl.

In a further embodiment of the invention as defined anywhere above, R⁶and R¹¹ are both H.

A further embodiment of the invention provides a compound according tothe formula 1b

or the formula 1c

wherein R³⁰ is -A-(C₀-C₆ alkylene)-B—(X—R¹²)_(q)—R²²

and A, B, X, R¹², q and R²² are as defined anywhere herein.

A further aspect of the invention provides a compound of Formula 2

wherein [LINKER] is selected from C₁-C₆ alkylene, C₂-C₆ alkenylene,C₂-C₆ alkynylene, a 5- to 10-membered carbocyclic group, aryl, and a 5-to 10-membered heterocyclic group containing one or more heteroatomsselected from N, O and S, the ring systems being optionally substitutedby one or more Z¹ groups; and

Z¹ is independently selected from OH, aryl, O-aryl, benzyl, O-benzyl,C₁-C₆ alkyl optionally substituted by one or more OH groups, C₁-C₆ alkyloptionally substituted by one or more halogen atoms, C₁-C₆ alkoxyoptionally substituted by one or more OH groups or C₁-C₄ alkoxy,NR¹⁹(SO₂)R²¹, (SO₂)NR¹⁹R²⁰, (SO₂)R²⁰, NR¹⁹C(O)R²⁰, C(O)NR¹⁹R²⁰,NR¹⁹C(O)NR²⁰R¹⁸, NR¹⁹C(O)OR²⁰, NR¹⁹R²¹, C(O)OR¹⁹, C(O)R¹⁹, SR¹⁹, OR¹⁹,oxo, CN, NO₂, and halogen, wherein R¹⁸, R¹⁹, R²⁰ and R²¹ are all asdefined anywhere herein.

The skilled person will appreciate that the compounds of Formula 2 aredimeric forms of the compounds of formula 1b or 1c.

In a yet further embodiment of the invention as defined anywhere above,there is provided a compound according to Formula I selected from:

DEFINITIONS

Terms used in the specification have the following meanings:

“Optionally substituted” means the group referred to can be substitutedat one or more positions by any one or any combination of the radicalslisted thereafter.

“optionally substituted by one or more Z groups” denotes that therelevant group may include one or more substituents, each independentlyselected from the groups included within the definition of Z. Thus,where there are two or more Z group substituents, these may be the sameor different.

“Halo” or “halogen”, as used herein, may be fluorine, chlorine, bromineor iodine.

“C₁-C₈-Alkyl”, as used herein, denotes straight chain or branched alkylhaving 1-8 carbon atoms. If a different number of carbon atoms isspecified, such as C₆ or C₃, then the definition is to be amendedaccordingly.

“C₁-C₈-Alkoxy”, as used herein, denotes straight chain or branchedalkoxy having 1-8 carbon atoms. If a different number of carbon atoms isspecified, such as C₆ or C₃, then the definition is to be amendedaccordingly.

The term “alkylene” denotes a straight chain or branched saturatedhydrocarbon chain containing between 1 and 8 carbon atoms. If adifferent number of carbon atoms is specified, such as C₆ or C₃, thenthe definition is to be amended accordingly.

“Amino-C₁-C₈-alkyl” and “amino-C₁-C₈-alkoxy” denote amino attached by anitrogen atom to C₁-C₈-alkyl, e.g., NH₂—(C₁-C₈)—, or to C₁-C₈-alkoxy,e.g., NH₂—(C₁-C₈)—O—. If a different number of carbon atoms isspecified, such as C₆ or C₃, then the definition is to be amendedaccordingly.

“C₁-C₈-Alkylamino” and “di(C₁-C₈-alkyl)amino” denote C₁-C₈-alkyl, ashereinbefore defined, attached by a carbon atom to an amino group. TheC₁-C₈-alkyl groups in di(C₁-C₈-alkyl)amino may be the same or different.If a different number of carbon atoms is specified, such as C₆ or C₃,then the definition is to be amended accordingly.

“Amino-(hydroxy)-C₁-C₈-alkyl” denotes amino attached by a nitrogen atomto C₁-C₈-alkyl and hydroxy attached by an oxygen atom to the sameC₁-C₈-alkyl. If a different number of carbon atoms is specified, such asC₆ or C₃, then the definition is to be amended accordingly.

“C₁-C₈-Alkylcarbonyl” and “C₁-C₈-alkoxycarbonyl”, as used herein, denoteC₁-C₈-alkyl or C₁-C₈-alkoxy, respectively, as hereinbefore defined,attached by a carbon atom to a carbonyl group. If a different number ofcarbon atoms is specified, such as C₆ or C₃, then the definition is tobe amended accordingly.

“C₃-C₈-Cycloalkylcarbonyl”, as used herein, denotes C₃-C₈-cycloalkyl, ashereinbefore defined, attached by a carbon atom to a carbonyl group. Ifa different number of carbon atoms is specified, such as C₆ or C₃, thenthe definition is to be amended accordingly.

“C₇-C₁₄-Aralkyl”, as used herein, denotes alkyl, e.g., C₁-C₄-alkyl, ashereinbefore defined, substituted by a C₆-C₁₀-aromatic carbocyclicgroup, as herein defined. If a different number of carbon atoms isspecified, such as C₆ or C₃, then the definition is to be amendedaccordingly.

“C₃-C₁₅-Carbocyclic group”, as used herein, denotes a carbocyclic grouphaving 3- to 15-ring carbon atoms that is saturated or partiallysaturated, such as a C₃-C₈-cycloalkyl. Examples of C₃-C₁₅-carbocyclicgroups include but are not limited to cyclopropyl, cyclobutyl,cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl or a bicyclic group,such as bicyclooctyl, bicyclononyl including indanyl and indenyl andbicyclodecyl. If a different number of carbon atoms is specified, suchas C₆, then the definition is to be amended accordingly.

“aryl” or “C₆-C₁₅-Aromatic carbocyclic group”, as used herein, denotesan aromatic group having 6- to 15-ring carbon atoms. Examples ofC₆-C₁₅-aromatic carbocyclic groups include, but are not limited to,phenyl, phenylene, benzenetriyl, naphthyl, naphthylene, naphthalenetriylor anthrylene. If a different number of carbon atoms is specified, suchas C_(m), then the definition is to be amended accordingly.

“4- to 8-Membered heterocyclic group”, “5- to 6-membered heterocyclicgroup”, “3- to 10-membered heterocyclic group”, “3- to 14-memberedheterocyclic group”, “4- to 14-membered heterocyclic group” and “5- to14-membered heterocyclic group”, refers, respectively, to 4- to8-membered, 5- to 6-membered, 3- to 10-membered, 3- to 14-membered, 4-to 14-membered and 5- to 14-membered heterocyclic rings containing atleast one ring heteroatom selected from the group consisting ofnitrogen, oxygen and sulphur, which may be saturated, partiallysaturated or unsaturated (aromatic). The heterocyclic group includessingle ring groups, fused ring groups and bridged groups. Examples ofsuch heterocyclic groups include, but are not limited to, furan,pyrrole, pyrrolidine, pyrazole, imidazole, triazole, isotriazole,tetrazole, thiadiazole, isothiazole, oxadiazole, pyridine, piperidine,pyrazine, oxazole, isoxazole, pyrazine, pyridazine, pyrimidine,piperazine, pyrrolidine, pyrrolidinone, morpholine, triazine, oxazine,tetrahyrofuran, tetrahydrothiophene, tetrahydrothiopyran,tetrahydropyran, 1,4-dioxane, 1,4-oxathiane, indazole, quinoline,indazole, indole, 8-aza-bicyclo[3.2.1]octane or thiazole.

A second aspect of the present invention provides for the use of acompound of formula (I) in any of the aforementioned embodiments, infree or pharmaceutically acceptable salt form, for the manufacture of amedicament for the treatment of an inflammatory or allergic condition,particularly an inflammatory or obstructive airways disease or mucosalhydration.

An embodiment of the present invention provides for the use of acompound of formula (I) in any of the aforementioned embodiments, infree or pharmaceutically acceptable salt form, for the manufacture of amedicament for the treatment of an inflammatory or allergic conditionselected from cystic fibrosis, primary ciliary dyskinesia, chronicbronchitis, chronic obstructive pulmonary disease, asthma, respiratorytract infections, lung carcinoma, xerostomia and keratoconjunctivitissire.

It is understood that any and all embodiments of the present inventionmay be taken in conjunction with any other embodiment to describeadditional embodiments of the present invention. Furthermore, anyelements of an embodiment are meant to be combined with any and allother elements from any of the embodiments to describe additionalembodiments. It is understood by those skilled in the art thatcombinations of substituents where not possible are not an aspect of thepresent invention.

Throughout this specification and in the claims that follow, unless thecontext requires otherwise, the word “comprise”, or variations, such as“comprises” or “comprising”, will be understood to imply the inclusionof a stated integer or step or group of integers or steps but not theexclusion of any other integer or step or group of integers or steps.

Especially preferred specific compounds of formula (I) are thosedescribed hereinafter in the Examples.

The compounds represented by formula (I) may be capable of forming acidaddition salts, particularly pharmaceutically acceptable acid additionsalts. Pharmaceutically acceptable acid addition salts of the compoundof formula (I) include those of inorganic acids, e.g., hydrohalic acids,such as hydrofluoric acid, hydrochloric acid, hydrobromic acid orhydroiodic acid, nitric acid, sulfuric acid, phosphoric acid; andorganic acids, e.g., aliphatic monocarboxylic acids, such as formicacid, acetic acid, trifluoroacetic acid, propionic acid and butyricacid; aliphatic hydroxy acids, such as lactic acid, citric acid,tartaric acid or malic acid; dicarboxylic acids, such as maleic acid orsuccinic acid; aromatic carboxylic acids, such as benzoic acid,p-chlorobenzoic acid, diphenylacetic acid, para-biphenyl benzoic acid ortriphenylacetic acid; aromatic hydroxy acids, such as o-hydroxybenzoicacid, p-hydroxybenzoic acid, 1-hydroxynaphthalene-2-carboxylic acid or3-hydroxynaphthalene-2-carboxylic acid; cinnamic acids, such as3-(2-naphthalenyl)propenoic acid, para-methoxy cinnamic acid orpara-methyl cinnamic acid; and sulfonic acids, such as methanesulfonicacid or benzenesulfonic acid. These salts may be prepared from compoundsof formula (I) by known salt-forming procedures.

Compounds of formula (I) which may contain acidic, e.g., carboxyl,groups, are also capable of forming salts with bases, in particular,pharmaceutically acceptable bases, such as those well-known in the art;suitable such salts include metal salts, particularly alkali metal oralkaline earth metal salts, such as sodium, potassium, magnesium orcalcium salts; or salts with ammonia or pharmaceutically acceptableorganic amines or heterocyclic bases, such as ethanolamines,benzylamines or pyridine. These salts may be prepared from compounds offormula (I) by known salt-forming procedures.

Stereoisomers are those compounds where there is an asymmetric carbonatom. The compounds exist in individual optically active isomeric formsor as mixtures thereof, e.g., as diastereomeric mixtures. The presentinvention embraces both individual optically active R and S isomers, aswell as mixtures thereof. Individual isomers can be separated by methodswell-known to those skilled in the art, e.g., chiral high performanceliquid chromatography (HPLC).

Tautomers are one of two or more structural isomers that exist inequilibrium and are readily converted from one isomeric form to another.

More specifically, for example, compounds of Formula Ia where R⁶ and/orR¹¹ are hydrogen may exist in one or both of the following tautomericforms:

Compounds according to Formula I may exist in corresponding tautomericforms.

Examples of tautomers include but are not limited to those compoundsdefined in the claims.

The compounds of the invention may exist in both unsolvated and solvatedforms. The term “solvate” is used herein to describe a molecular complexcomprising the compound of the invention and one or morepharmaceutically acceptable solvent molecules, e.g., ethanol. The term“hydrate” is employed when said solvent is water.

Synthesis

Generally, compounds according to Formula I can be synthesized by theroutes described in Scheme 1 and the Examples.

For instance, intermediate 1 can be reacted with intermediate 2 in anorganic solvent to provide compound 3 which can be isolated as the freebase. The free base can then be converted to a salt form by treatmentwith an appropriate acid.

Intermediates can be prepared from methods known by those skilled in theart or are commercially available.

In Scheme 1, R¹, R², R³, R⁴, R⁵, R⁶ and R¹¹ are as defined above; Y isCR⁷R⁸; X is CR⁹R¹⁰; n is 0; and R⁷, R⁸, R⁹ and R¹⁰ are also as definedabove. For compounds where n is 1 or 2, then the appropriate methyleneor ethylene linking groups are inserted between X and Y in the diaminereactant 2.

The compounds of Formula 1 and Formula 2 above can be prepared accordingto conventional routes described in the literature.

Compounds of formula (I), in free form, may be converted into salt form,and vice versa, in a conventional manners understood by those skilled inthe art. The compounds in free or salt form can be obtained in the formof hydrates or solvates containing a solvent used for crystallisation.Compounds of formula (I) can be recovered from reaction mixtures andpurified in a conventional manner. Isomers, such as stereoisomers, maybe obtained in a conventional manner, e.g., by fractionalcrystallisation or asymmetric synthesis from correspondinglyasymmetrically substituted, e.g., optically active, starting materials.

The compounds of formula (I) can be prepared, e.g., using the reactionsand techniques described below and in the Examples. The reactions may beperformed in a solvent appropriate to the reagents and materialsemployed and suitable for the transformations being effected. It will beunderstood by those skilled in the art of organic synthesis that thefunctionality present on the molecule should be consistent with thetransformations proposed. This will sometimes require a judgment tomodify the order of the synthetic steps or to select one particularprocess scheme over another in order to obtain a desired compound of theinvention.

The various substituents on the synthetic intermediates and finalproducts shown in the following reaction schemes can be present in theirfully elaborated forms, with suitable protecting groups where requiredas understood by one skilled in the art, or in precursor forms which canlater be elaborated into their final forms by methods familiar to oneskilled in the art. The substituents can also be added at various stagesthroughout the synthetic sequence or after completion of the syntheticsequence. In many cases, commonly used functional group manipulationscan be used to transform one intermediate into another intermediate, orone compound of formula (I) into another compound of formula (I).Examples of such manipulations are conversion of an ester or a ketone toan alcohol; conversion of an ester to a ketone; interconversions ofesters, acids and amides; alkylation, acylation and sulfonylation ofalcohols and amines; and many others. Substituents can also be addedusing common reactions, such as alkylation, acylation, halogenation oroxidation. Such manipulations are well-known in the art, and manyreference works summarize procedures and methods for such manipulations.Some reference works which gives examples and references to the primaryliterature of organic synthesis for many functional group manipulations,as well as other transformations commonly used in the art of organicsynthesis are March's Organic Chemistry, 5^(th) Edition, Wiley andChichester, Eds. (2001); Comprehensive Organic Transformations, Larock,Ed., VCH (1989); Comprehensive Organic Functional Group Transformations,Katritzky et al. (series editors), Pergamon (1995); and ComprehensiveOrganic Synthesis, Trost and Fleming (series editors), Pergamon (1991).It will also be recognized that another major consideration in theplanning of any synthetic route in this field is the judicious choice ofthe protecting group used for protection of the reactive functionalgroups present in the compounds described in this invention. Multipleprotecting groups within the same molecule can be chosen such that eachof these protecting groups can either be removed without removal ofother protecting groups in the same molecule, or several protectinggroups can be removed using the same reaction step, depending upon theoutcome desired. An authoritative account describing many alternativesto the trained practitioner is Greene and Wuts, Protective Groups inOrganic Synthesis, Wiley and Sons (1999).

Pharmacological Activity

Having regard to their blockade of the epithelial sodium channel (ENaC),compounds of formula (I), in free or pharmaceutically acceptable saltform, hereinafter alternately referred to as “agents of the invention”,are useful in the treatment of conditions which respond to the blockadeof the epithelial sodium channel, particularly conditions benefitingfrom mucosal hydration.

Diseases mediated by blockade of the epithelial sodium channel, includediseases associated with the regulation of fluid volumes acrossepithelial membranes. For example, the volume of airway surface liquidis a key regulator of mucociliary clearance and the maintenance of lunghealth. The blockade of the epithelial sodium channel will promote fluidaccumulation on the mucosal side of the airway epithelium therebypromoting mucus clearance and preventing the accumulation of mucus andsputum in respiratory tissues (including lung airways). Such diseasesinclude respiratory diseases, such as cystic fibrosis, primary ciliarydyskinesia, chronic bronchitis, chronic obstructive pulmonary disease(COPD), asthma, respiratory tract infections (acute and chronic; viraland bacterial) and lung carcinoma. Diseases mediated by blockade of theepithelial sodium channel also include diseases other than respiratorydiseases that are associated with abnormal fluid regulation across anepithelium, perhaps involving abnormal physiology of the protectivesurface liquids on their surface, e.g., xerostomia (dry mouth) orkeratoconjunctivitis sire (dry eye). Furthermore, blockade of theepithelial sodium channel in the kidney could be used to promotediuresis and thereby induce a hypotensive effect.

Treatment in accordance with the invention may be symptomatic orprophylactic.

Asthma includes both intrinsic (non-allergic) asthma and extrinsic(allergic) asthma, mild asthma, moderate asthma, severe asthma,bronchitic asthma, exercise-induced asthma, occupational asthma andasthma induced following bacterial infection. Treatment of asthma isalso to be understood as embracing treatment of subjects, e.g., of lessthan 4 or 5 years of age, exhibiting wheezing symptoms and diagnosed ordiagnosable as “wheezy infants”, an established patient category ofmajor medical concern and now often identified as incipient orearly-phase asthmatics. (For convenience this particular asthmaticcondition is referred to as “wheezy-infant syndrome”.)

Prophylactic efficacy in the treatment of asthma will be evidenced byreduced frequency or severity of symptomatic attack, e.g., of acuteasthmatic or bronchoconstrictor attack, improvement in lung function orimproved airways hyperreactivity. It may further be evidenced by reducedrequirement for other, symptomatic therapy, i.e., therapy for orintended to restrict or abort symptomatic attack when it occurs, e.g.,anti-inflammatory (e.g., cortico-steroid) or bronchodilatory.Prophylactic benefit in asthma may, in particular, be apparent insubjects prone to “morning dipping”. “Morning dipping” is a recognizedasthmatic syndrome, common to a substantial percentage of asthmatics andcharacterized by asthma attack, e.g., between the hours of about 4-6 am,i.e., at a time normally substantially distant from any previouslyadministered symptomatic asthma therapy.

Chronic obstructive pulmonary disease includes chronic bronchitis ordyspnea associated therewith, emphysema, as well as exacerbation ofairways hyperreactivity consequent to other drug therapy, in particular,other inhaled drug therapy. The invention is also applicable to thetreatment of bronchitis of whatever type or genesis including, e.g.,acute, arachidic, catarrhal, croupus, chronic or phthinoid bronchitis.

The agents of the invention may also be useful as acid-sensing ionchannel (ASIC) blockers. Thus they may be useful in the treatment ofconditions which respond to the blockade of the acid-sensing ionchannel.

The suitability of epithelial sodium channel blocker as a treatment of adisease benefiting from mucosal hydration, may be tested by determiningthe inhibitory effect of the channel blocker on ENaC in a suitablecell-based assay. For example single cells or confluent epithelia,endogenously expressing or engineered to overexpress ENaC can be used toassess channel function using electrophysiological techniques or ionflux studies. See methods described in: Hirsh et al., J Pharm Exp Ther(2004); Moody et al., Am J Physiol Cell Physiol (2005).

Epithelial sodium channel blockers, including the compounds of formula(I), are also useful as co-therapeutic agents for use in combinationwith other drug substances, such as anti-inflammatory, bronchodilatory,antihistamine or anti-tussive drug substances, particularly in thetreatment of cystic fibrosis or obstructive or inflammatory airwaysdiseases such as those mentioned hereinbefore, e.g., as potentiators oftherapeutic activity of such drugs or as a means of reducing requireddosaging or potential side effects of such drugs.

The epithelial sodium channel blocker may be mixed with the other drugsubstance in a fixed pharmaceutical composition or it may beadministered separately, before, simultaneously with or after the otherdrug substance.

Accordingly, the invention includes as a further aspect a combination ofepithelial sodium channel blocker with osmotic agents (hypertonicsaline, dextran, mannitol, Xylitol)+modifiers of CFTR function, bothwild-type and mutant (correctors+potentiators), e.g., those described inWO 2007/021982, WO 2006/099256, WO 2006/127588, WO 2004/080972, WO2005/026137, WO 2005/035514, WO 2005/075435, WO 2004/111014, WO2006/101740, WO 2004/110352, WO 2005/120497 and US 2005/0176761, ananti-inflammatory, bronchodilatory, antihistamine, anti-tussive,antibiotic or DNase drug substance, said epithelial sodium channelblocker and said drug substance being in the same or differentpharmaceutical composition.

Suitable antibiotics include macrolide antibiotics, e.g., tobramycin(TOBI™).

Suitable DNase drug substances include dornase alfa (Pulmozyme™), ahighly-purified solution of recombinant human deoxyribonuclease I(rhDNase), which selectively cleaves DNA. Dornase alfa is used to treatcystic fibrosis.

Other useful combinations of epithelial sodium channel blockers withanti-inflammatory drugs are those with antagonists of chemokinereceptors, e.g., CCR-1, CCR-2, CCR-3, CCR-4, CCR-5, CCR-6, CCR-7, CCR-8,CCR-9 and CCR10, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, particularly CCR-5antagonists, such as Schering-Plough antagonists SC-351125, SCH-55700and SCH-D; Takeda antagonists, such asN-[[4-[[[6,7-dihydro-2-(4-methyl-phenyl)-5H-benzo-cyclohepten-8-yl]carbonyl]amino]phenyl]-methyl]tetrahydro-N,N-dimethyl-2H-pyran-4-amin-iumchloride (TAK-770); and CCR-5 antagonists described in U.S. Pat. No.6,166,037 (particularly claims 18 and 19), WO 00/66558 (particularlyclaim 8), WO 00/66559 (particularly claim 9), WO 04/018425 and WO04/026873.

Suitable anti-inflammatory drugs include steroids, in particular,glucocorticosteroids, such as budesonide, beclamethasone dipropionate,fluticasone propionate, ciclesonide or mometasone furoate, or steroidsdescribed in WO 02/88167, WO 02/12266, WO 02/100879, WO 02/00679(especially those of Examples 3, 11, 14, 17, 19, 26, 34, 37, 39, 51, 60,67, 72, 73, 90, 99 and 101), WO 03/35668, WO 03/48181, WO 03/62259, WO03/64445, WO 03/72592, WO 04/39827 and WO 04/66920; non-steroidalglucocorticoid receptor agonists, such as those described in DE10261874, WO 00/00531, WO 02/10143, WO 03/82280, WO 03/82787, WO03/86294, WO 03/104195, WO 03/101932, WO 04/05229, WO 04/18429, WO04/19935 and WO 04/26248; LTD4 antagonists, such as montelukast andzafirlukast; PDE4 inhibitors, such as cilomilast (Ariflo®GlaxoSmithKline), Roflumilast (Byk Gulden), V-11294A (Napp), BAY19-8004(Bayer), SCH-351591 (Schering-Plough), Arofylline (AlmirallProdesfarma), PD189659/PD168787 (Parke-Davis), AWD-12-281 (Asta Medica),CDC-801 (Celgene), SelCID™ CC-10004 (Celgene), VM554/UM565 (Vernalis),T-440 (Tanabe), KW-4490 (Kyowa Hakko Kogyo), and those disclosed in WO92/19594, WO 93/19749, WO 93/19750, WO 93/19751, WO 98/18796, WO99/16766, WO 01/13953, WO 03/104204, WO 03/104205, WO 03/39544, WO04/000814, WO 04/000839, WO 04/005258, WO 04/018450, WO 04/018451, WO04/018457, WO 04/018465, WO 04/018431, WO 04/018449, WO 04/018450, WO04/018451, WO 04/018457, WO 04/018465, WO 04/019944, WO 04/019945, WO04/045607 and WO 04/037805; adenosine A2B receptor antagonists such asthose described in WO 02/42298; and beta-2 adrenoceptor agonists, suchas albuterol (salbutamol), metaproterenol, terbutaline, salmeterolfenoterol, procaterol, and especially, formoterol, carmoterol andpharmaceutically acceptable salts thereof, and compounds (in free orsalt or solvate form) of formula (I) of WO 0075114, which document isincorporated herein by reference, preferably compounds of the Examplesthereof, especially a compound of formula:

corresponding to indacaterol and pharmaceutically acceptable saltsthereof, as well as compounds (in free or salt or solvate form) offormula (I) of WO 04/16601, and also compounds of EP 1440966, JP05025045, WO 93/18007, WO 99/64035, USP 2002/0055651, WO 01/42193, WO01/83462, WO 02/66422, WO 02/70490, WO 02/76933, WO 03/24439, WO03/42160, WO 03/42164, WO 03/72539, WO 03/91204, WO 03/99764, WO04/16578, WO 04/22547, WO 04/32921, WO 04/33412, WO 04/37768, WO04/37773, WO 04/37807, WO 04/39762, WO 04/39766, WO 04/45618, WO04/46083, WO 04/80964, WO 04/108765 and WO 04/108676.

Suitable bronchodilatory drugs include anticholinergic or antimuscarinicagents, in particular, ipratropium bromide, oxitropium bromide,tiotropium salts and CHF 4226 (Chiesi), and glycopyrrolate, but alsothose described in EP 424021, U.S. Pat. No. 3,714,357, U.S. Pat. No.5,171,744, WO 01/04118, WO 02/00652, WO 02/51841, WO 02/53564, WO03/00840, WO 03/33495, WO 03/53966, WO 03/87094, WO 04/018422 and WO04/05285.

Suitable dual anti-inflammatory and bronchodilatory drugs include dualbeta-2 adrenoceptor agonist/muscarinic antagonists such as thosedisclosed in USP 2004/0167167, WO 04/74246 and WO 04/74812.

Suitable antihistamine drug substances include cetirizine hydrochloride,acetaminophen, clemastine fumarate, promethazine, loratidine,desloratidine, diphenhydramine and fexofenadine hydrochloride,activastine, astemizole, azelastine, ebastine, epinastine, mizolastineand tefenadine, as well as those disclosed in JP 2004107299, WO03/099807 and WO 04/026841.

In accordance with the foregoing, the invention also provides as afurther aspect a method for the treatment of a condition responsive toblockade of the epithelial sodium channel, e.g., diseases associatedwith the regulation of fluid volumes across epithelial membranes,particularly an obstructive airways disease, which comprisesadministering to a subject, particularly a human subject, in needthereof a compound of formula (I), in free form or in the form of apharmaceutically acceptable salt.

In another aspect the invention provides a compound of formula (I), infree form or in the form of a pharmaceutically acceptable salt, for usein the manufacture of a medicament for the treatment of a conditionresponsive to blockade of the epithelial sodium channel, particularly anobstructive airways disease, e.g., cystic fibrosis and COPD.

The agents of the invention may be administered by any appropriateroute, e.g. orally, e.g., in the form of a tablet or capsule;parenterally, e.g., intravenously; by inhalation, e.g., in the treatmentof an obstructive airways disease; intranasally, e.g., in the treatmentof allergic rhinitis; topically to the skin; or rectally. In a furtheraspect, the invention also provides a pharmaceutical compositioncomprising a compound of formula (I), in free form or in the form of apharmaceutically acceptable salt, optionally together with apharmaceutically acceptable diluent or carrier therefor. The compositionmay contain a co-therapeutic agent, such as an anti-inflammatory,broncho-dilatory, antihistamine or anti-tussive drug as hereinbeforedescribed. Such compositions may be prepared using conventional diluentsor excipients and techniques known in the galenic art. Thus oral dosageforms may include tablets and capsules. Formulations for topicaladministration may take the form of creams, ointments, gels ortransdermal delivery systems, e.g., patches. Compositions for inhalationmay comprise aerosol or other atomizable formulations or dry powderformulations.

When the composition comprises an aerosol formulation, it preferablycontains, e.g., a hydro-fluoro-alkane (HFA) propellant, such as HFA134aor HFA227 or a mixture of these, and may contain one or more co-solventsknown in the art, such as ethanol (up to 20% by weight), and/or one ormore surfactants, such as oleic acid or sorbitan trioleate, and/or oneor more bulking agents, such as lactose. When the composition comprisesa dry powder formulation, it preferably contains, e.g., the compound offormula (I) having a particle diameter up to 10 microns, optionallytogether with a diluent or carrier, such as lactose, of the desiredparticle size distribution and a compound that helps to protect againstproduct performance deterioration due to moisture, e.g., magnesiumstearate. When the composition comprises a nebulised formulation, itpreferably contains, e.g., the compound of formula (I) either dissolved,or suspended, in a vehicle containing water, a co-solvent, such asethanol or propylene glycol and a stabilizer, which may be a surfactant.

Further aspects of the invention include:

(a) a compound of formula (I) in inhalable form, e.g., in an aerosol orother atomisable composition or in inhalable particulate, e.g.,micronised form;

(b) an inhalable medicament comprising a compound of formula (I) ininhalable form;

(c) a pharmaceutical product comprising a compound of formula (I) ininhalable form in association with an inhalation device; and

(d) an inhalation device containing a compound of formula I in inhalableform.

Dosages of compounds of formula (I) employed in practising the presentinvention will of course vary depending, e.g., on the particularcondition to be treated, the effect desired and the mode ofadministration. In general, suitable daily dosages for administration byinhalation are of the order of 0.005-10 mg, while for oraladministration suitable daily doses are of the order of 0.05-100 mg.

Pharmaceutical Use and Assay

Compounds of formula (I) and their pharmaceutically acceptable salts,hereinafter referred to alternatively as “agents of the invention”, areuseful as pharmaceuticals. In particular, the compounds have good ENaCblocker activity and may be tested in the following assays.

Cell Culture

Human Bronchial Epithelial cells (HBECs) (Cambrex) were cultured underair-liquid interface conditions to provide a well differentiatedmucociliary phenotype.

HBECs were cultured using a modification of the method described by Grayand colleagues (Gray et al., 1996). Cells were seeded in plastic T-162flasks and were grown in bronchial epithelial cell growth medium (BEGM;Cambrex) supplemented with bovine pituitary extract (52 μg/mL),hydrocortisone (0.5 μg/mL), human recombinant epidermal growth factor(0.5 ng/mL), epinephrine (0.5 μg/mL), transferrin (10 μg/mL), insulin (5μg/mL), retinoic acid (0.1 μg/mL), triiodothyronine (6.5 μg/mL),gentamycin (50 μg/mL) and amphotericin B (50 ng/mL). Medium was changedevery 48 hours until cells were 90% confluent. Cells were then passagedand seeded (8.25×10⁵ cells/insert) on polycarbonate Snapwell inserts(Costar) in differentiation media containing 50% DMEM in BEGM with thesame supplements as above but without triiodothyronine and a finalretinoic acid concentration of 50 nM (all-trans retinoic acid). Cellswere maintained submerged for the first 7 days in culture, after whichtime they were exposed to an apical air interface for the remainder ofthe culture period. At this time, media was changed to DMEM:F12 mediacontaining 2% v/v Ultroser G for the remainder of culture. AmphotericinB was removed from all media 3 feeds prior to use in the UssingChambers. Cells were used between days 7 and 21 after establishment ofthe apical-air interface. At all stages of culture, cells weremaintained at 37° C. in 5% CO₂ in an air incubator.

Short Circuit Current (ISC) Measurements

Snapwell inserts were mounted in Vertical Diffusion Chambers (Costar)and were bathed with continuously gassed Ringer solution (5% CO₂ in O₂;pH 7.4) maintained at 37° C. containing (in mM): 120 NaCl, 25 NaHCO₃,3.3 KH₂PO₄, 0.8 K₂HPO₄, 1.2 CaCl₂, 1.2 MgCl₂, and 10 glucose. Thesolution osmolarity was between 280 and 300 mOsmol/kg H₂O for allphysiological salt solutions used. Cells were voltage clamped to 0 mV(model EVC4000; WPI). RT was measured by applying a 1- or 2-mV pulse at30-s intervals and calculating RT by Ohm's law. Data were recorded usinga PowerLab workstation (ADInstruments).

Test compounds were prepared as a 10 mM stock solution in DMSO (95%).Serial 3-fold dilutions were freshly prepared in an appropriate vehicle(distilled H₂O or Ringers solution). The initial concentration was addedto the apical chamber as a 1000× concentrate in 5 μL, resulting in afinal 1× concentration the 5 mL volume of the Ussing chamber. Subsequentadditions of compound were added in a 3.3 μL volume of the 1000×serially diluted stock solution. At the completion of theconcentration-response experiment, amiloride (10 μM) was added into theapical chamber to enable the total amiloride-sensitive current to bemeasured. An amiloride control IC₅₀ was established at the start of eachexperiment.

Results are expressed as the mean % inhibition of theamiloride-sensitive ISC. Concentration-response curves were plotted andIC₅₀ values generated using GraphPad Prism 3.02. Cell inserts weretypically run in duplicate and the IC₅₀ calculated on the mean %inhibition data.

Compounds of the Examples, herein below, generally have IC₅₀ values inthe data measurements described above below 10 μM. For example, thecompounds of the Examples shown below have the indicated IC₅₀ values.

IC₅₀ Ex (μM) 5 0.065 11 1.686 19 0.018 23 0.0335 25 0.270 26 0.011 290.005 32 0.018 34 0.095 35 0.031 39 0.0055 40 0.0055 41 0.0095 42 0.01143 0.013 44 0.0295 45 0.0426 48 0.0165 58 0.143 61 0.3465 62 0.013 640.0255 65 0.0395 70 0.074 71 0.042 76 0.012 86 0.008 91 0.0885 94 0.00996 0.037 99 0.019 118 0.175 126 0.025 128 0.0115 141 0.002 146 0.006 1470.016 185 0.062 215 0.036 220 0.0085 228 0.0935 232 0.054 235 0.364 2380.119 246 0.025 252 0.028

The invention is illustrated by the following Examples.

EXAMPLES Compounds of Formula Ib

are shown in Table 1. Methods for preparing such compounds are describedhereinafter. The table also shows mass spectrometry [M+H]⁺ data.

TABLE 1 M/s [M + Ex. Structure H]⁺ 1

284 2

270 3

270 4

408 5

461 6

418 7

404 8

376/378 9

400 10

328 11

310 12

415 13

404 14

270 15

296 16

310 17

390 18

390 19

464 20

464 21

464 22

464 23

517 24

418.2 25

418.2 26

446 27

356 28

506 29

506.37 30

447.1 31

313.1 32

446.1 33

467.0 34

430.98 35

481.0 36

445.1 37

425 38

325 39

626.4 40

607.42 41

607.98 42

510.4 43

529.05 44

499.0 45

542.91 46

552.1 47

469.17 48

510.23 49

510.1 50

483.1 51

535.1 52

499.1 53

469.14 54

487.0 55

472.98 56

468.1 57

480.1 58

521.1 59

528.2 60

469.08 61

597.07 62

530.21 63

553.54 64

529.54 65

530.46 66

513.40 67

547.42 68

561.04 69

601.10 70

564.10 71

587.50 72

530.10 73

599.10 74

615.20 75

545.10 76

529.41 77

524 78

571 79

557 80

543 81

529 82

588 83

586/ 588 84

597 85

618 86

644/ 646 87

582/ 584 88

540 89

568/ 570 90

600/ 602 91

581/ 583 92

512/ 514 93

785 94

[M + 2H)]²⁺ = 393 95

787 96

779 97

549 98

563 99

468 100

468 101

443 102

675 103

463 104

653 105

455 106

429 107

469 108

423 109

453 110

419 111

395 112

454 113

430 114

487 115

431 116

445 117

435 118

420 119

430 120

430 121

436 122

419 123

437 124

431 125

420 126

648.4 127

651.3 128

648.3 129

576.3 130

633.3 131

592.3 132

599.3 133

610.3 134

634.3 135

613.3 136

654.3 137

664.3 138

645.4 139

614.3 140

593.4 141

702.3 142

594.3 143

643.3 144

736.4 145

626.3 146

559.3 147

572.08 148

572.0 149

538.4 150

544.4 151

569.4 152

511.4 153

604.3 154

528.3 155

633.4 156

526.3 157

556.4 158

604.4 159

617.4 160

594.4 161

528.4 162

478.3 163

462.3 164

691.04 165

573.05 166

648.06 167

545.3 168

517.07 169

484.04 170

511.04 171

530.08 172

603.99 173

530.19 174

527.99 175

555.07 176

608.05 177

527.07 178

524.1 179

520.99 180

545.95 181

514.98 182

512.01 183

478.01 184

475.08 185

572.09 186

634.09 187

619.12 188

496.02 189

685.08 190

599.2 191

542.01 192

579.03 193

526.05 194

553.09 195

614.3 196

516.06 197

496.01 198

528.04 199

560.14 200

490.05 201

528.06 202

527.02 203

458.1 204

540.02 205

539.11 206

433.05 207

635.19 208

447.09 209

509.09 210

542.00 211

564.06 212

539.11 213

445.96 214

620.1 215

458.1 216

217

637.1 218

598.05 219

554.0 220

578.2 221

539.2 222

557.2 223

564.1 224

610.2 225

532.1 226

566.1 227

539.2 228

487.1 229

620.2 230

564.2 231

578.2 232

478.98 233

234

517.9 235

518.1 236

540.9 237

493.1 238

652.2 239

615.1 240

520.1 241

527.0 242

581.1 243

527.1 244

616.1 245

527.0 246

429 247

445 248

416 249

443 250

421 251

451 252

494.15 253

589.20

General Conditions

LCMS are recorded using a Phenomenex Gemini 50 mm×3.0 mm, 3 um column.Low pH methods use a gradient of 5-95% acetonitrile in water-0.1% TFA,high pH methods use 5-95% acetonitrile in water-0.1% NH₃. [M+H]⁺ referto monoisotopic molecular weights.

9-BBN 9-Borabicyclo[3.3.1]nonaneDBU Diazabicyclo[5.4.0]undec-7-eneDMF dimethylformamideDMSO dimethyl sulfoxideDCM dichloromethaneDEAD diethyl azodicarboxylateDIAD diisopropyl azodicarboxylateDIPEA diisopropylethylamineEDCI 1-ethyl-3-(3′-dimethylaminopropyl) carbodiimide EtOAc ethyl acetateHATU 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphateHPLC high performance liquid chromatographyIPA Isopropyl alcohol (iso-propanol)MeOH methanolMEMCl 2-methoxyethoxymethyl chlorideNMR nuclear magnetic resonancePS polymer supportedPPTS Pyridinium para-toluenesulfonatePEAX PE-anion exchange (e.g. Isolute® PE-AX columns from Biotage)SCX-2 strong cation exchange (e.g. Isolute® SCX-2 columns from Biotage)TEA triethylamineTHF tetrahydrofuranTFA trifluoroacetic acid

PREPARATION OF EXAMPLES

For clarity in describing the Examples described below. Examples 2, 9,and 10 are racemic mixtures. Examples 4, 13 and 29 are mixtures ofdiastereomers. Examples 24 and 25 are single enantiomers wherein thestereochemistry of the unassigned stereocentre is not determined. Allother examples are single enantiomers of defined stereochemistry.

Where not stated, the compounds are recovered from reaction mixtures andpurified using conventional techniques such as flash chromatography,filtration, recrystallisation and trituration.

Example 1 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[4,4-dimethyl-imidazolidin-(2Z)-ylidene]-amide

A suspension of1-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea(Intermediate A) (0.2 g, 0.517 mmol) in EtOH (2 ml) is treated withtriethylamine (0.029 ml, 0.258 mmol) followed by1,2-diamino-2-methylpropane (0.07 ml, 0.672 mmol) and stirred at refluxovernight. The resulting suspension is filtered under vacuum to affordthe title compound as a pale yellow solid; [M+H]⁺ 284

Example 2 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[4-methyl-imidazolidin-(2Z)-ylidene]-amide

This compound is prepared analogously to Example 1 by replacing1,2-diamino-2-methylpropane with 1,2,diaminopropane; [M+H]⁺ 270

Example 3 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[1-methyl-imidazolidin-(2Z)-ylidene]-amide

This compound is prepared analogously to Example 1 by replacing1,2-diamino-2-methylpropane with N-methylenediamine; [M+H]⁺ 270

Example 4 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid(4,5-diphenyl-imidazolidin-2-ylidene)-amide

This compound is prepared analogously to Example 1 by replacing1,2-diamino-2-methylpropane with 1,2 diphenylethylene diamine; [M+H]⁺408

Example 5

(4-{2-[(Z)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-imidazolidin-4-yl}-butyl)-carbamicacid benzyl ester

This compound is prepared analogously to Example 1 by replacing1,2-diamino-2-methylpropane with ((S)-5,6-Diamino-hexyl)-carbamic acidbenzyl ester (Intermediate B); [M+H]⁺ 461

Example 6 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[1-[4-(4-methoxy-phenyl)-butyl]-imidazolidin-(2Z)-ylidene]-amide

This compound is prepared analogously to Example 1 by replacing1,2-diamino-2-methylpropane withN*1*-[4-(4-methoxy-phenyl)-butyl]-ethane-1,2-diamine (Intermediate C);[M+H]⁺ 418

Example 7 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[1-[4-(4-hydroxy-phenyl)-butyl]-imidazolidin-(2Z)-ylidene]-amide

This compound is prepared analogously to Example 1 by replacing1,2-diamino-2-methylpropane with 4-[4-(2-amino-ethylamino)-butyl]-phenol(Intermediate C); [M+H]⁺ 404

Example 8 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(S)-4-(4-methoxy-benzyl)-imidazolidin-(2Z)-ylidene]-amide

This compound is prepared analogously to Example 1 by replacing1,2-diamino-2-methylpropane with (S)-3-(4-methoxy-phenyl)-propane-1,2diamine (Intermediate D); [M+H]⁺ 376

Example 9 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[4-(3,4-dichloro-phenyl)-imidazolidin-(2Z)-ylidene]-amide

This compound is prepared analogously to Example 1 by replacing1,2-diamino-2-methylpropane with1-(3,4-Dichloro-phenyl)-ethane-1,2-diamine (Intermediate E); [M+H]⁺ 400

Example 103-{2-[(Z)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-imidazolidin-4-yl}-propionicacid

This compound is prepared analogously to Example 1 by replacing1,2-diamino-2-methylpropane with 4,5-Diaminopentanoic aciddihydrochloride (Intermediate F); [M+H]⁺ 328

Examples 2-10

These compounds are recovered from reaction mixtures and purified usingconventional techniques such as flash chromatography, filtration,capture release resin or preparative HPLC.

Example 11 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid(octahydro-benzoimidazol-2-ylidene)-amide

This compound is prepared analogously to Example 1 by replacing1,2-diamino-2-methylpropane with cyclohexane-1,2-diamine. The reactionis carried out in propan-2-ol; [M+H]⁺ 310

Example 12 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-benzyl-1,3,8-triazaspiro[4.5]dec-(2Z)-ylidene]-amide

4-Amino-1-benzyl-piperidine-4-carbonitrile (Intermediate G) (200 mg,0.91 mmol) in dry propan-2-ol (10 ml) is treated with triethylamine(0.25 ml) followed by1-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea(Intermediate A) (355 mg, 0.91 mmol). The mixture is heated at 70° C.for 5 hours and then allowed to cool to room temperature. Theprecipitate is collected and washed with methanol to afford the titlecompound as a light yellow solid, 190 mg; [M+H]⁺ 415

Example 13 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[4-[3-(4-methoxy-phenyl)-propyl]-imidazolidin-(2Z)-ylidene]-amide

This compound is prepared analogously to Example 12 by replacing4-Amino-1-benzyl-piperidine-4-carbonitrile (Intermediate G) with5-(4-methoxy-phenyl)-pentane-1,2-diamine (Intermediate I); [M+H]⁺ 404

Example 14 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid(tetrahydro-pyrimidin-2-ylidene)-amide

1-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea(Intermediate A) (1.0 g, 2.58 mmol) is suspended in propan-2-ol (10 ml)and 1,3-diaminopropane (0.32 ml, 3.9 mmol) is added. The mixture isheated at 60° C. for 18 hours and then allowed to cool to roomtemperature and the solids present are collected by filtration. Thesolids are washed with THF and MeOH to yield the title compound as ayellow solid; [M+H]⁺ 270

Example 15 3,5-diamino-6-chloro-N-(1H-pyrrolo[1,2-c]imidazol-3(2H,5H,6H,7H,7aH)-ylidene)pyrazine-2-carboxamide

1-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea(Intermediate A) (195 mg, 0.5 mmol) is suspended in propan-2-ol (10 ml)and (S)-2-(aminomethyl)pyrrolidine (100 mg, 1 mmol) is added. Themixture is heated at 60° C. for 18 hours, allowed to cool to roomtemperature and the precipitate is removed by filtration. The filtrateis concentrated in vacuo and the residue purified by chromatography(SiO₂, DCM/MeOH) to afford the title compound as a light, yellow gum;[M+H]⁺ 296

Example 16 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[1,3-diaza-spiro[4.4]non-(2Z)-ylidene]-amide

A solution of crude 1-aminomethyl-cyclopentylamine (Intermediate J) (80mg, 0.70 mmol) in propan-2-ol (1.0 ml) is added to a suspension of1-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea(Intermediate A) (208 mg, 0.54 mmol) in propan-2-ol (1.08 ml) and heatedat 70° C. for 2 days. After cooling to room temperature, the reactionmixture is filtered under vacuum, and the solid is rinsed with MeOH. Thefiltrate is concentrated in vacuo to afford a bright yellow residuewhich is loaded onto a SCX-2 cartridge and eluted with 33% NH₃ (4 drops)in MeOH (5 ml×2). The methanolic ammonia fractions are combined andconcentrated in vacuo. Purification using mass directed preparative LCMSeluting with 95% Water+0.1% NH₃:5% Acetonitrile to affords the titlecompound; [M+H]⁺ 310.

Example 17 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(R)-4-[3-(4-hydroxy-phenyl)-propyl]-imidazolidin-(2E)-ylidene]-amide

To a stirred solution of (4-((R)-4,5-Diamino-pentyl)-phenol(intermediate K) (1.5 g, 7.72 mmol) in propan-2-ol (100 ml) at 30° C. isadded in one portion1-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea(Intermediate A) and the reaction is heated at 30° C. for 18 hoursfollowed by 50° C. for a further 18 hours. The reaction mixture isfiltered hot and the filtrate solvent is removed in vacuo to afford ayellow foam. The foam is purified by chromatography (SiO₂, DCM/MeOH/5%NH₃) to afford the title compound; [M+H]⁺ 390

Example 18 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(S)-4-[3-(4-hydroxy-phenyl)-propyl]-imidazolidin-(2E)-ylidene]-amide

This compound is prepared analogously to Example 17 replacing(4-((R)-4,5-Diamino-pentyl)-phenol (Intermediate K) with4-((S)-4,5-Diamino-pentyl)-phenol (intermediate L; [M+H]⁺ 390

Example 19 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(R)-4-{3-[4-((S)-2,3-dihydroxy-propoxy)-phenyl]-propyl}-imidazolidin-(2Z)-ylidene]-amide

To a stirred solution of 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(R)-4-[3-(4-hydroxy-phenyl)-propyl]-imidazolidin-(2E)-ylidene]-amide(Ex. 17) (1.0 g, 2.57 mmol) in 1,4 dioxane (38 ml) at 50° C. is added inone portion 0.5 M KOH (5.3 ml, 2.7 mmol) followed by (S)-(−)-Glycidiol(0.170 ml, 2.57 mmol). The resulting mixture is heated at 50° C. for 18hours and then further (S)-(−)-Glycidiol (0.07 ml, 1.05 mmol) is addedin one portion. The resulting mixture is heated at 50° C. for 60 hoursand then allowed to cool to room temperature. The solvent is removed invacuo to afford an orange oil which is dissolved in EtOAc/MeOH 9:1 (100ml) and washed with 1 M NaOH (50 ml). The organic layer is dried overNa₂SO₄ and the solvent is removed in vacuo to afford a brown/orangefoam. Purification by chromatography (SiO₂, DCM/MeOH/NH₃) affords thetitle compound as a yellow foam; [M+H]⁺ 464; ¹H NMR (400 MHz, DMSO-d6):1.65-1.40 (m, 4H), 2.52 (m, 2H), 3.13 (dd, J=9.6, 7.1 Hz, 1H), 3.42 (brd, J=4.7 Hz, 2H), 3.62 (dd, J=9.6, 9.6 Hz, 1H), 3.76 (m, 1H), 3.78 (m,1H), 3.80 (m, 1H), 3.94 (dd, J=9.5, 4.0 Hz, 1H), 4.62 (br s, 1H), 4.89(br s, 1H), 6.68 (br s, 2H), 6.82 (d, J=8.5 Hz, 2H), 7.09 (d, J=8.5 Hz,2H), 7.2-6.0 (br s, 1H), 8.18 (br s, 1H), 9.3-7.5 (br s, 1H),

Example 20 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(S)-4-{3-[4-((S)-2,3-dihydroxy-propoxy)-phenyl]-propyl}-imidazolidin-(2Z)-ylidene]-amide

To a solution of 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(S)-4-[3-(4-hydroxy-phenyl)-propyl]-imidazolidin-(2E)-ylidene]-amide(Example 18) (37.5 mg, 0.09 mmol) in Ethanol (2 ml) is addedtriethylamine (63 l, 0.45 mmol) and (S)-glycidol (6.07 l, 0.09 mmol).The resulting mixture is heated at reflux for 18 hours and then allowedto cool to room temperature. The reaction mixture is diluted with MeOH(1 ml) and purified on a Waters 3000 prep HPLC system, (Microsorb C18,Water (0.1% TFA):MeCN) to afford the title compound; [M+H]⁺ 464.

Example 21 (3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(R)-4-{3-[4-((R)-2,3-dihydroxy-propoxy)-phenyl]-propyl}-imidazolidin-(2Z)-ylidene]-amide

To a stirred solution of(R)-3-[4-((R)-4,5-Diamino-pentyl)-phenoxy]-propane-1,2-diol(Intermediate O) (32.8 mg, 0.122 mmol) in propan-2-ol (3 ml) is added1-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea(Intermediate A) (45.8 mg, 0.122 mmol) and the resultant reactionmixture is heated at 90° C. for 18 hours. The reaction is allowed tocool to room temperature and diluted with DMSO (1.5 ml) and purified ona Waters 3000 preperative HPLC system (Microsorb™ C18, Water (0.1%TFA):MeCN). The fractions containing product are passed through a 1 gSCX-2 cartridge which is eluted with 1:1 Water:MeCN (20 ml), MeCN (20ml) and 7M NH₃ in MeOH (20 ml). The ammonia elutions are concentrated invacuo to afford the title compound; [M+H]⁺ 464

Example 22 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(S)-4-{3-[4-((R)-2,3-dihydroxy-propoxy)-phenyl]-propyl}-imidazolidin-(2Z)-ylidene]-amidetrifluroacetate

This compound is prepared analogously to Example 21 replacing(R)-3-[4-((R)-4,5-Diamino-pentyl)-phenoxy]-propane-1,2-diol(Intermediate O) with(R)-3-[4-((S)-4,5-Diamino-pentyl)-phenoxy]-propane-1,2-diol(Intermediate P); [M+H]⁺ 464.

Example 23 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(R)-4-{3-[4-(2-morpholin-4-yl-2-oxo-ethoxy)-phenyl]-propyl}-imidazolidin-(2Z)-ylidene]-amide

This compound is prepared analogously to Example 21 replacing(R)-3-[4-((R)-4,5-Diamino-pentyl)-phenoxy]-propane-1,2-diol(Intermediate O) with2-[4-((R)-4,5-Diamino-pentyl)-phenoxy]-1-morpholin-4-yl-ethanone(Intermediate Q); [M+H]⁺ 517

Examples 24 and 25 Both Enantiomers of3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[4-[3-(4-methoxy-phenyl)-butyl]-imidazolidin-(2Z)-ylidene]-amide

The racemate of these compounds is prepared analogously to Example 12replacing 4-Amino-1-benzyl-piperidine-4-carbonitrile (Intermediate G)with 5-(4-methoxy-phenyl)-hexane-1,2-diamine (Intermediate K). Theenantiomers are separated by chiral HPLC:

Mobile phase: 100% EtOH (0.2% IPAm)Column: Chirapak-AD 25 cm×4.6 mm i.dFlow rate: 1 ml/min

UV 280 nM

Concentration 1 mg/mL

Inj Vol 10 μL Example 26 3,5-Diamino-6-chloro-pyrazine-2-carboyxlic acid[(S)-4-(4-benyloxy-2,2-dimethyl-butyl-imidazolidin-(2Z)-ylidene]-amideStep 1

DEAD (4.49 ml, 28 mmol) is added to a stirred suspension of((S)-5-benzyloxy-1-hydroxymethyl-3,-3-dimethyl-pentyl)-carbamic acidtert-butyl ester (prepared as described in EP 0702004 A2, Rueger et al.,10 g, 0.028 mmol), phthalimide (4.19 g, 0.028 mmol) andPS-triphenylphosphine (29.8 g, 56 mmol) in THF (500 ml), and theresulting reaction is stirred at room temperature for 3 days. Thereaction is filtered to remove the PS-triphenylphosphine resin and theresin is washed with EtOAc (2×50 ml). The solvent is removed in vacuoand the residue is purified by flash chromatography (SiO₂,EtOAc/iso-hexane) to afford[(S)-5-benzyloxy-1-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-3,3-dimethyl-pentyl]-carbamicacid tert-butyl ester as a white solid; [M+H]⁺ 481.

Step 2

Hydrazine (66.6 ml of a 1M solution in THF, 66.6 mmol) is added to asuspension of[(S)-5-benzyloxy-1-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-3,3-dimethyl-pentyl]-carbamicacid tert-butyl ester (4 g, 8.32 mmol) in ethanol (100 ml), and theresulting solution is heated at 40° C. overnight. A fluffy whiteprecipitate forms. The reaction is allowed to cool to room temperatureand diethyl ether (100 ml) is added and the resulting white suspensioncooled at 0° C. for 30 minutes. The white precipitate is removed byfiltration and the solvent removed in vacuo. The residue is then stirredwith diethyl ether (100 ml) for 1 hour, filtered and the solvent isremoved in vacuo to afford((S)-1-Aminomethyl-5-benzyloxy-3,3-dimethyl-pentyl)-carbamic acidtert-butyl ester as a pale yellow oil; [M+H]⁺ 351.

Step 3

Iodotrimethylsilane (1.63 ml, 11.94 mmol) is added dropwise to asolution of ((S)-1-Aminomethyl-5-benzyloxy-3,3-dimethyl-pentyl)-carbamicacid tert-butyl ester (2.79 g, 7.96 mmol) in DCM (30 ml) and theresulting yellow solution is stirred for 1 hour at room temperature. Thereaction is filtered and the filtrate diluted with DCM (50 ml) andwashed with 2 M NaOH (100 ml). The aqueous layer is allowed to standovernight and any product which has oiled out of solution is extractedinto EtOAc (100 ml). The organic layers are combined, dried over MgSO₄,and the solvent is removed in vacuo to yield(S)-Benzyloxy-4,4-dimethyl-hexane-1,2-diamine as a pale yellow oil;[M+H]₊251.

Step 4

A suspension of1-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea(Intermediate A) (2.56 g, 6.87 mmol) and(S)-Benzyloxy-4,4-dimethyl-hexane-1,2-diamine (1.72 g, 6.87 mmol) inpropan-2-ol (50 ml) is heated at 90° C. for 3 hours. The reaction isallowed to cool to room temperature, filtered to remove any insolublematerial and the filter paper is washed with MeOH (50 ml). The filtrateis loaded on to a SCX-2 cartridge which has been pre-eluted with MeOH.The cartridge is eluted with MeOH and then 7M NH₃ in MeOH. Uponstanding, a pale yellow solid crystallises out of the NH₃ in MeOHsolution. The solid is collected by filtration, washed with MeOH (20 ml)and dried in vacuo at 40° C. to afford the title compound. [M+H]+ 446.

Example 27 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(S)-4-(hydroxyl-2,2-dimethyl-butyl)-imidazolidin-(2Z)-ylidene]-amide

To a suspension of 3,5-Diamino-6-chloro-pyrazine-2-carboyxlic acid[(S)-4-(4-benyloxy-2,2-dimethyl-butyl-imidazolidin-(2Z)-ylidene]-amide(Ex. 26) (100 mg, 0.22 mmol) in DCM (5 ml) is added dropwiseiodotrimethylsilane (0.061 ml, 0.448 mmol). The resulting yellowsolution is heated at reflux for 2 days. The reaction is allowed to coolto room temperature and the yellow solid that has formed is collected byfiltration, dissolved in MeOH (3 ml) and loaded onto a 10 g SCX-2cartridge which has been pre-eluted with MeOH. The cartridge is elutedwith MeOH (30 ml) and 7M NH₃ in MeOH (30 ml). The pale yellow 7M NH₃ inMeOH wash is concentrated in vacuo to afford the title compound as ayellow solid. [M+H]⁺ 356.

Example 28 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(S)-4-{4-[4-(S)-2,3-dihydroxy-propoxy)-phenyl]-2,2-dimethyl-butyl}-imidazolidin-(2Z)-ylidene]-amideStep 1

(S)-Glycidol (0.36 ml, 5.5 mmol) is added to a solution of 4-iodophenol(1 g, 4.5 mmol) and triethylamine (31 ml, 0.2 mmol) in ethanol (5 ml)and the resulting light brown solution is heated at reflux for 15 hours.The reaction is allowed to cool to room temperature and the solventremoved in vacuo. The residue is purified by chromatography (SiO₂,EtOAc/iso-hexane) to afford (S)-3-(4-Iodo-phenoxy)-propane-1,2-diol as acolourless oil.

Step 2

2,2-Dimethoxypropane (1.94 ml, 15.8 mmol) and PPTS (0.079 mg, 0.32 mmol)are added to a solution of (S)-3-(4-Iodo-phenoxy)-propane-1,2-diol (0.93g, 3.16 mmol) in DMF (20 ml), and the resulting solution is left to stirat room temperature overnight. The solvent is removed in vacuo and theresidue is purified by chromatography (SiO₂, EtOAc:Iso-hexane) to afford(R)-4-(4-Iodo-phenoxymethyl)-2,2-dimethyl-[1,3]dioxolane as a colourlessoil.

Step 3

DEAD (0.63 ml, 4 mmol) is added to a suspension of((S)-1-Hydroxymethyl-3,3-dimethyl-pent-4-enyl)-carbamic acid tert-butylester (1 g, 4 mmol), phthalimide (588 mg, 4 mmol) andPS-triphenylphosphine (3.72 g, 8 mmol) in THF (50 ml) and the resultingsolution is stirred at room temperature overnight. The resin is removedby filtration, and the filtrate concentrated in vacuo. Purification byflash chromatography (SiO₂, EtOAc/iso-hexane) yields[(S)-1-(1,3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-3,3-dimethyl-pent-4-enyl]-carbamicacid tert-butyl ester as a white solid; [M+H—BOC]⁺ 273.

Step 4

9-BBN (4.63 ml of a 0.5 M solution in THF, 0.23 mmol) is added to asolution of[(S)-1-(1,3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-3,3-dimethyl-pent-4-enyl]-carbamicacid tert-butyl ester (0.43 g, 0.116 mmol) in THF (15 ml) and theresulting colourless solution is stirred at room temperature overnightAnhydrous DMF (15 ml) is added to the solution, followed by 3 M aqueousK₃PO₄ solution (0.77 ml, 2.3 mmol),(R)-4-(4-Iodo-phenoxymethyl)-2,2-dimethyl-[1,3]dioxolane (267 mg, 0.28mmol) and Pd(dppf)Cl₂.DCM (47 mg, 0.058 mmol). The reaction is stirredat room temperature for 3 hours, 50° C. for 2 hours and then is allowedto cool to room temperature and filtered through a pad of Celite™(filter material) which is washed with EtOAc (3×50 ml). The combinedfiltrates are washed with sat. aq. NaHCO₃ solution (30 ml), dried(MgSO₄) and the solvent removed in vacuo to afford a black oil. Multiplechromatography (SiO₂, EtOAc/iso-hexane) yields[(S)-5-[4-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-1-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-3,3-dimethyl-pentyl]-carbamicacid tert-butyl ester as a cream solid; [M+H—BOC]⁺ 481.

Step 5

Hydrazine (2.2 ml of a 1M solution in THF, 2.2 mmol) is added to asolution of[(S)-5-[4-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-1-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-3,3-dimethyl-pentyl]-carbamicacid tert-butyl ester (0.16 g, 0.28 mmol) in ethanol (5 ml), and theresulting colourless solution is heated at 45° C. overnight. Thereaction is allowed to cool to room temperature, and diethyl ether (30ml) is added and the resulting white suspension cooled at 0° C. for 30minutes. The white solid is removed by filtration, and the solventremoved in vacuo to yield{(S)-1-Aminomethyl-5-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-3,3-dimethyl-pentyl}-carbamicacid tert-butyl ester as a colourless oil; [M+H]⁺ 451.

Step 6

A solution of{(S)-1-Aminomethyl-5-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-3,3-dimethyl-pentyl}-carbamicacid tert-butyl ester (0.13 g, 0.28 mmol) and TFA (1 ml) in DCM (5 ml)is stirred at room temperature for 1 hour, then loaded onto an SCX-2cartridge which has been pre-eluted with MeOH. The cartridge is elutedwith MeOH (2×5 ml), followed by 7M NH₃ in MeOH (2×5 ml) to yield(S)-3-[4-((S)-5,6-Diamino-3,3-dimethyl-hexyl)-phenoxy]-propane-1,2-diolin 80% purity as a colourless oil; [M+H]⁺ 311

Step 7

A suspension of(S)-3-[4-((S)-5,6-Diamino-3,3-dimethyl-hexyl)-phenoxy]-propane-1,2-diol(60 mg, 0.19 mmol) and1-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea(Intermediate A) (72 mg, 0.19 mmol) in propan-2-ol (3 ml) is heated at80° C. for 35 minutes. The reaction mixture is allowed to cool to roomtemperature and diluted with MeOH until any solid dissolves. Thesolution is passed through a SCX-2 cartridge which is then eluted withfurther MeOH. The combined methanol elutions are concentrated in vacuo.Reverse phase chromatography (Isolute™ C18, Water/CH₃CN/0.1% TFA) yieldsthe title compound compound as a yellow solid; [M+H]+ 506

Example 29(E)-3,5-diamino-6-chloro-N-(4-(3-(4-((S)-2,3-dihydroxypropoxy)phenyl)propyl)-5-propylimidazolidin-2-ylidene)pyrazine-2-carboxamidehydrochloride Step 1

4-(4-Methoxyphenyl)butyric acid (25 g, 129 mmol) is dissolved in 48% HBr(125 ml) and AcOH (125 ml). The resultant solution is heated at 150° C.overnight. The resultant mixture is concentrated in vacuo and theresidue taken up in EtOAc (500 ml). This solution is washed with water(500 ml), dried (MgSO₄) and concentrated to give4-(4-Hydroxy-phenyl)-butyric acid as a tan solid; ¹H NMR (d6-DMSO): 1.72(2H, tt, J=7.4 and 7.8 Hz), 2.18 (2H, t, J=7.4 Hz), 2.45 (2H, t, J=7.8Hz), 6.66 (2H, dd, J=1.98 and 9.3 Hz), 6.96 (2H, dd, J=2.8 and 9.3 Hz),9.12 (1H, s), 12.0 (1H, s).

Step 2

4-(4-Hydroxy-phenyl)-butyric acid (22.1 g, 123 mmol) is dissolved in THF(750 ml) and borane-dimethyl sulfide (23.3 ml, 245 mmol) is slowlyadded. The yellow suspension formed is heated at reflux for 3 hoursuntil most of the solid slowly dissolves. The flask is removed from theheating mantle, and MeOH is slowly added until bubbling ceases and theresidual solid has dissolved. The flask is cooled to room temperatureand water (1 L) is added. The pH is corrected to 3 with AcOH, then themixture is extracted with EtOAc (2×500 ml). The organics are washed withbrine, dried (MgSO₄) and concentrated. The crude product is slurriedwith silica (500 g) in 25% EtOAc/iso-hexanes (1 L). This is filtered,then flushed with 50% EtOAc/iso-hexanes (2 L) to elute the product. Theorganics are concentrated to give 4-(4-Hydroxy-butyl)-phenol as a brownoil which crystallizes on standing; ¹H NMR (CDCl₃): 1.55-1.72 (4H, m),2.58 (2H, t, J=7.0 Hz), 3.1 (2H, br signal), 3.70 (2H, t, J=6.4 Hz),6.77 (2H, d, J=8.4 Hz), 7.05 (2H, d, J=8.4 Hz).

Step 3

To 4-(4-Hydroxy-butyl)-phenol (32.7 g, 197 mmol) in acetone (600 ml) isadded potassium carbonate (40.8 g, 295 mmol) followed by (S)-glycidol(13.7 ml, 207 mmol). The mixture is heated at reflux overnight. Furtherpotassium carbonate (20 g) is added, followed by (S)-glycidol (5 g) andthe mixture is heated at reflux for 72 hours. The suspension is cooled,filtered and the filtrate concentrated in vacuo. The residue ispartitioned between EtOAc (500 ml) and 5% citric acid solution (500 ml).The organics are separated, dried (MgSO₄) and concentrated in vacuo togive (S)-3-[4-(4-Hydroxy-butyl)-phenoxy]-propane-1,2-diol as a brownoil; ¹H NMR (CDCl₃): 1.56-1.74 (4H, m), 2.20 (1H, t, J=2.46 Hz), 2.61(2H, t, J=7.6 Hz), 3.68 (2H, t, J=6.2 Hz), 3.78 (1H, dd, J=5.4 and 11.5Hz), 3.86 (1H, dd, J=3.9 and 11.5 Hz), 4.0-4.16 (3H, m), 6.85 (2H, d,J=8.6 Hz), 7.12 (2H, d, J=8.6 Hz).

Step 4

To (S)-3-[4-(4-Hydroxy-butyl)-phenoxy]-propane-1,2-diol (43 g, 179 mmol)in THF (700 ml) is added 2,2-dimethoxypropane (94 ml, 760 mmol) followedby PPTS (4.5 g, 17.9 mmol). The resultant mixture is stirred at roomtemperature overnight. The solution is concentrated in vacuo and theresidue taken up in DCM (500 ml). This is washed with water, dried(MgSO₄) and concentrated in vacuo. The residue is purified through asilica plug (300 g) eluting with 10% followed by 25% EtOAc/iso-hexanes.The desired fractions are concentrated to give4-[4-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-butan-1-ol asa clear oil; ¹H NMR (CDCl₃): 1.42, (3H, s), 1.48 (3H, s), 1.53-1.73 (4H,m), 2.20 (1H, t, J=2.5 Hz), 2.60 (2H, t, J=7.2 Hz), 3.68 (2H, t, J=6.4Hz), 3.92 (2H, dt, J=5.8 and 8.5 Hz), 4.07 (1H, dd, J=5.4 and 9.5 Hz),4.19 (1H, dd, J=6.4 and 8.5 Hz), 4.49 (1H, p, J=5.7 Hz), 6.85 (2H, d,J=8.7 Hz), 7.11 (2H, d, J=8.7 Hz).

Step 5

To 4-[4-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-butan-1-ol(5.0 g, 17.8 mmol) in DCM (180 ml) is added Dess-Martin periodinane(7.56 g, 17.8 mmol). The yellowish solution is stirred at roomtemperature for 1 hour. The resultant yellow suspension is treated with1 N NaOH solution (200 ml) and stirred at room temperature for 30minutes. The organic phase is separated, dried (MgSO₄) and concentratedto give4-[4-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-butyraldehydeas a clear oil; ¹H NMR (CDCl₃): 1.42, (3H, s), 1.48 (3H, s), 1.95 (2H,dt, J=7.6 and 14.2 Hz), 2.46 (2H, dt, J=1.5 and 7.3 Hz), 2.62 (2H, t,J=7.6 Hz), 3.90-3.96 (2H, m), 4.07 (1H, dd, J=5.2 and 9.3 Hz), 4.19 (1H,dd, J=6.4 and 8.1 Hz), 4.49 (1H, p, J=5.8 Hz), 6.86 (2H, d, J=9.4 Hz),7.10 (2H, d, J=9.4 Hz), 9.77 (1H, t, J=1.6 Hz).

Step 6

To4-[4-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-butyraldehyde(4.28 g, 15.4 mmol) in THF (150 ml) is added tert-butyl sulfinamide(2.05 g, 16.9 mmol) followed by titanium ethoxide (6.5 ml, 30.8 mmol).The yellow solution formed is stirred at room temperature overnight. Thesolution is quenched with 1 N NaOH (200 ml) and EtOAc (100 ml) andstirred for 30 minutes at room temperature. The resultant mixture isfiltered through Celite™ (filter material) and the organic phase isseparated and dried (MgSO₄).

Concentration in vacuo gives 2-Methyl-propane-2-sulfinic acid[4-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-but-(E)-ylidene]-amideas a yellow oil; [M+H]⁺ 382.23

Step 7

To a solution of 2-Methyl-propane-2-sulfinic acid[4-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-but-(E)-ylidene]-amide(4.51 g, 11.8 mmol) in THF (120 ml) at 0° C. is added vinylmagnesiumbromide (11.8 ml of a 1 M solution in THF, 11.8 mmol) dropwise. Afteraddition is complete, the mixture is stirred at 0° C. for 30 minutesthen quenched with sat. aq. NH₄Cl solution (20 ml). This mixture isallowed to warm to room temperature and diluted with water (50 ml) andEtOAc (50 ml). The organic phase is separated, dried (MgSO₄) andconcentrated in vacuo. Purification by chromatography (SiO₂,EtOAc/iso-hexane) affords 2-Methyl-propane-2-sulfinic acid{4-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-1-vinyl-butyl}-amideas a mixture of diastereomers as a gum; [M+H]⁺ 410.39

Step 8

A solution of 2-methyl-propane-2-sulfinic acid{4-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-1-vinyl-butyl}-amide(1.0 g, 2.4 mmol) in DCM (25 ml) at −78° C. is saturated with oxygen,then ozone (generated using Fischer Technology Ozon Generator 500m)until a blue solution is obtained. Dimethyl sulfide (1.8 ml, 24 mmol) isthen added and the mixture stirred to room temperature over 30 minutes.The resultant solution is washed with water (25 ml) and the organicphase is concentrated under high vacuum at low temperature to give2-Methyl-propane-2-sulfinic acid{4-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-1-formyl-butyl}-amideas an oil; [M+H]⁺ 412.36

Step 9

To a solution of 2-methyl-propane-2-sulfinic acid{4-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-1-formyl-butyl}-amidein THF (20 ml) is added tert-butyl sulfinamide (323 mg, 2.7 mmol)followed by titanium ethoxide (1.0 ml, 4.8 mmol). The yellow solutionformed is stirred at room temperature overnight. The solution isquenched with 1N NaOH (50 ml) and EtOAc (50 ml) and stirred for 30minutes at room temperature. The resultant mixture is filtered throughCelite™ (filter material) and the organic phase separated and dried(MgSO₄). Concentration gives 2-Methyl-propane-2-sulfinic acid(4-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-1-{[(E)-2-methyl-propane-2-sulfinylimino]-methyl}-butyl)-amideas a mixture of diastereomers as a yellow oil; [M+H]⁺ 515.38

Step 10

To a solution of 2-methyl-propane-2-sulfinic acid(4-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-1-{[(E)-2-methyl-propane-2-sulfinylimino]-methyl}-butyl)-amide(907 mg, 1.7 mmol) in THF (20 ml) at 0° C. n-propylmagnesium chloride(1.76 ml of a 2M solution in diethyl ether, 3.52 mmol). The solution isstirred at 0° C. for 30 minutes then at room temperature for 3 hours. Afurther portion of n-propylmagnesium (1.76 ml of a 2M solution indiethyl ether, 3.52 mmol) is added and the mixture is stirred at roomtemperature overnight. The resluting mixture is quenched with sat. aq.NH₄Cl solution (50 ml) and extracted with EtOAc (2×50 ml). The organicphase is dried (MgSO₄) and concentrated in vacuo. The residue isdissolved in EtOAc (10 ml) and treated with 4M HCl/dioxan (10 ml). After10 minutes, the solution is concentrated in vacuo and the residuediluted with DCM (100 ml). This is treated with sat. aq. NaHCO₃ solution(100 ml) and the organic phase is removed and dried (MgSO₄). The DCMsolution is applied to a SCX-2 cartridge (10 g) and this is eluted withDCM and MeOH. The product is released with 2M NH₃ in MeOH, and themethanolic ammonia fraction concentrated to give(S)-3-[4-(4,5-Diamino-octyl)-phenoxy]-propane-1,2-diol as a mixture ofdiastereomers as a gum; [M+H]⁺ 515.38

Step 11

To a solution of (S)-3-[4-(4,5-Diamino-octyl)-phenoxy]-propane-1,2-diol(100 mg, 0.32 mmol) in propan-2-ol (5 ml) is added1-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea(Intermediate A) (121 mg, 0.32 mmol). The resulting suspension is heatedat 90° C. for 2 hours then cooled and concentrated in vacuo. The residueis dissolved in MeOH (20 ml) and applied to a 10 g SCX-2 cartridge. Thisis washed well with MeOH, water and MeCN, and then 2M NH₃ in MeOH. Themethanolic ammonia fraction is concentrated then purified bychromatography (SiO₂, 5-10% 2M NH3 in MeOH/DCM). Concentration of therelevant fractions gives the free base as a gum. This is dissolved inMeOH (10 ml) and treated with 1M HCl in diethyl ether (2 ml).Concentration yields the dihydrochloride salt of(E)-3,5-diamino-6-chloro-N-(4-(3-(4-((S)-2,3-dihydroxypropoxy)phenyl)propyl)-5-propylimidazolidin-2-ylidene)pyrazine-2-carboxamide as ayellow solid; [M+H]⁺ 506.37, 508.36 for Cl isotopes

Example 30(3-{(S)-2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-imidazolidin-4-yl}-propyl)-carbamicacid benzyl ester

1-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea(Intermediate A) (0.97 g, 3.72 mmol) is stirred in a three necked roundbottom flask fitted with a bleach trap and condenser and((S)-4,5-Diamino-pentyl)-carbamic acid benzyl ester (Intermediate S)(0.85 g, 3.38 mmol) in propan-2-ol (20 ml) is added. The reactionmixture is stirred at 85° C. for 66 hours. Purification by catch andrelease resin (SCX-2) followed by elution through a silica pad flushedwith EtOAc, ethanol and MeOH yields the title compound as an orangefoam; [M+H]⁺ 447.1

Example 31 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(S)-4-(3-amino-propyl)-imidazolidin-(2E)-ylidene]-amide

To a solution of(3-{(S)-2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-imidazolidin-4-yl}-propyl)-carbamicacid benzyl ester (Ex. 30) (0.44 g, 0.98 mmol) in DCM (20 ml) is addediodotrimethylsilane (0.27 ml, 1.96 mmol) in a dropwise manner. Theorange suspension is stirred at room temperature for 65 minutes.Purification by catch and release resin (SCX-2) eluting with MeOHfollowed by 7M NH₃ in MeOH yields the title compound as a yellow foam;[M+H]⁺ 313.1

Example 32 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(S)-4-[3-(3-benzyl-ureido)-propyl]-imidazolidin-(2E)-ylidene]-amide

To a solution of 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(S)-4-(3-amino-propyl)-imidazolidin-(2E)-ylidene]-amide (Ex. 31) (0.040g, 0.128 mmol) in DMF (2 ml) is added 1,1′-carbonyldiimidazole (0.023 g,0.141 mmol) and the reaction mixture is stirred for 1 hour at roomtemperature. Benzylamine (0.014 ml, 0.128 mmol) is added and additionalbenzylamine (0.014 ml, 0.128 mmol) is added at hourly intervals for atotal of 3 hours. Purification is by diluting the reaction with 2N NaOH(30 ml) and extracting the product into EtOAc (40 ml). The organic phaseis washed with 2N NaOH (30 ml), dried over MgSO₄ and the solventevaporated in vacuo to yield a yellow oil. The oil is dissolved inmethanol (0.75 ml) and diethyl ether (5 ml) added to triturate a yellowsolid. This solid is filtered off and the filtrate formed a furtherprecipitate. This yellow solid is collected by filtration and rinsedwith diethyl ether to give the title compound; [M+H]⁺ 446.1

Example 33 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(S)-4-(3-phenylmethanesulfonylamino-propyl)-imidazolidin-(2E)-ylidene]-amide

To a solution of 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(S)-4-(3-amino-propyl)-imidazolidin-(2E)-ylidene]-amide (Ex. 31) (0.030g, 0.096 mmol) in DMF (5 ml) at 5° C. is added alpha-toluensulfonylchloride (0.018 g, 0.096 mmol) and triethylamine (0.013 ml, 0.096 mmol).The solution is stirred for 10 minutes. Purification by reverse phasechromatography (Isolute™ C18, 0-100% MeCN in water −0.1% TFA) to affordsthe title compound as a yellow solid; [M+H]⁺ 467.0

Example 34 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(S)-4-(3-phenylacetylamino-propyl)-imidazolidin-(2E)-ylidene]-amide

To a solution of 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(S)-4-(3-amino-propyl)-imidazolidin-(2E)-ylidene]-amide (Ex. 31) (0.030g, 0.96 mmol) in DMF (2 ml), phenylacetyl chloride (0.013 ml, 0.096mmol) is added. The yellow solution is stirred at room temperature for10 minutes. Purification by catch and release resin (SCX-2) eluting withMeOH and 7M NH₃ in MeOH affords the title compound; [M+H]⁺ 430.98

Example 35 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(S)-4-(4-phenylmethanesulfonylamino-butyl)-imidazolidin-(2E)-ylidene]-amide

To a suspension of 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(S)-4-(4-amino-butyl)-imidazolidin-(2E)-ylidene]-amide (Intermediate T)(0.023 g, 0.071 mmol) in DMF (2 ml) is added triethylamine (0.010 ml,0.071 mmol) followed by alpha-toluenesulfonyl chloride (0.014 g, 0.071mmol). The suspension is stirred at room temperature for 30 minutes.Purification by reverse phase chromatography (Isolute™ C18, 0-100% MeCNin water −0.1% TFA) followed by catch and release resin (SCX-2) elutingwith MeOH and 7M NH₃ in MeOH gives the title compound as a yellow solid;[M+H]+ 481.0

Example 36 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(S)-4-(4-phenylacetyl amino-butyl)-imidazolidin-(2E)-ylidene]-amide

To a suspension of 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(S)-4-(4-amino-butyl)-imidazolidin-(2E)-ylidene]-amide (Intermediate T)(0.032 g, 0.098 mmol) in DMF (1 ml) is added triethylamine (0.014 ml,0.098 mmol) followed by phenylacetyl chloride (0.013 ml, 0.098 mmol).The suspension is stirred at room temperature for 90 minutes before afurther 0.5 equivalents of phenylacetyl chloride (0.006 ml, 0.049 mmol)is added. The reaction is left to stir at room temperature for a further18 hours. Purification by reverse phase chromatography (Isolute™ C18,0-100% MeCN in water −0.1% TFA) followed by catch and release resin(SCX-2) eluting with MeOH and 7M NH₃ in MeOH affords the title compoundas an off-white solid; [M+H]+ 445.1

Example 372-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carboxylicacid tert-butyl ester trifluoroacetate

A suspension of 4-amino-4-aminomethyl-piperidine-1-carboxylic acidtert-butyl ester (Intermediate U) (218 g, 0.95 mol) in tert-butanol (6L) and 1-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea(Intermediate A) (338 g, 0.82 mol) is stirred at 40° C. overnight. Thetemperature is then raised to 85° C. and the suspension stirred at thistemperature for a further 4 days. The reaction mixture is concentratedin vacuo and the residue is taken up in water (1 L), sonicated andheated to 45-50° C. The solid is collected by vacuum filtration andwashed with ice cold water, then dried under vacuum at 50° C. overnightto afford the title compound as a yellow solid; [M+H]⁺ 425.1.

Example 38 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride

To a stirred solution of 4M HCl in dioxane (1 L) is added2-[(E)-3,5-diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carboxylicacid tert-butyl ester trifluoroacetate (Ex. 37) (104 g, 193 mmol). Theresulting thick suspension is stirred at room temperature for 2 hours.The product is isolated by vacuum filtration, rinsing with dioxane. Thesolid is dried under vacuum at 50° C. to afford the title compound as adihydrochloride salt as a dark yellow solid; [M+H]⁺=325.

Example 39 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[(S)-3-phenyl-2-(toluene-4-sulfonylamino)-propionyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

To a solution of Tosyl-L-phenylalanine (1.0 g, 3.13 mmol) in DMF (25 ml)is added N-methyl morpholine (1.033 ml, 9.39 mmol) and3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride (Ex. 38)(1.37 g, 3.44 mmol), followed by HATU (1.31 g, 3.44 mmol) and theresulting solution is stirred at room temperature for 20 minutes. Thecrude product is diluted with water (300 ml) and the resultant solid isisolated. Purification by reverse phase chromatography (Isolute™ C18,0-100% MeCN in water −0.1% TFA) followed by catch and release resin(SCX-2) eluted with MeOH and 7M NH₃ in MeOH yields a yellow solid whichis triturated with MeOH and diethyl ether to give the title compound asa free base. The free base is stirred in 5M HCl at 100° C. for 30minutes forming a gum. MeOH (5 ml) is added to the gum and then allsolvent is removed in vacuo. The residue is triturated with MeOH anddiethyl ether to give the title compound; [M+H]⁺ 626.4; ¹H NMR(DMSO-d6): 1.12-1.71 (4H, m), 2.36-2.38 (3H, s), 2.59-2.83 (2H, m),2.93-3.52 (4H, m), 3.41-3.60 (2H, m), 4.42 (1H, m), 7.12 (2H, d, J=6.9Hz), 7.17-7.28 (3H, m), 7.35 (2H, d, J=7.7 Hz), 7.54-7.37 (2H, br), 7.57(2H, d, J=7.7 Hz), 8.12 (1H, d, J=9.0 Hz), 7.70-8.26 (2H, br), 9.22 (1H,s), 9.95 (1H, s), 10.99 (1H, s).

Example 40 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(1-benzenesulfonyl-1H-indole-3-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

To a solution of 1-(phenylsulfonyl)-1H-indole-3-carboxylic acid (1.0 g,3.32 mmol) in DMF (15 ml) is added HATU (1.388 g, 3.65 mmol) andN-methyl morpholine (1.095 ml, 9.96 mmol) and the solution is stirred atroom temperature for 5 minutes.3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride (Ex. 38)(1.452 g, 3.65 mmol) is added and the reaction stirred at roomtemperature for 45 minutes. The reaction mixture is diluted with water(100 ml) and the precipitate that forms is isolated by filtration. Thecrude product is suspended in 2N NaOH and extracted into EtOAc. Theorganic portion is dried over MgSO₄ and concentrated in vacuo to yield abrown solid. The solid is suspended in a 1:1 mixture of water (+0.1%TFA) and acetonitrile. A fine brown solid is removed by filtration andthe yellow filtrate is concentrated in vacuo until 10 ml of solventremains and a pale yellow solid has precipitated. This solid is washedwith 2N NaOH (60 ml) and then suspended in 2N NaOH (100 ml) andextracted into EtOAc (2×100 ml). The organic phases are combined, driedover MgSO₄ and concentrated in vacuo to yield a pale cream solid. Thecream solid is suspended in a 1:4 mixture of EtOAc: iso-hexane (100 ml)and the solid filtered off to give the free base of the title compound,which is suspended in 5 N HCl (20 ml) and stirred for 2 hours. MeOH (20ml) is added to dissolve all solid and the solvent is concentrated invacuo until a yellow solid precipitates. This solid is filtered off,rinsed with water and dried at 40° C. for 18 hours to give the titlecompound; [M+H]⁺ 607.42; ¹H NMR (DMSO-d6): 1.86-1.92 (4H, m), 3.42-3.63(4H, m), 3.68 (2H, s), 7.34 (1H, dd, J+7.5 Hz, J=7.5 Hz), 7.43 (1H, dd,J=7.5 Hz, J=7.5 Hz), 7.36-7.55 (2H, br), 7.62 (1H, d, J=7.5 Hz), 7.63(2H, m), 7.73 (1H, m), 7.99 (1H, d, J=7.5 Hz), 8.06 (2H, obs), 8.07 (1H,s), 7.50-8.16 (2H, br), 9.18 (1H, s), 9.77 (1H, s), 11.09 (1H, s).

Example 41 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[3-(3-isopropoxy-propylsulfamoyl)-benzoyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

To a solution of 3-(3-Isopropoxy-propylsulfamoyl)-benzoic acid(Intermediate V) (1.10 g, 3.65 mmol) in DMF (20 ml) is added HATU (1.53g, 4.02 mmol) and N-methyl morpholine (1.204 ml, 10.95 mmol) and thesolution is stirred at room temperature for 5 minutes.3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride (Ex. 38)(1.60 g, 4.02 mmol) is added and the reaction stirred at roomtemperature for 45 minutes. The reaction mixture is diluted with 2N NaOH(150 ml) and the crude product extracted into EtOAc (2×250 ml). Theorganic phase is dried over MgSO₄ and the solvent evaporated in vacuo toyield a yellow oil. Purification on a Waters preparative Delta 3000 HPLCusing a gradient of water (+0.1% TFA) and acetonitrile yields a yellowoil. 2N NaOH is added to the oil and the product is extracted into EtOAc(2×400 ml). The organic phases are combined, dried over MgSO₄ and thesolvent concentrated in vacuo to a volume of approximately 150 ml. Tothis solution is added iso-hexane (400 ml) and a pale yellow solidprecipitates. This solid is collected by filtration and rinsed withiso-hexane to afford the title compound; [M+H]⁺ 607.98; ¹H Nmr (DMSO):1.00 (6H, d, J=6.0 Hz), 1.55 (2H, m), 1.69-1.79 (4H, m), 2.81 (2H, t,5.9 Hz), 3.29 (2H, tr, J=6.0 Hz), 3.42 (1H, m), 3.44 (2H, br), 3.29-3.82(4H, m), 6.15-7.30 (3H, br), 7.66 (1H, d, J=7.4 Hz), 7.70 (1H, dd, J=7.4Hz, J=7.4 Hz), 7.76 (1H, s), 7.86 (1H, d, J=7.4 Hz), 7.44-8.00 (1H, br),8.00-9.05 (3H, br).

Example 42 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[2-(5-phenyl-4H-[1,2,4]triazol-3-yl)-acetyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

(5-Phenyl-4H[1,2,4]traizol-3-yl)acetic acid (0.48 g, 2.364 mmol), HATU(0.988 g, 2.6 mmol), 5-Diamino-6-chloro-pyrazine-2-carboxylic acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride (Ex. 38)(1.033 g, 2.60 mmol), DMF (20 ml) and N-methyl morpholine (0.78 ml, 7.08mmol) are added to a round bottomed flask and stirred at roomtemperature for 20 minutes. The crude product is precipitated from thereaction mixture by adding water (200 ml) and is isolated by filtration.Purification by reverse phase chromatography (Isolute™ C18, 0-100% MeCNin water −0.1% TFA) yields a yellow semi-solid. This is dissolved inMeOH (100 ml) and left to stand. An off white solid precipitates andthis is collected by filtration to give the title compound; [M+H]⁺510.0; ¹H NMR (DMSO-d6): 1.78-1.94 (4H, m), 3.67 (2H, s), 3.30-3.82 (4H,m), 4.05-4.08 (2H, m), 7.45-7.55 (3H m), 7.01-7.75 (3H, br), 8.05 (2H,d, J=7.1 Hz), 7.78-8.33 (2H, br), 9.24 (1H, s), 9.85 (1H, s), 11.04 (1H,s).

Example 43 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[3-(3-isopropyl-ureido)-benzoyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

3-(3-Isopropyl-ureido)-benzoic acid (Intermediate W) (1.08 g, 4.86 mmol)and HATU (2.03 g, 5.35 mmol) are stirred in DMF (25 ml) at roomtemperature and N-methyl morpholine (1.60 ml, 14.59 mmol) is added. Thesolution is stirred at room temperature for 5 minutes and5-Diamino-6-chloro-pyrazine-2-carboxylic acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride (Ex. 38)(2.13 g, 5.35 mmol) is added. The brown solution is stirred at roomtemperature for 45 minutes. The crude product is precipitated by theaddition of 2N NaOH and collected by filtration. The solid is purifiedby reverse phase chromatography (Isolute™ C18, 0-100% MeCN in water−0.1% TFA). The clean fractions are concentrated in vacuo toapproximately 30 ml and 2N NaOH added. The off white solid is collectedby filtration and rinsed with water to give the title compound; [M+H]⁺529.05; ¹H NMR (DMSO-d6): 1.09 (6H, d, J=6.5 Hz), 1.67-1.73 (4H, m),3.42 (2H, br), 3.75 (1H, septet, J=6.5 Hz), 3.31-3.79 (4H, br), 6.15(1H, d, J=7.5 Hz), 6.70 (2H, br), 6.40-7.01 (1H, br), 6.86 (1H, d, J=7.2Hz), 7.26 (1H, dd, J=8.3 Hz, J=7.2 Hz), 7.31 (1H, d, J=8.3 Hz), 7.53(1H, s), 8.36 (1H, br), 8.48 (1H, br), 8.55 (1H, s), 8.00-9.00 (1H, br).

Example 44 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(2-Benzo[b]thiophen-3-yl-acetyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-Amide

This compound is prepared analogously to Example 43 by replacing3-(3-Isopropyl-ureido)-benzoic acid (Intermediate W) withbenzo[b]thiophene-3-acetic acid. [M+H]⁺ 499.0; ¹H NMR (DMSO-d6):1.59-1.74 (4H, m), 3.42 (2H, s), 3.48-3.95 (4H, m), 3.97 (2H, s),6.20-7.11 (3H, br), 7.38 (1H, m), 7.39 (1H, m), 7.50 (1H, s), 7.83 (1H,d, J=7.3 Hz), 7.97 (1H, d, J=7.6 Hz), 7.75-9.30 (3H, br).

Example 45 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[5-oxo-1-(3-pyrrol-1-yl-propyl)-pyrrolidine-3-carbonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

A solution of 5-Oxo-1-(3-pyrrol-1-yl-propyl)-pyrrolidine-3-carboxylicacid (Intermediate X) (1.15 g, 4.85 mmol), HATU (2.03 g, 5.33 mmol), DMF(20 ml) and N-methyl morpholine (1.60 ml, 14.54 mmol) is stirred at roomtemperature for 5 minutes before5-Diamino-6-chloro-pyrazine-2-carboxylic acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride (Ex. 38)(1.731 g, 5.33 mmol) is added. After stirring for 60 minutes at roomtemperature EtOAc (200 ml) is added and the organic phase is washed with2N NaOH (2×100 ml) and brine (100 ml). The organic phase is dried overMgSO₄ and the solvent evaporated in vacuo. Purification by reverse phasechromatography (Isolute™ C18, 0-100% MeCN in water −0.1% TFA) followedby catch and release resin (SCX-2) eluting with MeOH and 7M NH₃ in MeOHyields a yellow oil. The oil is dissolved in DCM (10 ml) and product isprecipitated out of solution by the addition of iso-hexane to yield ayellow solid which is filtered and rinsed with iso-hexane to yield thetitle product; [M+H]⁺ 542.8; ¹H NMR (DMSO-d6): 1.64-1.70 (4H, m),1.84-1.89 (2H, m), 2.43-2.51 (2H, m), 3.39-3.43 (2H, m), 3.43-3.50 (2H,m), 3.55 (1H, m), 3.40-3.69 (4H, m), 3.84 (2H, m), 5.97 (2H, m),6.65-6.74 (2H, br), 6.75 (2H, m), 6.2-7.6 (1H, br), 7.6-9.5 (1H, br).

Example 46 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(6,7,8,9-tetrahydro-5H-carbazole-3-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

To a stirring solution of 6,7,8,9-Tetrahydro-5H-carbazole-3-carboxylicacid (0.05 g, 0.25 mmol) and HATU (0.11 g, 0.28 mmol) in dry DMF (5 ml)is added N-methyl morpholine (0.08 ml, 0.76 mmol). After 5 minutesstirring at room temperature, 5-Diamino-6-chloro-pyrazine-2-carboxylicacid [1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride(Ex. 38) (0.10 g, 0.28 mmol) is added and the reaction is left to stirat room temperature for 1 hour. Purification by reverse phasechromatography (Isolute™ C18, 0-100% MeCN in water) yields the titlecompound as a yellow powder; [M+H]⁺ 524.2

Example 47 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(1H-indazole-3-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

To a stirring solution of 1H-indazole-3-carboxylic acid (0.041 g, 0.25mmol) and HATU (0.096 g, 0.25 mmol) in dry DMF (4 ml) is added N-methylmorpholine (0.08 ml, 0.76 mmol). After 5 minutes,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride (Ex. 38)(0.10 g, 0.25 mmol) is added and the reaction left to stir at roomtemperature for 1 hour. Purification by reverse phase chromatography(Isolute™ C18, 0-100% MeCN in water −0.1% TFA) yields an oily residuethat is ultrasonicated in acetonitrile to give a yellow suspension. Theyellow solid is collected by filtration and rinsed with acetonitrile toafford the title compound; [M+H]⁺469.17

Example 48 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[2-(2,3-dimethyl-1H-indol-5-yl)-acetyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 47 by replacing1H-indazole-3-carboxylic acid with 2-(2,3-dimethyl-1H-indol-5-yl)aceticacid with 2-(2,3-dimethyl-1H-indol-5-yl)acetic acid. [M+H]⁺ 510.23

Example 49 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(1,2,3-trimethyl-1H-indole-5-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

To a stirring solution of 1,2,3-trimethyl-1H-indole-5-carboxylic acid(0.051 g, 0.25 mmol) and HATU (0.11 g, 0.28 mmol) in dry DMF (5 ml) isadded N-methyl morpholine (0.083 ml, 0.76 mmol). After 5 minutes5-Diamino-6-chloro-pyrazine-2-carboxylic acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride (Ex. 38)(0.10 g, 0.28 mmol) is added and the reaction left to stir at roomtemperature for 1 hour. Purification by chromatography (SiO₂, MeOH/DCM)yields the title compound; [M+H]⁺ 510.1

Example 50 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(1-methyl-1H-indazole-3-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 46 by replacing6,7,8,9-Tetrahydro-5H-carbazole-3-carboxylic acid with1-methyl-1H-indazole-3-carboxylic acid. [M+H]⁺ 483.1

Example 51 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(4-benzyloxy-benzoyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

5-Diamino-6-chloro-pyrazine-2-carboxylic acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride (Ex. 38)(0.05 g, 0.13 mmol), 4-(benzyloxy)benzoic acid (0.029 g, 0.13 mmol),HATU (0.05 g, 0.13 mmol), N-methyl morpholine (0.041 ml, 0.38 mmol) andDMF (2 ml) are stirred together at room temperature for 72 hours. Thereaction mixture is diluted with EtOAc (25 ml) and washed with water (25ml) and sat. NaHCO₃ (25 ml). The organic phase is dried over MgSO₄ andevaporated in vacuo to yield a yellow oil. The oil is dissolved in ethylacetate and a drop of methanol and iso-hexane are added. The resultingpale yellow solid is collected by filtration to give the title compound;[M+H]⁺ 535.1

Example 52 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(3-2,3-dihydro-benzofuran-5-yl-propionyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with 3-(2,3-dihydrobenzofuran-5-yl)propanoicacid. [M+H]⁺ 499.1

Example 53 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(1H-pyrrolo[2,3-b]pyridine-4-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 47 by replacing1H-indazole-3-carboxylic acid with1H-pyrrolo[2,3-b]pyridine-4-carboxylic acid; [M+H]⁺ 469.14

Example 54 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[3-(4-methoxy-phenyl)-propionyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

5-Diamino-6-chloro-pyrazine-2-carboxylic acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride (Ex. 38)(0.05 g, 0.13 mmol), 3-(4-methoxyphenyl)-propionic acid (0.023 g, 0.13mmol), HATU (0.048 g, 0.13 mmol), N-methyl morpholine (0.041 ml, 0.38mmol) and DMF (2 ml) are stirred together at room temperature for 48hours. The reaction mixture is diluted with EtOAc (50 ml) and product isextracted into 1 M HCl. The aqueous phase is basified to pH 12 with 2 NNaOH and product extracted into EtOAc (50 ml). The organic phase isdried over MgSO₄ and the solvent evaporated in vacuo to yield a brownglass. The product is triturated with MeOH and EtOAc to give a palebrown solid as the title compound; [M+H]⁺ 487.0

Example 55 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[3-(4-hydroxy-phenyl)-propionyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 49 by replacing1,2,3-trimethyl-1H-indole-5-carboxylic acid with13-(4-hydroxyphenyl)propionic acid; [M+H]⁺ 472.98

Example 56 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(1H-indole-2-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 46 by replacing6,7,8,9-Tetrahydro-5H-carbazole-3-carboxylic acid with1H-indole-2-carboxylic acid; [M+H]⁺ 468.1

Example 57 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(quinoline-5-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 46 by replacing6,7,8,9-Tetrahydro-5H-carbazole-3-carboxylic acid withquinoline-5-carboxylic acid; [M+H]⁺ 480.1

Example 58 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(4-methyl-2-phenyl-pyrimidine-5-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 45 by replacing5-Oxo-1-(3-pyrrol-1-yl-propyl)-pyrrolidine-3-carboxylic acid(Intermediate X) with 4-methyl-2-phenylpyrimidine-5-carboxylic acid;[M+H]⁺ 521.1

Example 59 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(4-benzyl-morpholine-2-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with 4-benzyl-2-morpholinecarboxylic acidhydrochloride; [M+H]⁺ 528.2

Example 60 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(1H-pyrrolo[2,3-b]pyridine-5-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 47 by replacing1H-indazole-3-carboxylic acid with1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid; [M+H]⁺ 469.1

Example 61 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[4-(4,6-dimethoxy-pyrimidin-2-ylmethoxy)-benzoyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with4-((4,6-dimethoxypyrimidin-2-yl)methoxy)benzoic acid; [M+H]⁺ 597.07

Example 62 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[2-(3-isopropyl-ureido)-pyridine4-carbonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with 2-(3-Isopropyl-ureido)-isonicotinic acid(intermediate Y) [M+H]⁺ 530.2; ¹H NMR (DMSO-d6): 1.13 (6H, d, J=6.5),1.77-1.94 (4H, m), 3.66 (2H, d, J=11), 3.25-3.99 (5H, m), 6.97 (1H, brm), 7.50 (1H, br s), 7.31-7.60 (2H, br s), 7.61 (1H, br s), 7.74-8.25(2H, br s), 8.28 (1H, d, J=5.5), 9.08-9.21 (1H, br s), 9.60-9.80 (1H, brs), 9.70-10.25 (1H, br s), 11.07 (s, 1H)

Example 634-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carbonyl}-indole-1-carboxylicacid isopropylamide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with1-isopropylcarbamoyl-1H-indole-4-carboxylic acid (Intermediate Z):[M+H]⁺ 553.5

Example 64 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[4-(3-isopropyl-ureido)-benzoyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with 4-(3-isopropyl-ureido)-benzoic acid(Intermediate AA); [M+H]⁺ 529.5

Example 65 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[6-(3-isopropyl-ureido)-pyridine-3-carbonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with 6-(3-isopropyl-ureido)-nicotinic acid(Intermediate AB); [M+H]⁺ 530.5

Example 66 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[3-(4-allyloxy-phenyl)-propionyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with 3-(4-allyloxy)phenyl)propanoic acid;[M+H]⁺ 513.4

Example 67 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-{2-[4-(2-methoxy-ethoxymethoxy)-phenyl]-acetyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with[4-(2-methoxy-ethoxymethoxy)-phenyl]-acetic acid (Intermediate AC);547.4

Example 68 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-{3-[4-(2-methoxy-ethoxymethoxy)-phenyl]-propionyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 2.13 by replacing4-(benzyloxy)benzoic acid with3-[4-(2-Methoxy-ethoxymethoxy)-phenyl]-propionic acid (Intermediate AD);[M+H]⁺ 561.0

Example 69 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(3-{4-[2-(tetrahydro-pyran-2yloxy)-ethoxy]-phenyl}-propionyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with3-{4-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-phenyl}-propionic acid(Intermediate AE); [M+H]⁺ 601.1

Example 70 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-{3-[4-(pyridin-4-ylmethoxy)-phenyl]-propionyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with3-[4-(Pyridin-4-ylmethoxy)-phenyl]-propionic acid (Intermediate AF);[M+H]⁺ 564.1

Example 71[4-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]dec-8-yl}-3-oxo-propyl)-phenoxy]-aceticacid tert-butyl

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with3-(4-tert-butoxycarbonylmethoxy-phenyl)-propionic acid (IntermediateAG); [M+H]⁺ 587.5

Example 72 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[3-(4-carbamoylmethoxy-phenyl)-propionyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with 3-(4-Carbamoylmethoxy-phenyl)-propionicacid (Intermediate AH); [M+H]⁺ 530.1

Example 731-[4-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]dec-8-yl}-3-oxo-propyl)-phenoxy]-cyclobutanecarboxylicacid ethyl ester

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with1-[4-(2-Carboxy-ethyl)-phenoxy]-cyclobutanecarboxylic acid ethyl ester(Intermediate AI); [M+H]⁺ 599.1

Example 742-[4-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]dec-8-yl}-3-oxo-propyl)-phenoxy]-2-methyl-propionicacid tert-butyl ester

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with2-[4-(2-Carboxy-ethyl)-phenoxy]-2-methyl-propionic acid tert-butyl ester(Intermediate AJ); [M+H]⁺ 615.2

Example 75[4-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]dec-8-yl}-3-oxo-propyl)-phenoxy]-aceticacid methyl ester

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with3-(4-Methoxycarbonylmethoxy-phenyl)-propionic acid (Intermediate AK);[M+H]⁺ 545.1

Example 764-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carbonyl}-benzoicacid tert-butyl ester

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with 4-(tert-Butoxycarbonyl)benzoic acid;[M+H]⁺ 529.4

Example 77 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(3-isopropyl-2-methyl-1H-indole-5-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with3-isopropyl-2-methyl-1H-indole-5-carboxylic acid; [M+H]⁺ 524

Example 783-[4-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]dec-8-yl}-3-oxo-propyl)-phenyl]-propionicacid propyl ester

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with3-[4-(2-Propoxycarbonyl-ethyl)-phenyl]-propionic acid (intermediate AL);[M+H]⁺ 571

Example 793-[4-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]dec-8-yl}-3-oxo-propyl)-phenyl]-propionicacid ethyl ester

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with3-[4-(2-Ethoxycarbonyl-ethyl)-phenyl]-propionic acid (intermediate AM);[M+H]⁺ 557

Example 803-[4-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]dec-8-yl}-3-oxo-propyl)-phenyl]-propionicacid methyl ester

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with3-[4-(2-Methoxycarbonyl-ethyl)-phenyl]-propionic acid (intermediate AN);[M+H]⁺ 543

Example 813-[4-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]dec-8-yl}-3-oxo-propyl)-phenyl]-propionicacid

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with 3,3′-(1,4-phenylene)dipropanoic acid;[M+H]⁺ 529

Example 82 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[1-(2-phenoxy-ethyl)-1H-indole-4-carbonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with1-(2-Phenoxy-ethyl)-1H-indole-4-carboxylic acid (Intermediate AO);[M+H]⁺ 588

Example 83 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[1-(2-p-tolyl-ethyl)1H-indole-4-carbonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with1-(2-p-Tolyl-ethyl)-1H-indole-4-carboxylic acid (Intermediate AP);[M+H]⁺ 586

Example 84 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-{1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-indole-4-carbonyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with1-[2-(Tetrahydro-pyran-2-yloxy)-ethyl]-1H-indole-4-carboxylic acid(Intermediate AQ); [M+H]⁺ 597

Example 85 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-{1-[2-(4-methoxy-phenoxy)-ethyl]-1H-indole-4-carbonyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with1-[2-(4-Methoxy-phenoxy)-ethyl]-1H-indole-4-carboxylic acid(Intermediate AR); [M+H]⁺ 618

Example 86 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-{1-[2-(4-tert-butyl-phenoxy)-ethyl]-1H-indole-4-carbonyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with1-[2-(4-tert-Butyl-phenoxy)-ethyl]-1H-indole-4-carboxylic acid(Intermediate AS); [M+H]⁺ 644

Example 87 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[1-(2-[1,3]dioxan-2-yl-ethyl)-1H-indole-4-carbonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with1-(2-[1,3]Dioxan-2-yl-ethyl)-1H-indole-4-carboxylic acid (IntermediateAT; [M+H]⁺ 582

Example 88 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[1-(2-hydroxy-ethyl)-2,3-dimethyl-1H-indole-5-carbonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with2,3-Dimethyl-1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-indole-5-carboxylicacid (Intermediate AU); [M+H]⁺ 540

Example 894-(4-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carbonyl}-indol-1-yl)-butyricacid methyl ester

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with1-(4,4,4-Trimethoxy-butyl)-1H-indole-4-carboxylic acid (IntermediateAW); [M+H]⁺ 568

Example 90 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-{1-[2-(2-methoxy-ethoxymethoxy)-ethyl]-1H-indole-4-carbonyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with1-[2-(2-Methoxy-ethoxymethoxy)-ethyl]-1H-indole-4-carboxylic acid(Intermediate AW); [M+H]⁺ 600

Example 91 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(1-diethylcarbamoylmethyl-1H-indole-4-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 51 by replacing4-(benzyloxy)benzoic acid with1-Diethylcarbamoylmethyl-1H-indole-4-carboxylic acid (Intermediate AX);[M+H]⁺ 581

Example 92 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[1-(2-hydroxy-ethyl)-1H-indole-4-carbonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

p-Toluenesulfonic acid monohydrate (1.6 mg, 0.0084 mmol) is added to astirred solution of 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid[8-{1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-indole-4-carbonyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide(Ex. 84) (50 mg, 0.084 mmol) in MeOH (3 ml) and the resulting solutionis stirred at room temperature for 3 hrs, then heated at 50° C. for 16hours. The solvent is removed in vacuo and the residue is dissolved inMeOH (3 ml) and loaded onto a 1 g PEAX cartridge which is eluted withMeOH (20 ml). The filtrate is concentrated in vacuo to afford the titlecompound; [M+H]⁺ 512/514

Example 93

A mixture of 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride (Ex. 38)(300 mg, 0.83 mmol), cis-1,4-cyclohexanedicarboxylic acid (72 mg, 0.42mmol), N-methyl morpholine (0.30 ml, 2.73 mmol) and HATU (315 mg, 0.83mmol) in anhydrous DMF is stirred at room temperature for 16 hours. Thereaction mixture is concentrated in vacuo and is subjected to columnchromatography (basic alumina, 0-3% MeOH in DCM) to obtain off-whitesolid. The product is dissolved in DCM and re-precipitated by additionof diethyl ether. The supernatant solvent mixture is decanted and theproduct is washed again with diethyl ether and dried under vacuum toafford the compound shown as off-white solid; [M+H]⁺ 785.

Example 94

This compound is prepared analogously to Example 93 by replacingcis-1,4-cyclohexanedicarboxylic acid withtrans-1,4-cyclohexanedicarboxylic acid; [M+2H]²⁺ 393

Example 95

This compound is prepared analogously to Example 93 by replacingcis-1,4-cyclohexanedicarboxylic acid with suberic acid; [M+H]⁺ 787

Example 96

This compound is prepared analogously to Example 93 by replacingcis-1,4-cyclohexanedicarboxylic acid with terephthalic acid; [M+H]⁺ 779

Example 97 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[2-(4-benzyloxy-phenyl)-acetyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

A mixture of 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride (Ex. 38)(300 mg, 0.83 mmol), 4-benzyloxyphenylacetic acid (200 mg, 0.83 mmol),N-methyl morpholine (0.40 ml, 3.64 mmol) and HATU (315 mg, 0.83 mmol) inanhydrous DMF (20 ml) is stirred at room temperature for 16 hours. Thereaction mixture is concentrated in vacuo and subjected to columnchromatography (basic alumina, 0-3% MeOH in DCM) to obtain pale yellowsolid. The product is dissolved in DCM and MeOH and re-precipitated byadding diethyl ether. The supernatant solvent mixture is decanted andthe product is washed again with diethyl ether and dried under vacuum toafford the title compound as a pale yellow solid; [M+H]⁺ 549.

Example 98 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[3-(4-benzyloxy-phenyl)-propionyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with 3-(4-benzyloxyphenyl)propionic acid;[M+H]⁺ 563

Example 99 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(1H-indole-4-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with indole-4-carboxylic acid; [M+H]⁺ 468

Example 100 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(1H-indole-5-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with indole-5-carboxylic acid; [M+H]⁺ 468

Example 101 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-phenylacetyl-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with phenylacetic acid; [M+H]⁺ 443

Example 102 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-{4-[6-((S)-2,3-dihydroxy-propoxy)-naphthalen-2-ylmethoxy]-benzoyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amideStep 1

3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-{4-[6-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2-ylmethoxy]-benzoyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amideis prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with4-[6-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2-ylmethoxy]-benzoicacid (Intermediate AY); [M+H]⁺ 715

Step 2:

To a solution of 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid[8-{4-[6-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2-ylmethoxy]-benzoyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide(0.16 g, 0.22 mmol) in MeOH (10 ml) is added SCX-2 resin (˜2 g), theresultant slurry is stirred for 0.5 hours and then the solvent isremoved in vacuo. The slurry is loaded onto a column of SCX-2 resin (˜3g) and eluted with MeOH and then with 2 M NH₃ in MeOH. The methanolicammonia fractions are concentrated in vacuo and the residue istriturated with diethyl ether to obtain3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-{4-[6-((S)-2,3-dihydroxy-propoxy)-naphthalen-2-ylmethoxy]-benzoyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amideas yellow solid; [M+H]⁺ 675

Example 103 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(4-chloro-benzoyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with p-chlorobenzoic acid; [M+H]⁺ 463

Example 104 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(4-{3-[4-((S)-2,3-dihydroxy-propoxy)-phenyl]-propoxy}-benzoyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 102 by replacing4-[6-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2-ylmethoxy]-benzoicacid, (Intermediate AY) with4-{3-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-propoxy}-benzoicacid (Intermediate AZ); [M+H]⁺ 653

Example 105 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[(E)-(3-phenyl-acryloyl)]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with trans-cinnamic acid; [M+H]⁺ 455

Example 106 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-benzoyl-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with benzoic acid; [M+H]⁺ 429

Example 107 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(benzofuran-5-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with benzofuran-5-carboxylic acid; [M+H]⁺469

Example 108 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-hexanoyl-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with hexanoic acid; [M+H]⁺ 423

Example 109 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(3-phenyl-propynoyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with phenylpropionic acid; [M+H]⁺ 453

Example 110 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(1H-imidazole-2-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with 2-imidazolecarboxylic acid; [M+H]⁺ 419

Example 111 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-isobutyryl-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with isobuteric acid; [M+H]⁺ 395

Example 112 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(4-cyano-benzoyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with p-cyanobenzoic acid; [M+H]⁺ 454

Example 113 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(pyridine-3-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with nicotinic acid; [M+H]⁺ 430

Example 1144-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carbonyl}-benzoicacid methyl ester

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with monomethyl terephthalate; [M+H]⁺ 487

Example 115 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(pyrimidine-5-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with pyrimidine-5-carboxylic acid; [M+H]⁺431

Example 116 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(4-hydroxy-benzoyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with 4-hydroxybenzoic acid; [M+H]⁺ 445

Example 117 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-cyclohexane carbonyl-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with cyclohexanecarboxylic acid; [M+H]⁺ 435

Example 118 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(oxazole-4-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with oxazole-4-carboxylic acid; [M+H]⁺ 420

Example 119 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(pyridine-2-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with 2-picolinic acid; [M+H]⁺ 430

Example 120 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(pyridine-4-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with isonicotinic acid; [M+H]⁺ 430

Example 121 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(piperidine-4-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amidehydrochloride

4 M HCl in dioxane (5 ml) is added to a solution of4-{2-[(E)-3,5-diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester (Intermediate BA) (0.14 g, 0.26 mmol) in dioxane(10 ml) and the reaction mixture is stirred at room temperature for 3hours. The reaction mixture is concentrated in vacuo and the yellowsolid obtained is triturated with DCM. The DCM layer is decanted and thecompound is washed with MeOH and dried under vacuum to afford the titlecompound as yellow solid; [M+H]⁺ 436

Example 122 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(1H-imidazole-4-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with 4-imidazolecarboxylic acid; [M+H]⁺ 419

Example 123 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(tetrahydro-pyran-4-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with tetrahydropyran-4-carboxylic acid;[M+H]⁺ 437

Example 124 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(pyrimidine-4-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with pyrimidine-4-carboxylic acid; [M+H]⁺431

Example 125 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(oxazole-5-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with oxazole-5-carboxylic acid; [M+H]⁺ 420

Example 126 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[3-(4-isobutoxy-piperidine-1-sulfonyl)-benzoyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amideStep 1

A solution of N,N-Diisopropylethylamine (0.0078 ml, 0.045 mmol) in THF(1 ml) is added to 4-Isobutoxy-piperidine (0.008 g, 0.05 mmol) followedby a solution of 3-(Chlorosulfonyl)benzoic acid (9.93 mg, 0.045 mmol)and shaken at room temperature for 48 hours. The solution is evaporatedunder vacuum to afford 3-(4-Isobutoxy-piperidine-1-sulfonyl)-benzoicacid which is used without purification; [M+H]⁺ 342.00

Step 2

3-(4-Isobutoxy-piperidine-1-sulfonyl)-benzoic acid (0.03 mmol, 10.2 mg)is treated with a solution of HATU (11.4 mg, 0.03 mmol) in DMF (1 ml)followed by a solution of 3,5-Diamino-6-chloro-pyrazine-2-carboxylicacid [1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride(Ex. 38) (11.9 mg, 0.03 mmol) and N-methyl morpholine (0.010 ml, 0.03mmol) in DMF (1 ml) and shaken at room temperature overnight. Thesolution is evaporated under vacuum, redissolved in DMSO (0.5 ml) andpurified by mass-directed preparative HPLC. The purified fractions areevaporated under vacuum to afford the title compound; [M+H]⁺ 648.4

Examples 127-145

These compounds, namely

-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-{3-[2-(1H-indol-3-yl)-ethylsulfamoyl]-benzoyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 127);-   1-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carbonyl}-benzenesulfonyl)-piperidine-3-carboxylic    acid ethyl ester (Ex. 128);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(3-cyclopentylsulfamoyl-benzoyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 127);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[3-(1-acetyl-piperidin-4-ylsulfamoyl)-benzoyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 130);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-{3-[(tetrahydro-furan-2-ylmethyl)-sulfamoyl]-benzoyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 131);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-{3-[(pyridin-3-ylmethyl)-sulfamoyl]-benzoyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 132);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-{3-[(2,2-dimethoxy-ethyl)-methyl-sulfamoyl]-benzoyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 133);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[3-(2,4-difluoro-benzylsulfamoyl)-benzoyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 134);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[3-(1-pyridin-4-yl-ethylsulfamoyl)-benzoyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 135);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[3-(2-phenyl-morpholine-4-sulfonyl)-benzoyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 136);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[3-(3-difluoromethoxy-benzylsulfamoyl)-benzoyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 137);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[3-(4-pyrrolidin-1-yl-piperidine-1-sulfonyl)-benzoyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 138);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-{3-[(5-methyl-pyrazin-2-ylmethyl)-sulfamoyl]-benzoyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 139);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[3-(dimethylcarbamoylmethyl-sulfamoyl)-benzoyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 140);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[3-(3-benzenesulfonyl-pyrrolidine-1-sulfonyl)-benzoyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 141);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-{3-[([1,3]dioxolan-2-ylmethyl)-sulfamoyl]-benzoyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 142);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-{3-[2-(pyridin-3-yloxy)-propylsulfamoyl]-benzoyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 143);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-{3-[4-(5-trifluoromethyl-pyridin-2-yl)-[1,4]diazepane-1-sulfonyl]-benzoyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 144);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[3-(1,1-dioxo-tetrahydro-1lambda*6*-thiophen-3-ylsulfamoyl)-benzoyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 145);    are made analogously to Examples 126 replacing    4-isobutoxy-piperidine in step 1 with the appropriate amines which    are all commercially available. The compounds are recovered from the    reaction mixture and purified using conventional techniques.

Example 146 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-{3-[3-(4-chlorophenyl)-[1,2,4]oxadiazol-5-yl]-propionyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-amidetrifluoroacetate

N-methyl morpholine (33 l, 0.3 mmol) is added to3-(3-p-Tolyl-[1,2,4]oxadiazol-5-yl)-propionic acid (0.1 mmol), followedby HATU (41.8 mg, 0.11 mmol) dissolved in peptide grade DMF (250 l) and3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride (Ex. 38)(40 mg, 0.1 mmol) dissolved in peptide grade DMF (250 l). The reactionis sealed and shaken overnight at room temperature. Purification is bymass-directed preparative HPLC to give the title compound; [M+H]⁺ 559.3

Example 147 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[1-(toluene-4-sulfonyl)-1H-pyrrole-3-carbonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

A solution of 1-(Toluene-4-sulfonyl)-1H-pyrrole-3-carboxylic acid (0.023g, 0.085 mmol) in NMP (850 l) is added to PS-carbodiimide (190 mg of 1.3mmol/g loading, 0.24 mmol), followed by a solution of3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride (Ex. 38)(0.08 mmol) and N-methyl morpholine (8 l, 0.08 mmol) in NMP (1 ml), andthe resulting reaction mixture is shaken at room temperature. Thereaction mixture is filtered and the resin is washed with NMP (1 ml).The collected filtrate is concentrated in vacuo and the residues arepurified by mass-directed preparative HPLC. The purified fractions areevaporated under vacuum to afford the title compound; [M+H]⁺ 572.08

Example 148 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[1-(3,4-difluoro-benzyl)-6-oxo-1,6-dihydro-pyridine-3-carbonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

A solution of1-(3,4-Difluoro-benzyl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid(0.15 mmol) in NMP (0.5 ml) is added to a solution of3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride (Ex. 38)(0.049 g, 0.15 mmol) and N-methyl morpholine (0.033 ml, 0.30 mmol) inNMP (1 ml), followed by a solution of HATU (0.11 g, 0.3 mmol) in NMP(0.5 ml). The reaction mixture is shaken at room temperature overnight.The reaction mixture is purified by mass-directed preparative HPLC.Fractions containing pure product are eluted through SCX-2 cartridges(Biotage 1 g/6 ml cartridge), and the cartridge is washed with MeOH (4ml), followed by 3M NH₃ in MeOH solution (4 ml) to afford the titlecompound; [M+H]⁺ 572.0

Examples 149-213

These compounds, namely 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-[4-(3-phenyl-isoxazol-5-yl)-butyryl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-amide(Ex. 149);

-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[4-(5-fluoro-2,3-dihydro-indol-1yl)-4-oxo-butyryl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-amide    (Ex. 150);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-{4-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5yl]-butyryl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-amide    (Ex. 151);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(4-1H-indazol-3-yl-butyryl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-amide    (Ex. 152);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[4-(5-methanesulfonyl-2,3-dihydro-indol-1yl)-4-oxo-butyryl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-amide    (Ex. 153);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(4-benzothiazol-2-yl-butyryl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-amide    (Ex. 154);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[4-(5-dimethylsulfamoyl-2,3-dihydro-indol-1yl)-4-oxo-butyryl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-amide    (Ex. 155);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[4-(2-oxo-2,3-dihydro-1H-indol-3yl)-butyryl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-amide    (Ex. 156);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[4-(6-dimethylamino-9H-purin-8yl)-butryrl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-amide    (Ex. 157);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[4-(2-oxo-3-pyridin-3yl-2,3-dihydro-benzoimidazol-1-yl)-butyryl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-amide    (Ex. 158);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[4-(2-oxo-3-pyridine-3ylmethyl-2,3-dihydro-indol-1-yl)-butryrl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-amide    (Ex. 159);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[4-(9-oxo-3,3a,4,9,10,10a-hexahydro-1H-2-aza-benzol[F]azulen-2yl)-butyryl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-amide    (Ex. 160);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[4-(6-amino-9H-purine-8yl)-butyryl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-amide    (Ex. 161);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(4-oxo-4-pyrrolidin-1-yl-butyryl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-amide    (Ex. 162);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(4-[1,2,4]triazol-1-yl-butyryl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-amide    (Ex. 163);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(5-dibenzylsulfamoyl-1-methyl-1H-pyrrole-2-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 164);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-{4-[3-(4-chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-butyryl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 165);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-{4-[(naphthalene-1-sulfonylamino)-methyl]-benzoyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 166);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-{2[3-(4-chlorophenyl)-[1,2,4]oxadiazol-5-yl]-acetyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-amide    (Ex. 167);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[3-(3-methoxy-propoxy)-benzoyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 168);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(2-benzotriazol-2-yl-acetyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 169) 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(2-benzotriazol-2-yl-acetyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 170);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[4-(2-isopropoxy-ethylamino)-benzoyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 171);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[6-oxo-1-(3-trifluoromethyl-benzyl)-1,6-dihydro-pyridine-3-carbonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 172);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[6-(4-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 173);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[3-(4-fluoro-phenyl)-5-methyl-isoxazole-4-carbonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 174);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-{3-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-propionyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 175);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[2-(4-trifluoromethoxy-phenoxy)-acetyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 176);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-{2-[4-(2-oxo-imidazolidin-1-yl)-phenyl]-acetyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 177);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[3-(3-phenyl-isoxazol-5-yl)-propionyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 178);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[2-(4-methanesulfonyl-phenyl)-acetyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 179);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[2-(4-chloro-phenyl)-thiazole-4-carbonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 180);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 181);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[5-(pyridin-3-yloxy)-furan-2-carbonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 182);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[3-(4-methyl-thiazol-5-yl)-propionyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 183);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(2-methyl-5-propyl-2H-pyrazole-3-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 184);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[(S)-2-acetylamino-3-(4-isopropoxy-phenyl)-propionyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 185);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[3-(cyclohexyl-methyl-sulfamoyl)-4-methoxy-benzoyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 186);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-{2-[4-(3,5-dimethyl-benzenesulfonyl)-piperazin-1-yl]-acetyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 187);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(3-1H-indol-3-yl-propionyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 188);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-{3-[4-(4,6-dimethyl-pyrimidin-2-ylsulfamoyl)-phenylcarbamoyl]-propionyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 189); (Ex. 190);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[3-(2-oxo-5-trifluoromethyl-2H-pyridin-1-yl)-propionyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 191);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[3-(4-sulfamoyl-phenylcarbamoyl)-propionyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 192);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(1-benzyl-5-oxo-pyrrolidine-3-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 193);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[(R)-2-acetylamino-3-(1H-indol-3-yl)-propionyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 194);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[4-(1-benzenesulfonyl-1H-pyrrol-3-yl)-4-oxo-butyryl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-amide    (Ex. 195);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(1-furan-2-ylmethyl-5-oxo-pyrrolidine-3-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 196);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(6-pyrazol-1-yl-pyridine-3-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 197);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[3-((R)-1-phenyl-ethylcarbamoyl)-propionyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 198);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[1-(4-chloro-benzyl)-5-oxo-pyrrolidine-3-carbonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 199);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[2-(3-tert-butyl-isoxazol-5-yl)-acetyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 200);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[6-(2,2,2-trifluoro-ethoxy)-pyridine-3-carbonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 201);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(4-methyl-2-pyridin-3-yl-thiazole-5-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 202);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(3-pyridin-3-yl-propionyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 203);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(5-dimethylsulfamoyl-2-methyl-furan-3-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 204);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(1-ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 205);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(2-pyrazol-1-yl-acetyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 206);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-{3-chloro-5-methoxy-4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-benzoyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 207);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(3-imidazol-1-yl-propionyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 208);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(1-benzyl-1H-imidazole-4-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 209);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[2-(1,1-dioxo-1lambda*6*-thiomorpholin-4-yl)-3-methyl-butyryl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 210);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[4-(toluene-4-sulfonylamino)-butyryl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 211);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 212);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(3-hydroxy-pyridine-2-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 213);    are made analogously to Examples 146, 147 or 148 replacing the    carboxylic acid reagents with the appropriate carboxylic acids which    are all commercially available or prepared as described in section    ‘Preparation of Intermediate Compounds’. The compounds are recovered    from the reaction mixture and purified using conventional    techniques.

Example 2141-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triayrazine-2-carbonylimino]-1,3,8-triazenesulfonyl)-piperidine-3-carboxylicacid

1-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carbonyl}-benzenesulfonyl)-piperidine-3-carboxylicacid ethyl ester (Ex. 128) (0.29 g, 0.45 mmol) is dissolved in THF (4ml) and 2M LiOH (0.22 ml, 0.45 mmol) added. The yellow solution isstirred at room temperature for 5 hours. On concentration in vacuo theresulting sticky yellow solid is ultrasonicated in water (15 ml) untilcomplete dissolution. The pH is adjusted to pH 2 by addition of 1 N HCl.The resultant yellow solid is collected by filtration and rinsed withwater to yield the title compound; [M+H]⁺ 620.1

Example 2152-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carboxylicacid benzylamide

To a solution of benzylamine (0.017 ml, 0.154 mmol) in DMF (1 ml) isadded 1,1′-carbonyldiimidazole (0.03 g, 0.17 mmol) and the resultingsolution is stirred at room temperature for 45 minutes. To this is added5-Diamino-6-chloro-pyrazine-2-carboxylic acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride (Ex. 38)(0.05 g, 0.15 mmol) and the yellow suspension is stirred for 24 hours.Purification by reverse phase chromatography (Isolute™ C18, 0-100% MeCNin water −0.1% TFA) followed by catch and release resin (SCX-2) elutingwith MeOH and 7M NH₃ in MeOH affords the title compound as an off whitesolid; [M+H]⁺ 458.1

Examples 216-231

These compounds, namely

-   2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carboxylic    acid phenylamide (Ex. 216),-   2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carboxylic    acid [1-(toluene-4-sulfonyl)-1H-indol-5-yl]-amide (Ex. 217);-   2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carboxylic    acid 3-(4-chloro-phenoxymethyl)-benzylamide (Ex. 218);-   2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carboxylic    acid [3-(2,4-dichloro-phenyl)-propyl]-amide (Ex. 219);-   2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carboxylic    acid [2-(3-benzyloxy-phenyl)-ethyl]-amide (Ex. 220);-   2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carboxylic    acid [2-(5,6-dimethyl-1H-indol-3-yl)-ethyl]-amide (Ex. 221);-   2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carboxylic    acid 4-morpholin-4-ylmethyl-benzylamide (Ex. 222);-   2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carboxylic    acid 3-benzyloxy-benzylamide (Ex. 223);-   2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carboxylic    acid (2-{4-[2-(4-fluoro-phenyl)-ethoxy]-phenyl}-ethyl)-amide (Ex.    224);-   2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carboxylic    acid [2-(3,5-dimethoxy-phenyl)-ethyl]-amide (Ex. 225);-   2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carboxylic    acid [3-(4-methoxy-naphthalen-1-yl)-propyl]-amide (Ex. 226);-   2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carboxylic    acid [2-(4,6-dimethyl-1H-indol-3-yl)-ethyl]-amide (Ex. 227);-   2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carboxylic    acid (3-pyridin-2-yl-propyl)-amide (Ex. 228);-   2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carboxylic    acid {2-[4-(4-phenyl-butoxy)-phenyl]-ethyl}-amide (Ex. 229);-   2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carboxylic    acid [2-(4-phenoxy-phenyl)-ethyl]-amide (Ex. 230);-   2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carboxylic    acid [2-(4-benzyloxy-phenyl)-ethyl]-amide (Ex. 231);    are prepared by an analogous procedure to Example 215, replacing    benzylamine with the appropriate amines which are either    commercially available or synthesized as described in the section    ‘Preparation of Intermediate compounds’. The compounds are recovered    from reaction mixtures and purified using conventional techniques    such as flash chromatography, filtration, recrystallisation and    trituration.

Example 232 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-phenylmethanesulfonyl-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

To a solution of 5-Diamino-6-chloro-pyrazine-2-carboxylic acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride (Ex. 38)(0.05 g, 0.15 mmol) in DMF (2 ml) is added alpha-toluenesulfonylchloride (0.04 g, 0.20 mmol) and triethylamine (0.02 ml, 0.15 mmol) andthe yellow solution is stirred at room temperature for 2 hours.Purification by reverse phase chromatography (Isolute™ C18, 0-100% MeCNin water −0.1% TFA) followed by catch and release resin (SCX-2) elutingwith MeOH and 7M NH₃ in MeOH affords the title compound as a yellowsolid; [M+H]⁺ 478.98

Examples 233-245

The following compounds, namely

-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-benzenesulfonyl-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 233);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(1-methyl-1H-indole-4-sulfonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 234);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(1-methyl-1H-indole-5-sulfonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 235);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(7-chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 236);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(2-phenyl-ethanesulfonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 237);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 238);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(4-phenyl-5-trifluoromethyl-thiophene-3-sulfonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 239);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(5-cyano-2-methoxy-benzenesulfonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 240);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[2-(4-chloro-phenyl)-ethanesulfonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 241);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-(2-phenyl-3H-benzoimidazole-5-sulfonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 242);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[2-(2-chloro-phenyl)-ethanesulfonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 243);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 244);-   3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid    [8-[2-(3-chloro-phenyl)-ethanesulfonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide    (Ex. 245);    are prepared by an analogous procedure to Example 232, replacing    alpha-toluenesulfonyl chloride with the appropriate sulfonyl    chlorides which are either commercially available or synthesized as    described in the section ‘Preparation of Intermediate compounds’.    The compounds are recovered from reaction mixtures and purified    using conventional techniques such as flash chromatography,    filtration, recrystallisation and trituration.

Example 246 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(1-phenyl-ethyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

A mixture of1-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea(Intermediate A) (1.7 g, 4.54 mmol) and4-aminomethyl-1-(1-phenyl-ethyl)-piperidin-4-ylamine (Intermediate BM)(1.6 g, 4.59 mmol) in propan-2-ol (50 ml) is stirred at 80° C. for 16hours. The reaction mixture is concentrated in vacuo and purified bycolumn chromatography (basic alumina, 0-2% MeOH in DCM) to obtain paleyellow solid. The compound obtained is further dissolved in MeOH andprecipitated by adding diethyl ether. The supernatant solvent mixture isdecanted and the product is washed again with diethyl ether and driedunder vacuum to afford the title compound as off-white solid; [M+H]⁺ 429

Example 247 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(4-methoxy-benzyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 246 by replacing4-aminomethyl-1-(1-phenyl-ethyl)-piperidin-4-ylamine (Intermediate BM)with 4-aminomethyl-1-(4-methoxy-benzyl)-piperidin-4-ylamine(Intermediate BN) [M+H]⁺ 445.

Example 248 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-pyridin-4-ylmethyl-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 246 by replacing4-aminomethyl-1-(1-phenyl-ethyl)-piperidin-4-ylamine (Intermediate BM)with 4-aminomethyl-1-pyridin-4-ylmethyl-piperidin-4-ylamine(Intermediate BO); [M+H]⁺=416

Example 249 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-(3-phenyl-propyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 246 by replacing4-aminomethyl-1-(1-phenyl-ethyl)-piperidin-4-ylamine (Intermediate BM)with 4-aminomethyl-1-(3-phenyl-propyl)-piperidin-4-ylamine (IntermediateBP) [M+H]⁺ 443

Example 250 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-cyclohexylmethyl-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide

This compound is prepared analogously to Example 246 by replacing4-aminomethyl-1-(1-phenyl-ethyl)-piperidin-4-ylamine (Intermediate BM)with 4-aminomethyl-1-cyclohexylmethyl-piperidin-4-ylamine (IntermediateBQ) [M+H]⁺ 421

Example 251 (E)-tert-Butyl2′-(3,5-diamino-6-chloropyrazine-2-carbonylimino)-8-azaspiro[bicyclo[3.2.1]octane-3,4′-imidazolidine]-8-carboxylate

This compound is prepared analogously to Example 246 by replacing4-aminomethyl-1-(1-phenyl-ethyl)-piperidin-4-ylamine (Intermediate BM)with 3-amino-3-aminomethyl-8-aza-bicyclo[3.2.1]octane-8-carboxylic acidtert-butyl ester (Intermediate BR) [M+H]⁺ 451

Example 252(E)-N-(8-(1H-indole-4-carbonyl)-8-azaspiro[bicyclo[3.2.1]octane-3,4′-imidazolidine]-2′-ylidene)-3,5-diamino-6-chloropyrazine-2-carboxamideStep 1

Iodotrimethylsilane (0.23 ml, 1.66 mmol) is added to a suspension of(E)-tert-Butyl2′-(3,5-diamino-6-chloropyrazine-2-carbonylimino)-8-azaspiro[bicyclo[3.2.1]octane-3,4′-imidazolidine]-8-carboxylate(Ex. 251) (500 mg, 1.11 mmol) in DCM (10 ml). DMF (5 ml) is then addedand the reaction is stirred at room temperature overnight.Iodotrimethylsilane (0.5 ml) is added and the reaction mixture isconcentrated in vacuo. The yellow solid is suspended in DCM andcollected by filtration. The solid is dissolved in 1:1 MeOH/DCM andloaded onto an SCX-2 cartridge eluted with DCM followed by MeOH andNH3/MeOH. The methanolic ammonia fractions are concentrated in vacuo toafford(E)-3,5-diamino-6-chloro-N-(8-azaspiro[bicyclo[3.2.1]octane-3,4′-imidazolidine]-2′-ylidene)pyrazine-2-carboxamideas a yellow gum; [M+H]+ 351

Step 2

(E)-3,5-diamino-6-chloro-N-(8-azaspiro[bicyclo[3.2.1]octane-3,4′-imidazolidine]-2′-ylidene)pyrazine-2-carboxamide(170 mg, 0.49 mmol) is dissolved in DMF (10 ml) along with HATU (184 mg,0.49 mmol) and 4-indole-carboxylic acid (78 mg, 0.49 mmol). N-Methylmorpholine (160 ml, 1.45 mmol) is added and the solution stirred at roomtemperature overnight. The mixture is then concentrated in vacuo. EtOAc(100 ml) is added and the solution washed with water (100 ml). Theorganic phase is dried (MgSO₄) and concentrated in vacuo. Purificationby flash chromatography (SiO₂, DCM/MeOH) gives the title compound as ayellow solid; [M+H]⁺ 494.15, 496.27 for Cl isotopes.

Example 253(E)-3,5-diamino-N-(8-(3-(4-(benzyloxy)phenyl)propanoyl)-8-azaspiro[bicyclo[3.2.1]octane-3,4′-imidazolidine]-2′-ylidene)-6-chloropyrazine-2-carboxamide

(E)-3,5-diamino-6-chloro-N-(8-azaspiro[bicyclo[3.2.1]octane-3,4′-imidazolidine]-2′-ylidene)pyrazine-2-carboxamide(prepared as described for Ex. 252) (280 mg, 0.798 mmol) is dissolved inDMF (8 ml) along with HATU (303 mg, 0.798 mmol) and3-(4-benzyloxy-phenyl)-propionic acid (205 mg, 0.798 mmol). N-Methylmorpholine (0.263 ml, 2.394 mmol) is added and the solution stirred atroom temperature for 6 hours. The mixture is then concentrated in vacuo.EtOAc (100 ml) is added and the solution washed with water (100 ml). Theorganic phase is dried (MgSO₄) and concentrated. The residue isdissolved in MeOH (20 ml) and dry loaded onto silica (5 g). Purificationby flash chromatography (SiO₂, DCM/MeOH) gives the title compound as atan solid; [M+H]⁺ 589.20, 591.19 for Cl isotopes.

PREPARATION OF INTERMEDIATE COMPOUNDS Intermediate A1-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothioureahydroiodide Method 1

This compound is prepared according to Cragoe, Edward J., Jr.;Woltersdorf, Otto W., Jr.; De Solms, Susan Jane.Heterocyclic-substituted pyrazinoylguanidines, and a pharmaceuticalcomposition containing them. EP 17152 Page 4

Method 2 Step 1

A stirred suspension of 3,5-diamino-6-chloro-pyrazine-2-carboxylic acidmethyl ester (110 g, 542.9 mmol) in MeOH (500 ml) at 5-10° C. (ice-bath)is treated dropwise with a suspension of lithium hydroxide (46.6 g, 1111mmol) in water (500 ml). The reaction mixture is heated to 50° C. for 5hours then cooled to room temperature and stirred overnight. Theresulting precipitate is collected by filtration and dried in a vacuumoven to afford Lithium 3,5-diamino-6-chloro-pyrazine-2-carboxylic acidas the lithium salt (di-hydrate); [M−Li]⁻ 187

Step 2

A stirred suspension of S-methyl-iso-thiourea sulphate (10 g, 35.9 mmol)in toluene (75 ml) is treated with 4 M NaOH (15 ml) at room temperature.To the two-phase mixture is added di-tert butyl dicarbonate (3.27 g, 15mmol) in one portion. The reaction mixture is stirred at roomtemperature for 1 hour, then heated to 60° C. overnight. The organicportion is separated, washed with brine solution, then dried overNa₂SO₄, filtered and concentrated in vacuo to a viscous oil, whichcrystallised under high vacuum to afford tert-Butylamino(methylthio)methylenecarbamate as a colourless solid.

Step 3

A stirring suspension of lithium3,5-diamino-6-chloro-pyrazine-2-carboxylic acid (22.6 g, 98.03 mmol) inDMF (400 ml) is treated portionwise with HATU (41 g, 107.83 mmol), underan inert atmosphere of nitrogen. The reaction mixture is stirred at roomtemperature for 2 hours and then tert-butylamino(methylthio)methylenecarbamate (20.5 g, 107.83 mmol) is addedportion wise over a period of 10 minutes. The reaction mixture isstirred at room temperature for a further 1.5 hours then heated to 50°C. and stirred overnight. The resulting precipitate is hot filtered,washing with water and dried in a vacuum oven (40° C.) overnight toafford tert-Butyl(3,5-diamino-6-chloropyrazine-2-carboxamido)(methylthio)methylenecarbamate; [M+H]⁺ 361

Step 4

tert-Butyl(3,5-diamino-6-chloropyrazine-2-carboxamido)(methylthio)methylenecarbamate (50 g, 139 mmol) is slurried in DCM (500 ml). TFA (53.4 ml,693 mmol) is dissolved in DCM (100 ml) and added dropwise over 45 minsto form a brown solution. The solution is stirred at room temperatureovernight, after which time a yellow precipitate has formed. The solidis collected by filtration, and dried in vacuo to yield the titlecompound; [M+H]⁺ 261.1

Intermediate B ((S)-5,6-Diamino-hexyl)-carbamic acid benzyl ester Step 1

A solution of BOC-lysinol-(Z)—OH (0.5 g, 1.36 mmol) in dry THF (1 ml)under an inert atmosphere of argon is treated with PS-triphenylphosphine(0.91 g, 3.00 mmol/g loading). To this mixture is added phthalimide (0.2g, 1.36 mmol) and DEAD (0.24 ml, 1.50 mmol) in dry THF (4 ml) and thereaction mixture is stirred at room temperature overnight. The resin isremoved by filtration under vacuum and the filtrate is concentrated invacuo. Purification of the crude white solid by chromatography on silicaeluting with 20-50% EtOAc in iso-hexane (1% TEA) affords[(S)-5-Benzyloxycarbonylamino-1-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-pentyl]-carbamicacid tert-butyl ester as a white crystalline solid; [M+H]⁺ 496

Step 2

A solution of[(S)-5-benzyloxycarbonylamino-1-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-pentyl]-carbamicacid tert-butyl ester (0.63 g, 1.27 mmol) in DCM (5.1 ml) and EtOH (5.1ml) is treated with hydrazine hydrate (0.318 g, 6.35 mmol) and thereaction mixture is stirred at room temperature overnight. A whiteprecipitate forms which is removed by filtration and washed with DCM(3×10 ml). The filtrate is concentrated in vacuo and redissolved in DCM(15 ml) and MeOH (2 ml). Undissolved material is removed by filtrationand the filtrate is concentrated in vacuo. The resulting oily yellowsolid is purified by chromatography on silica eluting with 10-50% MeOHin DCM (1% TEA) to afford((S)-1-Aminomethyl-5-benzyloxycarbonylamino-pentyl)-carbamic acidtert-butyl ester as a clear oil; [M+H]⁺ 366

Step 3

A solution of((S)-1-aminomethyl-5-benzyloxycarbonylamino-pentyl)-carbamic acidtert-butyl ester (0.24 g, 0.657 mmol) in DCM (2.4 ml) is treateddropwise with TFA (0.6 ml) and stirred at room temperature for 3 days.The solvent is removed in vacuo to afford((S)-5,6-Diamino-hexyl)-carbamic acid benzyl ester as a yellow oil;[M+H]⁺ 266

Intermediate C

A mixture of 4-[4-(2-amino-ethylamino)-butyl]-phenol andN*1*-[4-(4-methoxy-phenyl)-butyl]-ethane-1,2-diamine

Step 1

A solution of 4-methoxyphenylbutryric acid (6.99 g, 36 mmol) in THF (70ml) is treated with EDCI (7.6 g, 36.9 mmol) followed byN-ethylmorpholine (9.2 ml, 72 mmol). After stirring at room temperaturefor 1 hour, N—BOC-ethylene diamine (5.84 g, 36 mmol) is added and theresulting mixture is stirred at room temperature overnight. The reactionis quenched by addition of saturated sodium hydrogen carbonate solutionand extracted with EtOAc. The organic portion is washed with citric acidsolution, brine, dried (MgSO₄) and concentrated in vacuo until 25 ml ofsolvent remained. The suspension is filtered to afford{2-[4-(4-Methoxy-phenyl)-butyrylamino]-ethyl}-carbamic acid tert-butylester: as a white solid.

Step 2

A solution of {2-[4-(4-methoxy-phenyl)-butyrylamino]-ethyl}-carbamicacid tert-butyl ester (6 g, 17.88 mmol) in dry THF (60 ml) under aninert atmosphere of Argon is treated carefully with borane.THF complex(53.88 ml, 1M Borane in THF). The reaction mixture is heated at refluxfor 2 hours and then allowed to cool to room temperature overnight. Themixture is quenched by addition of MeOH and then heated to 70° C. for afurther 2 hours. After cooling to room temperature, the solvent isremoved in vacuo to afford{2-[4-(4-Methoxy-phenyl)-butylamino]-ethyl}-carbamic acid tert-butylester as a viscous oil; [M+H]⁺ 323

Step 3

A suspension of {2-[4-(4-methoxy-phenyl)-butylamino]-ethyl}-carbamicacid tert-butyl ester (5.85 g, 18.1 mmol) in HBr (30 ml of a 48%solution) is heated at reflux for 2 hours. After cooling to roomtemperature, the solvent is removed in vacuo. The crude residue issuspended in EtOAc and filtered to afford a solid which consisted of amixture of 4-[4-(2-amino-ethylamino)-butyl]-phenol andN*1*-[4-(4-methoxy-phenyl)-butyl]-ethane-1,2-diamine in approximately1:1 ratio; [M+H]⁺ 209 and 223.

Intermediate D (S)-3-(4-methoxy-phenyl)-propane-1,2 diamine

(S)-2-Amino-3-(4-methoxy-phenyl)-propionamide is prepared according tothe procedure described on page 3880, Method 2.1.3 of Journal ofPhysical Chemistry B, 108(12), 3879-3889; 2004 and is reducedanalogously to Intermediate C.

Intermediate E 1-(3,4-Dichloro-phenyl)-ethane-1,2-diamine

This compound is prepared according to the procedure described on page907, Method 5 in the Journal of Medicinal Chemistry (1973), 16(8),901-8.

Intermediate F 4,5-Diaminopentanoic acid dihydrochloride

This compound is prepared according to the procedure described in‘Radiolabeling chelating compounds comprising sulfur atoms, with metalradionuclides.’ EP 300431 page 12, Intermediate 3.

Intermediate G 4-Amino-1-benzyl-piperidine-4-carbonitrile Step 1

To a solution of ammonium chloride (1.73 g, 32.3 mmol) in water (20 ml)is added a 30% ammonia solution (2 ml) followed by1-benzyl-4-piperidone. After 20 minutes sodium cyanide (1.47 g, 30 mmol)is added portionwise over 15 minutes. After stirring for one hour, water(50 ml) is added and the products are extracted with DCM (3×50 ml),dried (MgSO₄) filtered and concentrated in vacuo. Purification bychromatography on silica eluting with 50-100% EtOAc in iso-hexaneaffords 4-Aminomethyl-1-benzyl-piperidine-4-ylamine; [M+H]⁺ 216

Step 2

To a solution of lithium aluminium hydride (1 M in THF, 10.4 ml) in drydiethyl ether (15 ml), cooled to 0° C., under an argon atmosphere isadded dropwise 4-amino methyl-1-benzyl-piperidine-4-ylamine (900 mg,4.18 mmol) in dry diethyl ether (15 ml). The reaction mixture is heatedat reflux for 24 h and then cooled to 0° C. Water (0.25 ml) is addedfollowed by a 15% aqueous NaOH (0.25 ml) and then water (0.7 ml). Afterwarming to room temperature MgSO₄(150 mg) is added and stirred for 15minutes. The solids are removed by suction filtration and the filtrateevaporated to give an oil. The solids are extracted with refluxingdiethyl ether (80 ml) using a Soxhlet extractor for 14 hours. Thediethyl ether is removed in vacuo and the two oils combined and purifiedby chromatography on silica eluting with 10-25% 2M ammonia in methanolsolution in dichloromethane to give4-Amino-1-benzyl-piperidine-4-carbonitrile; [M+H]⁺ 220

Intermediate H5-[4-((R)-2,2-Dimethyl-[1,3]dioxolane-4-ylmethoxy)-phenyl]-pentane-1,2-diamineStep 1

To 3-(4-hydroxyphenyl)-1-propanol (10 g, 66 mmol) and potassiumcarbonate (13.5 g, 100 mmol) in acetone (200 ml) is added (S)-glycidol(6.5 ml, 100 mmol). The mixture is heated at reflux for 18 hours. Aftercooling to room temperature the solvent is removed in vacuo and theresidue partitioned between EtOAc and water. The aqueous layer isfurther extracted twice with EtOAc and the combined organic portions arewashed with water, brine, dried (MgSO₄), filtered and concentrated invacuo. The crude residue is purified by flash column chromatography onsilica eluting with 1:1 EtOAc/iso-hexane to afford(S)-3-[4-(3-Hydroxy-propyl)-phenoxy]-propane-1,2-diol as a white solid;¹H NMR (CDCl₃): 1.20 (1H, br), 1.85 (2H, pent, J=6.8 Hz), 1.98 (1H, br),2.58 (1H, br), 2.65 (2H, tr, J=6.9 Hz), 3.56 (2H, tr, J=6.8 Hz), 3.72(1H, m), 3.83 (1H, m), 4.00 (2H, dd, J=2.1 Hz, J=6.5 Hz), 4.09 (1H, br),6.82 (2H, d, J=7.4 Hz), 7.10 (2H, d, J=7.4 Hz).

Step 2

To (S)-3-[4-(3-hydroxy-propyl)-phenoxy]-propane-1,2-diol (11.5 g, 50.9mmol) in dry DMF (150 ml) is added pyridinium p-toluenesulfonate (1.28g, 5 mmol) and 2,2-dimethoxypropane (31 ml, 250 mmol). The mixture isstirred at room temperature for 18 hours and then the solvent is removedin vacuo. The residue is dissolved in EtOAc (150 ml) and washed withwater, saturated aqueous sodium hydrogen carbonate solution, brine,dried (MgSO₄) and concentrated in vacuo. The residue is purified bychromatography on silica eluting with 1:4 EtOAc/iso-hexane to 1:1EtOAc/iso-hexane to afford(3-[4-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-propan-1-olas a colourless oil; ¹H NMR (CDCl₃): 1.25 (1H, br), 1.39 (3H, s), 1.43(3H, s), 1.85 (2H, pent, J=6.9 Hz), 2.63 (2H, tr, J=6.9 Hz), 3.63 (2H,tr, J=6.9 Hz), 3.90 (2H, m), 4.02 (1H, m), 4.12 (1H, m), 4.50 (1H, pent,J=6.8 Hz), 6.82 (2H, d, J=7.4 Hz), 7.10 (2H, d, J=7.4 Hz).

Step 3

To(3-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-propan-1-ol(12.2 g, 46 mmol) in dry ether (150 ml) is added TEA (12.8 ml, 92 mmol).The mixture is cooled to 0° C. and treated dropwise with methanesulfonylchloride (5.3 ml, 69 mmol). The reaction mixture is allowed to warm toroom temperature and then stirring continued for 3 hours. The resultingmixture is washed with water (2×100 ml), saturated aqueous sodiumhydrogencarbonate, brine, dried (MgSO₄) and concentrated in vacuo togive Methanesulfonic acid3-[4-((R)-2,2-dimethyl[1,3]dioxolan-4-ylmethoxy)-phenyl]-propylester asa white solid; ¹H NMR (CDCl₃): 1.39 (3H, s), 1.43 (3H, s), 2.02 (2H,pent, J=6.9 Hz), 2.63 (2H, tr, J=6.9 Hz), 3.00 (3H, s), 3.90 (2H, m),4.05 (1H, m), 4.14 (3h, m), 4.46 (1H, pent, J=6.8 Hz), 6.82 (2H, d,J=7.4 Hz), 7.10 (2H, d, J=7.4 Hz).

Step 4

Methanesulfonic acid3-[4-((R)-2,2-dimethyl[1,3]dioxolan-4-ylmethoxy)-phenyl]-propylester(11.8 g, 34.2 mmol) in acetone (200 ml) is treated with lithium bromide(8.9 g, 100 mmol) and then heated at reflux for 5 h. After cooling toroom temperature, the mixture is concentrated in vacuo. The resultingresidue is dissolved in EtOAc (150 ml), washed with water (2×50 ml),brine, dried (MgSO₄), filtered and concentrated in vacuo to give an oil.Purification by chromatography on silica eluting with 4:1iso-hexane/EtOAc gives(R)-4-[4-(3-Bromo-propyl)-phenoxymethyl]-2,2-dimethyl-[1,3]dioxolane asa colourless oil which solidifies; ¹H NMR (CDCl₃): 1.39 (3H, s), 1.43(3H, s), 2.02 (2H, pent, J=6.9 Hz), 2.63 (2H, tr, J=6.9 Hz), 3.38 (2H,tr, J=6.9 Hz), 3.90 (2H, m), 4.02 (1H, m), 4.15 (1H, m), 4.46 (1H, pent,J=6.9 Hz), 6.82 (2H, d, J=7.4 Hz), 7.10 (2H, d, J=7.4 Hz).

Step 5

A solution of N-(diphenylmethylene)aminoacetonitrile (5.14 g, 23.4 mmol)in DCM (12 ml) is treated with(R)-4-[4-(3-bromo-propyl)-phenoxymethyl]-2,2-dimethyl-[1,3]dioxolane(8.1 g, 24 mmol) in DCM (12 ml) and cooled to 0° C. 48% aqueous NaOH (20ml) is added followed by benzyltriethylammonium chloride (530 mg, 2.4mmol) and the resulting mixture is allowed to warm to room temperature.After stirring vigorously for 4 hours mixture is diluted with DCM (100ml) and the aqueous portion is removed. The organic layer is washed withwater (2×50 ml), brine, dried (MgSO₄), filtered and concentrated invacuo. The crude product is purified by chromatography on silica elutingwith 15:1 iso-hexane/diethyl ether to 4:1 iso-hexane/diethyl ether toyield2-(Benzhydrylidene-amino)-5-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]pentanenitrileas a yellow oil; ¹H NMR (CDCl₃): mix of diastereoisomers 1.39 (3H, s),1.43 (3H, s), 1.71 (2H, m), 1.80-1.98 (2H, m), 2.52 (2H, tr, J=7.0 Hz)3.90 (2H, m), 4.02 (1H, m), 4.10-4.22 (2H, m), 4.47 (1H, pent, J=6.9Hz), 6.82 (2H, d, J=7.4 Hz), 7.05 (2H, d, J=7.4 Hz), 7.19 (2H, m), 7.35(2H, tr, J=7.2 Hz), 7.40-7.50 (4H, m), 7.60 (2H, d, J=7.1 Hz).

Step 6

To a solution of2-(benzhydrylidene-amino)-5-[44(R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]pentanenitrile(7.2 g, 15.5 mmol) in THF (50 ml) is added a 2M HCl (aq) (5 ml). Thesolution is heated at 40° C. for 4 hours and then allowed to cool toroom temperature. The pH is adjusted to pH 9-10 using saturated aqueoussodium hydrogen carbonate solution and the organic solvent is removed invacuo. The crude residue is dissolved in EtOAc (100 ml) and washed withwater, brine, dried (MgSO₄), filtered and concentrated in vacuo. Theresulting residue is purified by chromatography on silica eluting with5:1 to 1:1 iso-hexane/ethyl aEtOAc and 1% triethylamine to yield2-Amino-5-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-pentanenitrileas a colourless oil which solidifies; ¹H NMR (CDCl₃): mixture ofdiastereoisomers 1.39 (3H, s), 1.43 (3H, s), 1.70-1.87 (4H, m), 2.60(2H, tr, J=7.1 Hz), 3.62 (1H, br), 3.90 (2H, m), 4.00-4.18 (2H, m), 4.48(1H, pent, J=6.9 Hz), 6.82 (2H, d, J=7.4 Hz), 7.10 (2H, d, J=7.4 Hz).[M+H]⁺ 305

Step 7

A solution of2-amino-5-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-pentanenitrile(1.7 g, 4.28 mmol) in a 2M ammonia in methanol solution (50 ml) ispassed through a H-CUBE apparatus fitted with a Raney nickel CatCart at50° C. and a hydrogen pressure of 50 bar and a flow rate of 1.5 ml/min.After 5 hours of continuous cycling of the solution the reaction mixtureis concentrated in vacuo to give5-[4-((R)-2,2-Dimethyl-[1,3]dioxolane-4-ylmethoxy)-phenyl]-pentane-1,2-diamineas a light-yellow oil; [M+H]⁺ 309

Intermediate I 5-(4-Methoxy-phenyl)-pentane-1,2-diamine

This compound is prepared analogously to Intermediate H by replacing(3-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-propan-1-olwith 4-(4-methoxyphenyl)-1-butanol.

Intermediate J 1-Aminomethyl-cyclopentylamine Step 1

To a cooled 0° C. solution of (1-cyano-cyclopentyl)-carbamic acidtert-butyl ester (430 mg, 2.04 mmol) in dry THF (4.3 ml) under anatmosphere of argon is added dropwise 1.0 M LiAlH₄ (6.13 ml, 6.13 mmol).The reaction mixture is allowed to warm to room temperature and stirredfor 3.5 hours. The mixture is then re-cooled to 0° C. and cautiouslyquenched with water (0.4 ml):15% NaOH (0.8 ml):water (1.2 ml) (1:2:3eq). The resultant mixture is filtered through Celite® (filter material)to remove the inorganic solids and rinsed with MeOH. The filtrate isconcentrated in vacuo, to yield a white solid, which is purified bychromatography on silica eluting with 30% MeOH in DCM to afford(1-Aminomethyl-cyclopentyl)-carbamic acid tert-butyl ester; [M+H]⁺ 215.

Step 2

Iodotrimethylsilane (0.091 ml, 0.67 mmol) is added dropwise to asolution of (1-aminomethyl-cyclopentyl)-carbamic acid tert-butyl ester(120 mg, 0.56 mmol) in DCM (2.4 ml) and left to stir overnight. Theresulting suspension is quenched with MeOH (2.4 ml) and concentrated invacuo to yield 1-Aminomethyl-cyclopentylamine as a dark oil, which isused without further purification.

Intermediate K (4-((R)-4,5-Diamino-pentyl)-phenol Steps 1 and 2

(R)-2-tert-Butoxycarbonylamino-5-(4-tert-butoxy-phenyl)-pentanoic acidethyl ester is prepared according to the procedure of Ding, Chuanyong.;Ma, Rujian.; Rong, Guobin. Preparation of w-Phenyl-(2S)-N-Boc-amino AcidEthyl esters; Chinese Journal of Organic Chemistry Vol 26(12) 2006, 1694&1695, replacing Ethyl Boc-L-pyroglutamate with EthylBoc-D-pyroglutamate & Bromomethyl-benzene with1-Bromo-4-tert-butoxy-benzene in Example 2a, using preparation steps2.2, 2.3, and 2.5; [M+H]⁺ 394

Step 3

(R)-2-tert-Butoxycarbonylamino-5-(4-tert-butoxy-phenyl)-pentanoic acidethyl ester (179 g, 460 mmol) is dissolved in 7M NH₃ in MeOH (400 ml,2800 mmol) and stirred at room temperature for 4 days. The reaction isconcentrated in vacuo keeping the temperature below 30° C. to afford[(R)-4-(4-tert-Butoxy-phenyl)-1-carbamoyl-butyl]-carbamic acidtert-butyl ester [M+H]⁺ 364

Step 4

A solution of [(R)-4-(4-tert-Butoxy-phenyl)-1-carbamoyl-butyl]-carbamicacid tert-butyl ester (167 g, 458 mmol) in 1 M HCl in Et₂O (4000 ml) isstirred at room temperature for 3 days. After this time, a white solidforms which is collected by filtration and washed with Et₂O to yield(R)-2-Amino-5-(4-hydroxy-phenyl)-pentanoic acid amide; [M+H]⁺ 209

Step 5

To a stirred solution of (R)-2-Amino-5-(4-hydroxy-phenyl)-pentanoic acidamide (5 g, 24.01 mmol) in THF (250 ml) is added imidazole (4.90 g, 72mmol), followed by tert-butyldimethylchlorosilane (3.98 g, 26.4 mmol).The resulting solution is heated at 70° C. for 4 hours and then allowedto cool to room temperature. Dilution with Et₂O (200 ml) washing withwater (2×100 ml) and brine (100 ml), drying MgSO₄, and concentration invacuo yields(R)-2-Amino-5-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-pentanoic acidamide; [M+H]⁺ 323

Step 6

A solution of(R)-2-Amino-5-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-pentanoic acidamide (7.74 g, 24 mmol) in THF is stirred at 5° C. and borane (96 ml ofa 1 M solution in THF, 96 mmol) is added. The mixture is stirred at 5°C. until a homogeneous mixture is obtained and then stirred at roomtemperature for 30 minutes and 35° C. for 3 hours. After this time,further borane (24 ml of a 1 M solution in THF, 24 mmol) is added andthe reaction is heated at 35° C. for 18 hours. After this time, afurther portion of borane (24 ml of a 1 M solution in THF, 24 mmol) isadded and the reaction heated at 35° C. for a further 24 hours. Afterthis time, the reaction is cooled to 10° C., and quenched by addingdropwise to MeOH (50 ml) at −5° C. After allowing to warm to roomtemperature the solvent is removed in vacuo to afford a yellow oil. Theoil is dissolved in MeOH (250 ml) and SCX-2 silica (180 g, 0.63 mmol/g,120 mmol) is added. The silica suspension is shaken for 18 hours, thesilica is removed by filtration, washed with MeOH (3×100 ml), thensuspended in 7M NH₃ in MeOH and shaken for 18 hours. The silica isremoved by filtration and the 7M NH₃ in MeOH is removed in vacuo toafford the title compound as a yellow oil; [M+H]⁺ 195

Intermediate L 4-((S)-4,5-Diamino-pentyl)-phenol

This compound is prepared analogously to Intermediate K (NVP-QBM333),replacing Ethyl Boc-D-pyroglutamate in step 1 with EthylBoc-L-pyroglutamate; [M+H]⁺ 195

Intermediate M (R)-tert-butyl5-(4-hydroxyphenyl)pentane-1,2-diyldicarbamate

To a solution of (4-((R)-4,5-Diamino-pentyl)-phenol (Intermediate K)(775 mg, 1.99 mmol) in DCM (10 ml) is added triethylamine (1.14 ml, 8.08mmol) and a solution of di-tert-butyl dicarbonate (1.33 g, 6.08 mmol) inDCM (10 ml) and the resulting solution is stirred at room temperaturefor 18 hours. The solvent is removed in vacuo and the residue purifiedby chromatography (SiO₂, EtOAc/iso-hexane) to afford the title compound;[M+H]⁺ 395

Intermediate N (S)-tert-butyl5-(4-hydroxyphenyl)pentane-1,2-diyldicarbamate

This compound is prepared analogously to Intermediate M, (R)-tert-butyl5-(4-hydroxyphenyl)pentane-1,2-diyldicarbamate replacing Intermediate K,(4-((R)-4,5-Diamino-pentyl)-phenol with Intermediate L,4-((S)-4,5-Diamino-pentyl)-phenol; [M+H]⁺ 395

Intermediate O(R)-3-[4-((R)-4,5-Diamino-pentyl)-phenoxy]-propane-1,2-diol Step 1

Triethylamine (8.37 l, 0.06 mmol) and (R)-(+)-glycidol (96 l, 1.442mmol) are added to a solution of (R)-tert-butyl5-(4-hydroxyphenyl)pentane-1,2-diyldicarbamate (Intermediate M) (474 mg,1.20 mmol) in EtOH (5 ml) and the resulting solution is heated at 90° C.for 18 hours. The reaction is allowed to cool to room temperature andconcentrated in vacuo. Purification by chromatography (SiO₂,EtOAc/iso-hexane) affords{(R)-2-tert-Butoxycarbonylamino-5-[4-((R)-2,3-dihydroxy-propoxy)-phenyl]-pentyl}-carbamicacid tert-butyl ester; [M+H]⁺ 469

Step 2

{(R)-2-tert-Butoxycarbonylamino-5-[4-((R)-2,3-dihydroxy-propoxy)-phenyl]-pentyl}-carbamicacid tert-butyl ester (94 mg, 0.201 mmol) is stirred with a solution of1 M HCl in Et₂O (3 ml) for 18 hours and then loaded onto a 1 g SCX-2cartridge washed with MeOH (30 ml), followed by 7M NH₃ in MeOH (30 ml).The NH₃ fraction is concentrated in vacuo to give the title compound,(R)-3-[4-((R)-4,5-Diamino-pentyl)-phenoxy]-propane-1,2-diol IntermediateH (R)-3-[4-((R)-4,5-Diamino-pentyl)-phenoxy]-propane-1,2-diol; [M+H]⁺269

Intermediate P(R)-3-[4-((S)-4,5-Diamino-pentyl)-phenoxy]-propane-1,2-diol

This compound is prepared analogously to Intermediate O replacing(R)-tert-butyl 5-(4-hydroxyphenyl)pentane-1,2-diyldicarbamate(Intermediate M with (S)-tert-butyl5-(4-hydroxyphenyl)pentane-1,2-diyldicarbamate (Intermediate N); [M+H}⁺269

Intermediate Q2-[4-((R)-4,5-Diamino-pentyl)-phenoxy]-1-morpholin-4-yl-ethanone

(R)-tert-butyl 5-(4-hydroxyphenyl)pentane-1,2-diyldicarbamate(Intermediate M) (446 mg, 0.565 mmol) is dissolved in DMF (10 ml) andCs₂CO₃ (368 mg, 1.131 mmol) and 2-bromo-1-morpholinoethanone (118 mg,0.565 mmol) are added. The reaction is stirred at room temperature for40 minutes, then diluted with water (20 ml) and extracted with EtOAc(2×50 ml). The organic layers are dried over MgSO₄ and the solventconcentrated in vacuo to give a clear oil. Purification bychromatography on a Waters 3000 prep HPLC system (Microsorb™ C18Water/MeCN+0.1% TFA) yields a clear oil, which is dissolved in dioxane(4 ml) and treated with 4 M HCl in dioxane (4 ml) and stirred at roomtemperature for 4 days. Concentration in vacuo affords a white foamwhich is dissolved in MeOH (3 ml) and loaded onto a 10 g SCX-2 cartridgewhich is washed with MeOH (60 ml) and 7M NH₃ in MeOH (60 ml). The NH₃fractions are combined and concentrated in vacuo to give the titlecompound as a colourless oil; [M+H}⁺ 322

Intermediate R 5-(4-Methoxy-phenyl)-hexane-1,2-diamine

This compound is prepared analogously to Intermediate I by replacing4-(4-methoxyphenyl)-1-butanol with 4-(4-methoxyphenyl)-1-pentanol.

Intermediate S ((S)-4,5-Diamino-pentyl)-carbamic acid benzyl ester Step1

Concentrated HCl (15 ml) is added to a suspension ofN—BOC—N—Z-L-ornithine (5.00 g, 13.65 mmol) in 2,2-dimethoxypropane (150ml). An endotherm occurs and the resulting solution is left to stir atroom temperature for 6 hours. The solvent is then reduced in vacuo toapproximately 50 ml and diethyl ether (100 ml) is added to turn thesolution turbid. On stirring a thick white suspension forms. The whitesolid is collected by filtration and rinsed with diethyl ether (100 ml).The white solid is dissolved in MeOH (30 ml) and diethyl ether (200 ml)is added to precipitate a white solid that is collected by filtrationand rinsed with diethyl ether. The solid is dissolved in DCM and washedwith 2 N NaOH (75 ml). The organic phase is dried over MgSO₄ and thesolvent evaporated in vacuo to yield(S)-2-Amino-5-benzyloxycarbonylamino-pentanoic acid methyl ester as acolourless oil; [M+H]⁺ 280.78

Step 2

(S)-2-Amino-5-benzyloxycarbonylamino-pentanoic acid methyl ester (2.80g, 9.99 mmol) and 7M NH₃ in MeOH (20 ml) is stirred at room temperaturefor 72 hours. The reaction mixture is evaporated to dryness in vacuo toyield a white solid. The white solid is suspended in diethyl etherbefore filtration and drying to yield((S)-4-Amino-4-carbamoyl-butyl)-carbamic acid benzyl ester.

Step 3

((S)-4-Amino-4-carbamoyl-butyl)-carbamic acid benzyl ester (1.87 g,7.071 mmol) is suspended in dry THF (40 ml) and cooled to 10° C. in anice bath under nitrogen. Borane (28.3 ml of a 1 M solution in THF, 28.3mmol) is added. The ice bath is removed and the suspension heated to 70°C. and then left to stir at this temperature for 3 hours. Further borane(28.3 ml of a 1 M solution in THF, 28.3 mmol) is added and then after anhour the same amount of 1M borane in THF is added again. After a finalhour at 70° C. the reaction mixture is quenched with MeOH (40 ml). Thesolvent is reduced in vacuo to approximately 50 ml. This is diluted with5 M HCl (100 ml) and washed with diethyl ether (3×100 ml). The aqueousphase is basified to pH12 with 2N NaOH and product extracted into EtOAc(3×100 ml). The organic phases are combined, dried over MgSO₄ and thesolvent evaporated in vacuo to yield the title compound as a colourlessoil.

Intermediate T 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(S)-4-(4-amino-butyl)-imidazolidin-(2E)-ylidene]-amide

To a suspension of(4-{(S)-2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-imidazolidin-4-yl}-butyl)-carbamicacid benzyl ester (Ex. 5) (0.110 g, 0.239 mmol) in dry DCM (20 ml) isadded iodotrimethylsilane (0.130 ml, 0.956 mmol). The reaction mixtureis stirred at room temperature for 3.5 hours. MeOH is added to thesuspension yielding a solution. Purification by catch and release resin(SCX-2) eluting with MeOH and 7 M NH₃ in MeOH yields the title compoundas a brown oil; [M+H]⁺ 327.1

Intermediate U 4-Amino-4-aminomethyl-piperidine-1-carboxylic acidtert-butyl ester Step 1

To a solution of 4-amino-4-cyano-piperidine-1-carboxylic acid tert-butylester (11.5 g, 51.0 mmol) in pyridine (20 ml) at 0° C. is addedtrifluoroacetic anhydride (11.0 ml) slowly and the reaction mixture isstirred at 0° C. for 4 h. The reaction mixture is diluted with DCM,washed with brine, dried over Na₂SO₄ and concentrated in vacuo. Theresidue obtained is dissolved in DCM and re-precipitated by addingpetroleum ether. The supernatant solvent mixture is decanted and theproduct is washed again with petroleum ether and dried under vacuum toafford 4-Cyano-4-(2,2,2-trifluoro-acetylamino)-piperidine-1-carboxylicacid tert-butyl ester as an oil; ¹H NMR (d₆-DMSO): 1.40 (9H, s),1.81-1.88 (2H, m), 2.26-2.32 (2H, m), 2.99-3.15 (2H, m), 3.79-3.82 (2H,m), 10.1 (1H, s).

Step 2

To a solution ofcyano-4-(2,2,2-trifluoro-acetylamino)-piperidine-1-carboxylic acidtert-butyl ester (10.0 g, 31.0 mmol) in EtOH (150 ml) is added Raneynickel (˜1.5 g) and the reaction mixture is stirred under an atmosphereof hydrogen for 3 days. A further quantity of Raney nickel (˜1.5 g) isadded and the reaction mixture is further stirred for 2 days. Thereaction mixture is filtered through a plug of Celite™ (filter material)and the filtrate is concentrated in vacuo to obtain4-Aminomethyl-4-(2,2,2-trifluoro-acetylamino)-piperidine-1-carboxylicacid tert-butyl ester as a viscous oil that is used crude withoutfurther purification.

Step 3 4-Amino-4-aminomethyl-piperidine-1-carboxylic acid tert-butylester

To a solution of4-aminomethyl-4-(2,2,2-trifluoro-acetylamino)-piperidine-1-carboxylicacid tert-butyl ester in MeOH (70 ml) is added a 30% aqueous solution ofammonia (70 ml) and the reaction mixture is stirred at 80° C. overnight.The reaction mixture is concentrated in vacuo to4-Amino-4-aminomethyl-piperidine-1-carboxylic acid tert-butyl ester as abrown oil that is used crude without further purification; [M+H]⁺ 230.

Intermediate V 3-(3-Isopropoxy-propylsulfamoyl)-benzoic acid

3-Isopropoxypropylamine (1.1 eq.) is dissolved in THF with stirring atroom temperature. N,N-diisopropylethylamine (1 eq.) is added followed bymethyl 3-(chlorosulfonyl)benzoic acid (1 eq.). The reaction mixture isstirred at room temperature for 2 hours before the solvent is evaporatedin vacuo to yield the crude titled product.

Intermediate W 3-(3-Isopropyl-ureido)-benzoic acid

A suspension of 3-Aminobenzoic acid (20 g, 145.8 mmol) in THF (300 ml)is heated to 60° C. to form a clear solution. I-propylisocyanate (14.9g, 175 mmol) is added over 30 minutes. During the addition the productstarts to precipitate. After complete addition toluene (300 ml) isadded. The reaction mixture is stirred at 60° C. for 4.5 hours. Theheating bath is removed and the mixture is stirred overnight at roomtemperature. Finally the suspension is filtered and washed with amixture of 1:1 THF:toluene (200 ml). The product is dried at 60° C. for18 hours to yield 3-(3-Isopropyl-ureido)-benzoic acid

Intermediate X 5-Oxo-1-(3-pyrrol-1-yl-propyl)-pyrrolidine-3-carboxylicacid Step 1

To a solution of 5-Oxo-pyrrolidine-3-carboxylic acid methyl ester (1eq.) in dry DMF is added NaH (1.1 eq.) followed by1-(3-bromo-propyl)-1H-pyrrole (1 eq.). The reaction mixture is stirredat room temperature overnight. Purification is by normal phasechromatography to yield5-Oxo-1-(3-pyrrol-1-yl-propyl)-pyrrolidine-3-carboxylic acid methylester.

Step 2

To a cooled solution (0° C.) of5-Oxo-1-(3-pyrrol-1-yl-propyl)-pyrrolidine-3-carboxylic acid methylester in THF, 0.2M LiOH is added and RM is stirred for 3 hours graduallywarming to room temperature. Reaction mixture is acidified with 1N HCland product extracted into ethyl acetate. The organic phase is washedwith brine, dried over magnesium sulphate and the solvent evaporated invacuo to yield 5-oxo-1-(3-pyrrol-1-yl-propyl)-pyrrolidine-3-carboxylicacid.

Intermediate Y 2-(3-Isopropyl-ureido)-isonicotinic acid Step 1

To a solution of ethyl 2-aminoisonicotinate (500 mg, 3.01 mmol) in DMF(10 ml) is added triethylamine (1.26 ml, 9.03 mmol) and then isopropylisocyanate (512 mg, 6.02 mmol). The reaction mixture is heated in amicrowave at 140° C. for 2 hours.

The reaction mixture is diluted with EtOAc, washed with water (×5),brine, dried (MgSO₄) and concentrated in vacuo. Chromatography (SiO₂,MeOH/DCM) affords 2-(3-Isopropyl-ureido)-isonicotinic acid ethyl ester;[M+H]⁺ 252

Step 2

To a solution of 2-(3-Isopropyl-ureido)-isonicotinic acid ethyl ester(130 mg, 0.52 mmol) in MeOH (5 ml) is added 2 M NaOH (2.5 ml) and theresulting solution is stirred for 1.5 hours at room temperature. Thesolvent is removed in vacuo and sat. aq. NH₄Cl solution is added. The pHof the aqueous phase is adjusted to 1 using 1 M HCl and the productextracted into EtOAc, dried (MgSO₄) the solvent removed in vacuo toafford 2-(3-Isopropyl-ureido)-isonicotinic acid as a white solid; [M+H]⁺224

Intermediate Z 1-Isopropylcarbamoyl-1H-indole-4-carboxylic acid

This compound is prepared analogously to Intermediate Y by replacingethyl 2-aminoisonicotinate in step 1 with methyl indol-4-carboxylate;[M+H]⁺ 247

Intermediate AA 4-(3-Isopropyl-ureido)-benzoic acid

This compound is prepared analogously to Intermediate Y by replacingethyl 2-aminoisonicotinate in step 1 with methyl 4-aminobenzoate; [M+H]⁺237.

Intermediate AB 6-(3-Isopropyl-ureido)-nicotinic acid

This compound is prepared analogously to Intermediate Y by replacingethyl 2-aminoisonicotinate in step 1 with methyl 6-aminonicotinate;[M+H]⁺ 224.

Intermediate AC [4-(2-Methoxy-ethoxymethoxy)-phenyl]-acetic acid Step 1

To a solution of methyl 4-hydroxyphenylacetate (200 mg, 1.20 mmol) inDCM (5 ml) is added DIPEA (0.315 ml, 1.81 mmol), and then MEMCl (0.204ml, 1.81 mmol), and the resulting reaction mixture is stirred for 2hours at room temperature. An additional portion of MEMCl (0.102 ml, 1mmol) and of DIPEA (0.158 ml, 1 mmol) are added, and the reactionmixture is stirred for a further 16 hours. An additional portion ofMEMCl (0.102 ml, 1 mmol) and of DIPEA (0.158 ml, 1 mmol) are added andthe reaction mixture is stirred for 3 hours. The reaction mixture isdiluted with DCM and washed with 0.5 M HCl, 1 M NaOH and then 0.5 M HCl,dried (MgSO₄) and concentrated in vacuo to afford[4-(2-Methoxy-ethoxymethoxy)-phenyl]-acetic acid methyl ester

Step 2

To a solution of [4-(2-Methoxy-ethoxymethoxy)-phenyl]-acetic acid methylester (192 mg, 0.76 mmol) in MeOH (3 ml) is added 2 M NaOH (3 ml). Thereaction mixture is stirred for 16 hours at room temperature. Thesolvent is removed in vacuo and the residue dissolved in EtOAc andwashed with sat. aq. NH₄Cl solution, dried (MgSO₄) and concentrated invacuo to yield [4-(2-Methoxy-ethoxymethoxy)-phenyl]-acetic acid

Intermediate AD 3-[4-(2-Methoxy-ethoxymethoxy)-phenyl]-propionic acid

This compound is prepared analogously to Intermediate AC by replacingmethyl 4-hydroxyphenylacetate in step 1 withmethyl-3-(4-hydroxyphenyl)propionate.

Intermediate AE3-{4-[2-(Tetrahydro-pyran-2-yloxy)-ethoxy]-phenyl}-propionic acid Step 1

Methyl 3-(4-hydroxyphenyl)propianoate (0.1 g, 0.55 mmol) is dissolved inDMF (5 ml) and NaH (0.033 g of a 60% dispersion in mineral oil, 0.83mmol) is added. The reaction mixture is stirred at room temperature for15 minutes then 2-(2-bromethoxy)tetrahydro-2-H-pyran (0.109 ml, 0.72mmol) is added and the reaction mixture is left to stir for 18 hours.Dilution with EtOAc (50 ml), washing with water (25 ml), saturatedNaHCO₃ (25 ml) and brine (25 ml), drying over MgSO₄, and concentrationin vacuo yields3-{4-[2-(Tetrahydro-pyran-2-yloxy)-ethoxy]-phenyl}-propionic acid methylester as a colourless oil; [M+H]⁺ 309

Step 2

3-{4-[2-(Tetrahydro-pyran-2-yloxy)-ethoxy]-phenyl}-propionic acid methylester (0.12 g, 0.39 mmol) is dissolved in MeOH (3 ml) and 2M NaOHsolution (3 ml) is added and the resulting solution is stirred at roomtemperature for 18 hours. The reaction mixture is diluted with saturatedammonium chloride solution (20 ml) and extracted with EtOAc (100 ml×2).The organic phased are combined, dried over MgSO₄, the solvent removedin vacuo to yield the title compound as a colourless oil; [M+H]⁺=295

Intermediate AF 3-[4-(Pyridin-4-ylmethoxy)-phenyl]-propionic acid Step 1

To a solution of Methyl 3-(4-hydroxyphenyl)propanoate (0.5 g, 2.77 mmol)in dry DMF (10 ml) is added potassium carbonate (0.76 g, 5.55 mmol)followed by 4-(bromomethyl)pyridine hydrobromide (0.7 g, 2.77 mmol). Thereaction mixture is stirred at room temperature overnight then pouredinto water (80 ml) and extracted with EtOAc (40 ml). The organic phaseis washed with brine, dried (MgSO₄) and the solvent removed in vacuo toyield a dark brown oil. Chromatography (SiO₂, EtOAc) yields3-[4-(Pyridin-4-ylmethoxy)-phenyl]-propionic acid methyl ester as acolourless oil; [M+H]+ 272.0

Step 2

To a solution of 3-[4-(Pyridin-4-ylmethoxy)-phenyl]-propionic acidmethyl ester (0.28 g, 1.03 mmol) in THF (5 ml) and MeOH (5 ml) at roomtemperature is added 2 N LiOH (0.52 ml, 1.032 mmol) and the resultingsolution is stirred overnight. Further 2 N LiOH (0.103 ml) is added andthe reaction mixture stirred for a further 1 hour. The reaction mixtureis concentrated in vacuo and the residue is diluted with water (50 ml)followed by EtOAc. The aqueous phase is acidified to pH2 with 1 N HCl,and extracted with DCM. The organic phase is concentrated to a third ofits volume in vacuo until a white powder precipitates which is collectedby filtration to yield the title compound; [M+H]⁺ 258.0

Intermediate AG 3-(4-tert-Butoxycarbonylmethoxy-phenyl)-propionic acidStep 1

To a stirring solution of methyl 3-(4-hydroxyphenyl)propanoate (2 g,11.10 mmol) in dry DMF (30 ml) at room temperature is added potassiumcarbonate (1.53 g, 11.10 mmol) followed by tert-butyl 2-bromoacetate(2.17 g, 11.10 mmol). The reaction mixture is purged with nitrogen, thenstoppered and left stirring at room temperature for 7 days. The reactionmixture is poured into water (200 ml) and extracted with EtOAc (100 ml),washed with brine, dried (MgSO₄), filtered and evaporated in vacuo toyield a pale yellow oil. Flash chromatography (SiO₂, EtOAc/iso-hexane)yields 3-(4-tert-Butoxycarbonylmethoxy-phenyl)-propionic acid methylester as a clear oil.

Step 2

To a solution of 3-(4-tert-Butoxycarbonylmethoxy-phenyl)-propionic acidmethyl ester (2.70 g, 9.17 mmol) in THF (80 ml) is added 0.2N lithiumhydroxide (45.9 ml, 9.17 mmol) at 0° C. and the reaction mixture isstirred at 0° C. for 4.5 hours. 1M HCl (15 ml) is added and the productis extracted using EtOAc (×3). The organic phase is dried (Na₂SO₄) andconcentrated in vacuo to yield a white solid. Flash chromatography(SiO₂, 10% EtOAc in CH₂Cl₂, then 20% EtOAc in CH₂Cl₂) yields3-(4-tert-Butoxycarbonylmethoxy-phenyl)-propionic acid as a white solid.

Intermediate AH 3-(4-Carbamoylmethoxy-phenyl)-propionic acid

This compound is prepared analogously to Intermediate AG by replacingtert-butyl 2-bromoacetate in step 1 with 2-bromoacetamide; [M+H]¹ 530.1

Intermediate AI 1-[4-(2-Carboxy-ethyl)-phenoxy]-cyclobutanecarboxylicacid ethyl ester

This compound is prepared analogously to Intermediate AG by replacingtert-butyl 2-bromoacetate in step 1 with ethyl1-bromocyclobutane-carboxylate; [M+H]⁺ 293.0

Intermediate AJ 2-[4-(2-Carboxy-ethyl)-phenoxy]-2-methyl-propionic acidtert-butyl ester

This compound is prepared analogously to Intermediate AG by replacingtert-butyl 2-bromoacetate in step 1 with tert-butyl 2-bromoisobutyrate.¹H NMR (DMSO-d6): 1.40 (9H, s), 1.48 (6H, s), 2.49 (2H, t, J=7.5), 2.75(2H, t, J=7.5), 6.71 (2H, d, J=8.5), 7.11 (2H, d, J=8.50), 12.10 (1H,s).

Intermediate AK 3-(4-Methoxycarbonylmethoxy-phenyl)-propionic acid Step1

To a solution of 3-(4-hydroxyphenyl)propanoic acid (3.32 g, 20 mmol) indry DMF (20 ml) is carefully added 1,1′-carbonyldiimidazole (3.24 g, 20mmol) portionwise. The reaction mixture is stirred at 40° C. for 2 hoursafter which time DBU (6.02 ml, 40 mmol) and tert-butanol (4.78 ml, 50mmol) are added and the reaction mixture is now stirred at 65° C. for 2days. The reaction mixture is allowed to cool to room temperature andpoured into water (50 ml) and the product is extracted with diethylether (3×30 ml). The organics are combined, dried (MgSO₄) and thesolvent removed in vacuo to give a yellow oil. Purification by flashchromatography (SiO₂, EtOAc/iso-hexane) yields3-(4-Hydroxy-phenyl)-propionic acid tert-butyl ester as a colourlessoil. 1H NMR (DMSO-d6) 9.1 (1H, s), 7.0 (2H, d, J=8.45), 6.65 (2H, d,J=8.45), 2.7 (2H, t, J=7.28), 2.4 (2H, t, J=7.28), 1.4 (9H, s).

Step 2

To a solution of −(4-Hydroxy-phenyl)-propionic acid tert-butyl ester (1g, 4.50 mmol) in dry DMF (20 ml) at room temperature under argon isadded potassium carbonate (0.62 g, 4.50 mmol) followed by methylbromoacetate (0.43 ml, 4.50 mmol) and the reaction mixture is stirred atroom temperature. The reaction mixture is diluted with EtOAc and washedwith water, dried (MgSO₄) and evaporated in vacuo to yield a clearcolourless liquid. Purification on a Waters 3000 prep HPLC system (C18,MeCN/water) yields 3-(4-Methoxycarbonylmethoxy-phenyl)-propionic acidtert-butyl ester as a pale yellow oil.

Step 3

To 3-(4-Methoxycarbonylmethoxy-phenyl)-propionic acid tert-butyl ester(0.097 g, 0.33 mmol) is added a 90% solution of TFA in DCM (2 ml) andthe resulting solution is stirred at room temperature for 1 hour. Thesolvents are removed in vacuo to yield3-(4-Methoxycarbonylmethoxy-phenyl)-propionic acid as an off-whitepowder; [M+H−18]⁺ 256.0

Intermediate AL 3-[4-(2-Propoxycarbonyl-ethyl)-phenyl]-propionic acid

To a solution of 3,3′-(1,4-phenylene)dipropanoic acid (250 mg, 1.125mmol) DCM (15 ml) is added 4-dimethylaminopyridine (137 mg, 1.125 mmol)and propanol (3 ml, 40.1 mmol). The solution is cooled to 0° C. anddicyclohexylcarbodiimide (232 mg, 1.125 mmol) is added and the resultingsolution is stirred at 0° C. for 30 minutes and 2 hours at roomtemperature. Concentration in vacuo affords a white solid which issuspended in Et₂O (50 ml) and filtered to remove any insoluble material.The filtrate is concentrated in vacuo and purification by chromatography(SiO₂, EtOAc/iso-hexane) affords the title compound.

Intermediate AM 3-[4-(2-Ethoxycarbonyl-ethyl)-phenyl]-propionic acid

This compound is prepared analogously to Intermediate AL replacingpropanol with ethanol.

Intermediate AN 3-[4-(2-Methoxycarbonyl-ethyl)-phenyl]-propionic acid

This compound is prepared analogously to Intermediate AL replacingpropanol with methanol.

Intermediate AO 1-(2-Phenoxy-ethyl)-1H-indole-4-carboxylic acid Step 1

NaH (60% dispersion in mineral oil, 68.5 mg, 1.71 mmol) is added tosolution of methyl indole-4-carboxylate (200 mg, 1.142 mmol) in DMF (5ml) and the resulting suspension is stirred at room temperature for 20minutes. After this time (2-bromoethoxy)benzene (298 mg, 1.484 mmol) isadded and the reaction is stirred at room temperature for 18 hours.Dilution with EtOAc (50 ml) and washing with water (25 ml×2), saturatedNaHCO₃ (25 ml) and brine (25 ml), drying over MgSO₄, concentration invacuo and purification by chromatography (SiO₂, EtOAc/iso-hexane)affords 1-(2-Phenoxy-ethyl)-1H-indole-4-carboxylic acid methyl ester;[M+H]⁺ 296

Step 2

1-(2-Phenoxy-ethyl)-1H-indole-4-carboxylic acid methyl ester (185 mg,0.626 mmol) is suspended in a mixture of MeOH (3 ml) and 2 M NaOH (2ml). The suspension is stirred at room temperature for 2 hours, THF (1ml) is added and the reaction is heated at 60° C. for 1 hour. Thereaction is allowed to cool to room temperature and diluted with sat.NH₄Cl solution (10 ml), extracted with EtOAc (10 ml×3), dried overMgSO₄, and concentrated in vacuo to give the title compound; [M+H]⁺ 282

Intermediate AP 1-(2-p-Tolyl-ethyl)-1H-indole-4-carboxylic acid

This compound is prepared analogously to Intermediate AO replacing(2-bromoethoxy)benzene with 4-methylphenethyl bromide; [M+H]⁺ 280

Intermediate AQ1-[2-(Tetrahydro-pyran-2-yloxy)-ethyl]-1H-indole-4-carboxylic acid

This compound is prepared analogously to Intermediate AO replacing(2-bromoethoxy)benzene with 2-(2-bromoethoxy)tetrahydro-2H-pyran; [M+H]⁺290

Intermediate AR 1-[2-(4-Methoxy-phenoxy)-ethyl]-1H-indole-4-carboxylicacid

This compound is prepared analogously to Intermediate AO replacing(2-bromoethoxy)benzene with 1-(2-bromoethoxy)-4-methoxybenzene; [M+H]⁺312

Intermediate AS1-[2-(4-tert-Butyl-phenoxy)-ethyl]-1H-indole-4-carboxylic acid

This compound is prepared analogously to Intermediate AO replacing(2-bromoethoxy)benzene with 1-(2-bromoethoxy)-4-tert-butylbenzene;[M+H]⁺ 338

Intermediate AT 1-(2-([1,3]Dioxan-2-yl-ethyl)-1H-indole-4-carboxylicacid

This compound is prepared analogously to Intermediate AO replacing(2-bromoethoxy)benzene with (2-bromoethyl)1,3-dioxane; [M+H]⁺ 276

Intermediate AU2,3-Dimethyl-1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-indole-5-carboxylicacid

This compound is prepared analogously to Intermediate AO replacing(2-bromoethoxy)benzene with (2-(2-bromoethoxy)tetrahydro-2H-pyran andreplacing Methyl indole-4-carboxylate with2,3-dimethyl-1H-indole-5-carboxylate; [M+H]⁺ 318

Intermediate AV 1-(4,4,4-Trimethoxy-butyl)-1H-indole-4-carboxylic acid

This compound is prepared analogously to Intermediate AO1-(2-Phenoxy-ethyl)-1H-indole-4-carboxylic acid replacing(2-bromoethoxy)benzene with trimethyl 4-bromoorthobutyrate.

Intermediate AW1-[2-(2-Methoxy-ethoxymethoxy)-ethyl]-1H-indole-4-carboxylic acid Step 1

NaH (60% dispersion in mineral oil, 86 mg, 2.14 mmol) is added to asolution of methyl indole-4-carboxylate (250 mg, 1.427 mmol) in DMF (20ml) and the resulting suspension is stirred at room temperature for 30minutes. After this time (2-(2-bromoethoxy)tetrahydro-2H-pyran (388 mg,1.86 mmol) is added and the reaction is stirred at room temperature for22 hours. Dilution with EtOAc (50 ml), washing with water (25 ml×3),saturated NaHCO₃ (25 ml×2) and brine (25 ml), drying over MgSO₄,concentration in vacuo and purification by chromatography (SiO₂,DCM/MeOH) affords1-[2-(Tetrahydro-pyran-2-yloxy)-ethyl]-1H-indole-4-carboxylic acidmethyl ester; [M+H]⁺ 304

Step 2

To a solution of1-[2-(Tetrahydro-pyran-2-yloxy)-ethyl]-1H-indole-4-carboxylic acidmethyl ester (120 mg, 0.396 mmol) in MeOH (10 ml) is addedp-toluenesulfonic acid monohydrate (7.25 mg, 0.04 mmol). The reaction isstirred at room temperature for 16 hours and the solvent is removed invacuo. The residue is dissolved in MeOH (3 ml) and loaded onto a 1 gPEAX cartridge washed with MeOH (20 ml). The filtrate is concentrated invacuo to give 1-(2-Hydroxy-ethyl)-1H-indole-4-carboxylic acid methylester; [M+H]⁺ 220

Step 3

To a solution of −(2-Hydroxy-ethyl)-1H-indole-4-carboxylic acid methylester in DCM (3 ml) is added DIPEA (0.129 ml, 0.739 mmol) and1-Chloromethoxy-2-methoxy-ethane (0.084 ml, 0.739 mmol). The solution isstirred at room temperature for 72 hours. The reaction is diluted withDCM (50 ml) and washed with 0.5 M HCl (20 ml), 1 M NaOH (20 ml) and 0.5M HCl (20 ml). The organic layer is dried over MgSO₄ and the solvent isremoved in vacuo. Purification by chromatography (SiO₂, DCM/MeOH)affords 1-[2-(2-Methoxy-ethoxymethoxy)-ethyl]-1H-indole-4-carboxylicacid methyl ester; [M+H]⁺ 308

Step 4

To a solution of1-[2-(2-Methoxy-ethoxymethoxy)-ethyl]-1H-indole-4-carboxylic acid methylester (69 mg, 0.225 mmol) in MeOH (2 ml) is added 2 M NaOH (1 ml) andthe reaction is stirred at room temperature for 19.5 hours, then for 2hours at 50° C. The reaction is allowed to cool to room temperature andthe solvent removed in vacuo. To the residue is added sat. NH₄Cl (10ml), and the product is extracted with EtOAc (5×25 ml), washed withbrine (10 ml), dried over Na₂SO₄, and the solvent is removed in vacuo,to give the title compound1-[2-(2-Methoxy-ethoxymethoxy)-ethyl]-1H-indole-4-carboxylic acid;[M+H]⁺ 294

Intermediate AX 1-Diethylcarbamoylmethyl-1H-indole-4-carboxylic acidStep 1

Methyl indole-4-carboxylate (50 mg, 2.85 mmol) and2-chloro-N,N-diethylacetamide (854 mg, 5.71 mmol) are dissolved in DMF(10 ml) and to the solution is added potassium carbonate (986 mg, 7.14mmol). The reaction is heated using microwave radiation at 100° C. for 2hours, then diluted with DCM (60 ml) and washed with water (5×10 ml).Drying over MgSO₄, concentration in vacuo, and trituration with Et₂Oaffords 1-Diethylcarbamoylmethyl-1H-indole-4-carboxylic acid methylester; [M+H]⁺ 289.

Step 2

To a solution of Diethylcarbamoylmethyl-1H-indole-4-carboxylic acidmethyl ester (480 mg, 1.665 mmol) in MeOH (5 ml) is added 2 M NaOH (5ml). The reaction is heated at 50° C. for 20 hours and then allowed tocool to room temperature. The solvent is removed in vacuo and theresidue dissolved in water (10 ml). The pH of the solution is adjustedto 5 using 1 M HCl and the resulting solid is collected by filtration togive the title compound 1-Diethylcarbamoylmethyl-1H-indole-4-carboxylicacid; [M+H]⁺ 275

Intermediate AY4-[6-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2-ylmethoxy]-benzoicacid Step 1

To a solution of methyl 6-hydroxy-2-naphthoate (4.55 g, 22.5 mmol) inanhydrous acetone (60 ml) are added S-(−)-glycidol (2.0 g, 27.0 mmol)and K₂CO₃ (9.3 g, 67.3 mmol). The reaction mixture is heated to refluxfor 3 days. The reaction mixture is filtered through Celite™ (filtermaterial) and the filtrate is concentrated in vacuo to afford6-((S)-2,3-Dihydroxy-propoxy)-naphthalene-2-carboxylic acid methyl esteras a white solid; ¹H NMR (DMSO-d₆): 3.49 (2H, t, J=6.0 Hz), 3.85-3.88(1H, m), 3.89 (3H, s), 4.02 (1H, dd, J=9.9, 6.0 Hz), 4.16 (1H, dd,J=9.9, 4.0 Hz), 4.73 (1H, t, J=6.0 Hz), 5.04 (1H, d, J=5.2 Hz), 7.26(1H, dd, J=9.0, 2.0 Hz), 7.41 (1H, d, J=2.0 Hz), 7.88-7.94 (2H, m), 8.04(1H, d, J=9.0 Hz), 8.55 (1H, s).

Step 2

To 6-((S)-2,3-dihydroxy-propoxy)-naphthalene-2-carboxylic acid methylester (0.9 g, 3.26 mmol) in anhydrous DMF (10 ml) is added2,2-dimethoxypropane (2.0 ml, 16.3 mmol) and pyridiniump-toluenesulfonate (0.08 g, 0.32 mmol) and the reaction mixture isstirred at room temperature for 16 hours. The reaction mixture isconcentrated in vacuo and the residue is dissolved in EtOAc. The EtOAclayer is washed with 10% NaHCO₃, water, and brine, dried over anhydrousNa₂SO₄ and the solvent is evaporated in vacuo to obtain6-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalene-2-carboxylicacid methyl ester as solid; ¹H NMR (DMSO-d6): 1.32 (3H, s), 1.37 (3H,s), 3.78-3.82 (1H, m), 3.88 (3H, s), 4.11-4.20 (3H, m), 4.45-4.50 (1H,m), 7.26 (1H, dd, J=9.0, 2.0 Hz), 7.45 (1H, d, J=2.0 Hz), 7.88 (1H, d,J=9.0 Hz), 7.93 (1H, d, J=9.0 Hz), 8.04 (1H, d, J=9.0 Hz), 8.55 (1H, s).

Step 3

To a solution of6-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalene-2-carboxylicacid methyl ester (1.0 g, 3.16 mmol) in anhydrous THF (20 ml) at 0° C.is added LiAlH4 (1.9 ml of a 2M solution in THF, 3.8 mmol). The reactionmixture is stirred at room temperature overnight. The reaction mixtureis concentrated in vacuo and the residue is purified by columnchromatography (SiO2, DCM) to afford[6-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2-yl]-MeOH asa colourless viscous oil which solidified on standing; 1H NMR (d6-DMSO):1.32 (3H, s), 1.37 (3H, s), 3.78 (1H, dd, J=8.3, 6.0 Hz), 4.01-4.15 (3H,m), 4.45-4.48 (1H, m), 4.60 (2H, d, J=6.0 Hz), 5.24 (1H, t, J=6.0 Hz),7.14 (1H, dd, J=8.5, 2.5 Hz), 7.32 (1H, d, J=2.5 Hz), 7.41 (1H, dd,J=8.5, 1.5 Hz), 7.33-7.80 (3H, m).

Step 4

A mixture of methyl 4-hydroxybenzoate (0.5 g, 3.28 mmol),[6-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2-yl]-methanol(0.9 g, 3.12 mmol) and triphenylphosphine (0.83 g, 3.16 mmol) in DCM (20ml) is cooled to 0° C. Diethyl azodicarboxylate (0.5 ml, 3.17 mmol) isadded dropwise. The reaction mixture is stirred at room temperatureovernight. The reaction mixture is concentrated in vacuo and purified bycolumn chromatography (SiO₂, EtOAc/iso-hexane) to obtain white solid.The product obtained is once again purified by column chromatography(neutral alumina, EtOAc/petroleum ether) to obtain4-[6-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2-ylmethoxy]-benzoicacid methyl ester as white solid; ¹H NMR (d₆-DMSO): 1.32 (3H, s), 1.38(3H, s), 3.77-3.82 (4H, m), 4.08-4.16 (3H, m), 4.46-4.49 (1H, m), 5.30(2H, s), 7.15-7.21 (3H, m), 7.37 (1H, d, J=2.0 Hz), 7.53 (1H, dd,J=8.50, 1.5 Hz), 7.83 (2H, dd, J=9.0, 6.0 Hz), 7.92 (3H, m).

Step 5

To a solution of4-[6-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2-ylmethoxy]-benzoicacid methyl ester (0.46, 1.09 mmol) in THF/water (10 ml of a 1:1mixture) is added lithium hydroxide (0.15 g, 3.57 mmol). The reactionmixture is stirred at room temperature overnight, then at 70° C. for 24h. The reaction mixture is cooled to room temperature, neutralized with1.5 M HCl and the white solid obtained is collected by vacuumfiltration, washed with water and dried under vacuum to afford4-[6-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2-ylmethoxy]-benzoicacid. [M]⁻ 407.

Intermediate AZ4-{3-[4-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-propoxy}-benzoicacid

This compound is prepared analogously to Intermediate AY by replacing[6-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2-yl]-methanolin Step 4 with3-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-propan-1-ol;¹H NMR (DMSO-d6): 1.30 (3H, s), 1.35 (3H, s), 1.97-2.01 (2H, m), 2.68(2H, t, J=7.5 Hz), 3.72-3.75 (1H, m), 3.93-4.00 (4H, m), 4.06-4.10 (1H,m), 4.38 (1H, dd, J=6.0, 5.0), 6.87 (2H, d, J=9.0 Hz), 6.92 (2H, d,J=9.0 Hz), 7.14 (2H, d, J=, 9.0 Hz), 7.84 (2H, d, J=9.0 Hz).

Intermediate BA4-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4.5]decane-8-carbonyl}-piperidine-1-carboxylicacid tert-butyl ester

This compound is prepared analogously to Example 97 by replacing4-benzyloxyphenylacetic acid with 1-Boc-piperidine-4-carboxylic acid;[M+H]⁺ 536.

Intermediate BB 4-[(Naphthalene-1-sulfonylamino)-methyl]-benzoic acid

4 N NaOH solution (30 ml) is added to a suspension of4-(aminomethyl)benzoic acid (5.01 g, 31.82 mmol) in acetone (100 ml).Toluene (100 ml) is added and the reaction is heated at 40° C. to obtaindissolution. The solution is cooled to 0° C. and treated with1-naphthalene sulfonyl chloride (12 g, 51.35 mmol) in acetone (100 ml)and the resulting reaction mixture is stirred for 3 hours. The reactionis acidified using citric acid and concentrated in vacuo. The residue istaken up in EtOAc and washed with water. The aqueous layer is backextracted with EtOAc and the combined organic layers are washed withwater, brine, dried (Na₂SO₄) and the solvent removed in vacuo to yield alight brown solid. Trituration with Et₂O yields the title compound.

Intermediate BC 3-(Cyclohexyl-methyl-sulfamoyl)-4-methoxy-benzoic acidStep 1

A solution of methyl 3-(chlorosulfonyl)-4-methoxybenzoate (2.0 g, 7.56mmol) and diisopropylethylamine (1.94 ml, 11.34 mmol) in DCM (50 ml) istreated with N-methyl cyclohexylamine (0.70 ml, 9.07 mmol) at 0° C. Thesolution is stirred at room temperature for 3 hours and N-methylcyclohexylamine (0.70 ml, 9.07 mmol) is added. The solution ispartitioned between DCM (250 ml) and 0.5 N HCl (100 ml). The organiclayer is washed with 0.5 N HCl (2×100 ml), sat. aq. NaHCO₃ (2×100 ml)and water (100 ml), dried over MgSO₄, and the solvent removed in vacuoto yield a yellow oil. Crystallisation (iPr₂O/EtOAc) yields3-(Cyclohexyl-methyl-sulfamoyl)-4-methoxy-benzoic acid methyl ester asyellow crystals; [M+H] 342.

Step 2

A solution of 3-(Cyclohexyl-methyl-sulfamoyl)-4-methoxy-benzoic acidmethyl ester (1.50 g, 4.39 mmol) in 1,4 dioxane (40 ml) is treated with2 N NaOH (10 ml) and the resulting solution is stirred at roomtemperature for 21 hours. The solvent is removed in vacuo and ice cold 2N HCl (25 ml) is added and the white solid which forms is extracted intoDCM (150 ml). The organic layer is washed with water, dried (MgSO₄) andthe solvent removed in vacuo to yield the title compound as a whitesolid; [M−1]⁻ 326.

Intermediate BD3-Chloro-5-methoxy-4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-benzoic acidStep 1

A mixture of 5-chlorovanillin acid (5.0 g, 24.6 mmol) and conc. HCl (5ml) in MeOH (100 ml) is heated at reflux for 48 hours. The solvent isremoved in vacuo and water is added to the residue to yield a whiteprecipitate, which is collected by filtration, washed with water, andthen dissolved in Et₂O. The solution is dried (Na₂SO₄) and the solventremoved in vacuo to yield 3-Chloro-4-hydroxy-5-methoxy-benzoic acidmethyl ester as a white solid.

Step 2

Triphenylphosphine (6.4 g, 24.4 mmol) and DIAD (4.8 ml, 202.2 mmol) areadded to a solution of 3-Chloro-4-hydroxy-5-methoxy-benzoic acid methylester (2.5 g, 11.5 mmol) in THF (40 ml) at 0° C. and the resultingsolution is stirred for 2 hours at 0° C. and 16 hours at roomtemperature. The solvent is removed in vacuo, and water is added to theresidue. The product is extracted in EtOAc, dried (Na₂SO₄) and thesolvent removed in vacuo to afford a yellow oil. Flash chromatography(SiO₂, EtOAc/MeOH) yields3-Chloro-5-methoxy-4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-benzoic acidmethyl ester as an orange solid.

Step 3

A solution of3-Chloro-5-methoxy-4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-benzoic acidmethyl ester (3.7 g, 10.7 mmol) in 2 N NaOH (20 ml) and THF (40 ml) isheated at reflux for 1 hour. The reaction mixture is washed with Et₂O.The aqueous phase is concentrated in vacuo, and water (50 ml) is added.The pH is adjusted to 3-4 using 2 N HCl. To this solution is added DOWEX50WX4 (previously washed with MeOH, 2 N HCl and water), and theresulting mixture is stirred at room temperature for 1 hour. The resinis filtered, washed with water, and the product is released from theresin by washing with MeOH/NH₄OH. The solution is concentrated in vacuo,diluted with DCM and MeOH, dried (Na₂SO₄) and the solvent removed invacuo to yield the title compound as a light cream solid.

Intermediate BE

Step 1

To a stirred solution of diethyl amine (500 ml, 4.8 mol) in Et₂O (1200ml) is added sulfuryl chloride (177.3 ml, 2.19 mol) over 80 minutes at−15° C. The reaction is stirred at room temperature for 2.5 hours. Et₂O(1000 ml) is added and the white solid present is removed by filtration,and washed with Et₂O (2000 ml). The combined filtrates are concentratedunder reduced pressure to yield as a colourless oil.

Step 2

To a stirred solution of trans-4-(aminomethyl)-cyclohexane carboxylicacid (10 g, 63.6 mmol) in 1 N NaOH (153 ml) is added (10.91 g, 63.6mmol) and the resulting mixture is stirred at room temperature for 15hours. The reaction is cooled to 10° C. and conc. HCl solution (15 ml)is added and the mixture stirred for 10 minutes at this temperature.White crystals form which are isolated by filtration and washed withEt₂O (40 ml) to yield the title compound.

Intermediate BF 3-(3-Phenyl-isoxazol-5-yl)-propionic acid

This compound is prepared as described by G. S. d'Alcontres; C Caristi;A Ferlazzo; M Gattuso, J. Chem. Soc. Perkin 1, (1976) 16, 1694.

Intermediate BG 3-(4-Chloro-phenoxymethyl)-benzylamine

This compound is prepared as described in US 2008200523.

Intermediate BH 2-{4-[2-(4-Fluoro-phenyl)-ethoxy]-phenyl}-ethylamineStep 1

A suspension of 4-Hydroxybenzyl cyanide (7.9 g, 59.57 mmol),1-(2-Bromoethyl)-4-fluoro-benzene (17.4 g, 71.48 mmol), potassiumcarbonate (19.8 g, 143 mmol) and sodium iodide (2.68 g, 17.87 mmol) inacetonitrile (120 ml) is heated at reflux for 44 hours. The reactionmixture is cooled and filtered and the solvent removed in vacuo to yielda dark brown oil. Flash chromatography (SiO₂, EtOAc/iso-hexane) yields{4-[2-(4-Fluoro-phenyl)-ethoxy]-phenyl}-acetonitrile as a yellow oil.

Step 2

2 N NaOH solution (45.2 ml, 90.3 mmol) is added to a solution of{4-[2-(4-Fluoro-phenyl)-ethoxy]-phenyl}-acetonitrile (3.29 g, 12.9 mmol)in EtOH (45.2 mol) followed by Al—Ni Alloy (2.5 g) and the resultingreaction mixture is stirred for 1 hour at room temperature. The reactionmixture is filtered and the EtOH removed in vacuo. The product isextracted into DCM (2×80 ml), dried (MgSO₄) and the solvent removed invacuo to yield the title compound as a yellow oil.

Intermediate BI 2-(4,6-Dimethyl-1H-indol-3-yl)-ethylamine

This compound is prepared as described in EP 620222

Intermediate BJ 2-[4-(4-Phenyl-butoxy)-phenyl]-ethylamine

This compound is prepared as described in WOP 2004016601

Intermediate BK 4-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylchloride

This compound is prepared as described in WO 2005026134

Intermediate BL 2-Phenyl-3H-benzoimidazole-5-sulfonyl chloride

This compound is prepared as described in EP 1205475

Intermediate BM 4-Aminomethyl-1-(1-phenyl-ethyl)-piperidin-4-ylamineStep 1

1-(1-Phenyl-ethyl)-piperidin-4-one is prepared according to theprocedure described on page 525 of J. Org. Chem. 1991, 56(2), 513-528.

To a mixture of 1-(1-phenyl-ethyl)-piperidin-4-one (10.9 g, 53.6 mmol),ammonium chloride (4.3 g, 80.4 mmol) and 30% aqueous ammonia solution(30 ml) in water (30 ml) at room temperature is added sodium cyanide(4.0 g, 81.6 mmol) portion wise. The reaction mixture is stirred at roomtemperature for 18 hours, then diluted with water and extracted withDCM. The organic phase is washed with brine, dried over Na₂SO₄, filteredand concentrated in vacuo to obtain4-Amino-1-(1-phenyl-ethyl)-piperidine-4-carbonitrile as a brown oil;[M+H]⁺ 230.

Step 2

4-Aminomethyl-1-(1-phenyl-ethyl)-piperidin-4-ylamine is preparedanalogously to Intermediate U by replacing4-amino-4-cyano-piperidine-1-carboxylic acid tert-butyl ester in Step 1with 4-amino-1-(1-phenyl-ethyl)-piperidine-4-carbonitrile; [M+H]⁺ 234.

Intermediate BN 4-Aminomethyl-1-(4-methoxy-benzyl)-piperidin-4-ylamine

This compound is prepared analogously to Intermediate BM by replacing1-(1-phenyl-ethyl)-piperidin-4-one with1-(4-methoxybenzyl)piperidin-4-one in step 2; ¹H NMR (DMSO-d6):1.46-1.64 (4H, m), 2.38-2.55 (4H, m), 2.67 (2H, s), 3.26 (2H, s), 4.08(3H, s), 6.87 (2H, d, J=8.2 Hz), 7.18 (2H, d, J=8.2 Hz).

Intermediate BO 4-Aminomethyl-1-pyridin-4-ylmethyl-piperidin-4-ylamineStep 1

To a solution of4-aminomethyl-4-(2,2,2-trifluoro-acetylamino)-piperidine-1-carboxylicacid tert-butyl ester (Intermediate U, Step 2) (5.0 g, 15.4 mmol) in DCM(50 ml) at 0° C. is added pyridine (10 ml) followed by trifluoroaceticanhydride (3.5 ml, 25.3 mmol) and the reaction mixture is stirred atroom temperature for 16 hours. The reaction mixture is diluted with DCM,washed with brine, dried over Na₂SO₄ and concentrated in vacuo. Theresidue obtained is dissolved in diethyl ether and re-precipitated byadding petroleum ether. The solvent mixture is decanted and the soliddried under vacuum to afford4-(2,2,2-Trifluoro-acetylamino)-4-[(2,2,2-trifluoro-acetylamino)-methyl]-piperidine-1-carboxylicacid tert-butyl ester; [M+H]⁺ 420.

Step 2

To a solution of4-(2,2,2-trifluoro-acetylamino)-4-[(2,2,2-trifluoro-acetylamino)-methyl]-piperidine-1-carboxylicacid tert-butyl ester (5.25 g, 12.5 mmol)

in dioxane (50 ml) is added 4 M HCl in dioxane (15 ml) and the reactionmixture is stirred at room temperature for 3 hours. The reaction mixtureis concentrated in vacuo and the off-white solid obtained dissolved inthe minimum amount of MeOH and re-precipitated by adding diethyl ether.The supernatant solvent mixture is decanted and the product is washedagain with diethyl ether and dried under vacuum to afford2,2,2-Trifluoro-N-{4-[(2,2,2-trifluoro-acetylamino)-methyl]-piperidin-4-yl}-acetamidehydrochloride; [M+H]⁺ 322.

Step 3

To a suspension of NaH (170 mg of a 60% dispersion in mineral oil, 4.25mmol) in anhydrous DMF (20 ml) is added2,2,2-trifluoro-N-{4-[(2,2,2-trifluoro-acetylamino)-methyl]-piperidin-4-yl}-acetamidehydrochloride) (500 mg, 1.4 mmol) followed by 4-bromomethylpyridinehydrobromide (350 mg, 1.4 mmol). The reaction mixture is stirred at roomtemperature for 3 hours. The reaction mixture is quenched with sat.NH₄Cl solution and is concentrated in vacuo. The residue is purified bycolumn chromatography (basic alumina, MeOH/DCM) to obtain2,2,2-Trifluoro-N-[1-pyridin-4-ylmethyl-4-(2,2,2-trifluoro-acetylamino)-piperidin-4-ylmethyl]-acetamideas off-white solid; [M+H]⁺ 413

Step 4

To a solution of2,2,2-trifluoro-N-[1-pyridin-4-ylmethyl-4-(2,2,2-trifluoro-acetylamino)-piperidin-4-ylmethyl]-acetamide(200 mg, 0.49 mmol) in MeOH (10 ml) is added 30% aqueous ammoniasolution (10 ml) and the reaction mixture is stirred at 60° C. for 3 h.The reaction mixture is concentrated in vacuo to obtain4-Aminomethyl-1-pyridin-4-ylmethyl-piperidin-4-ylamine as a colourlessgummy oil that is used without further purification; ¹H NMR (DMSO-d6):1.63-1.77 (4H, m), 2.45-2.54 (4H, m), 2.49 (2H, s), 3.57 (3H, s), 7.30(2H, d, J=5.5 Hz), 8.68 (2H, d, J=5.5 Hz).

Intermediate BP 4-Aminomethyl-1-(3-phenyl-propyl)-piperidin-4-ylamine

This compound is prepared analogously to Intermediate BO by replacing-bromomethylpyridine hydrobromide (Step 3) with 1-bromo-3-phenylpropane;[M+H]⁺ 248

Intermediate BQ 4-Aminomethyl-1-cyclohexylmethyl-piperidin-4-ylamine

This compound is prepared analogously to Intermediate BO by replacing-bromomethylpyridine hydrobromide (Step 3) with cyclohexylmethylbromide.This intermediate is used crude in the preparation of Example 250.

Intermediate BR3-Amino-3-aminomethyl-8-aza-bicyclo[3.2.1]octane-8-carboxylic acidtert-butyl ester

This compound is prepared analogously to Intermediate BM by replacing1-(1-phenyl-ethyl)-piperidin-4-one (Step 1) with N-Boc-nortropinone; ¹HNMR (DMSO-d6): 1.40 (9H, s), 1.63-1.85 (8H, m), 2.79 (2H, s), 4.06 (2H,s).

1-21. (canceled)
 22. A compound according to formula 2

wherein [LINKER] is selected from C₁-C₆ alkylene, C₂-C₆ alkenylene,C₂-C₆ alkynylene, a 5- to 10-membered carbocyclic group, aryl, and a 5-to 10-membered heterocyclic group containing one or more heteroatomsselected from N, O and S, the ring systems being optionally substitutedby one or more Z¹ groups; and Z¹ is independently selected from OH,aryl, O-aryl, benzyl, O-benzyl, C₁-C₆ alkyl optionally substituted byone or more OH groups, C₁-C₆ alkyl optionally substituted by one or morehalogen atoms, C₁-C₆ alkoxy optionally substituted by one or more OHgroups or C₁-C₄ alkoxy, NR¹⁹(SO₂)R²¹, (SO₂)NR¹⁹R²⁰, (SO₂)R²⁰,NR¹⁹C(O)R²⁰, C(O)NR¹⁹R²⁰, NR¹⁹C(O)NR²⁰R¹⁸, NR¹⁹C(O)OR²⁰, NR¹⁹R²¹,C(O)OR¹⁹, C(O)R¹⁹, SR¹⁹, OR¹⁹, oxo, CN, NO₂, and halogen; R¹⁸ and R²⁰are each independently selected from H and C₁-C₆ alkyl; R¹⁹ and R²¹ areeach independently selected from H; C₁-C₈ alkyl; C₃-C₈ cycloalkyl; C₁-C₄alkoxy-C₁-C₄ alkyl; (C₀-C₄ alkyl)-aryl optionally substituted by one ormore groups selected from C₁-C₆ alkyl, C₁-C₆ alkoxy and halogen; (C₀-C₄alkyl)-3- to 14-membered heterocyclic group, the heterocyclic groupincluding one or more heteroatoms selected from N, O and S, optionallysubstituted by one or more groups selected from halogen, oxo, C₁-C₆alkyl and C(O)C₁-C₆ alkyl; (C₀-C₄ alkyl)-O-aryl optionally substitutedby one or more groups selected from C₁-C₆ alkyl, C₁-C₆ alkoxy andhalogen; and (C₀-C₄ alkyl)-O-3- to 14-membered heterocyclic group, theheterocyclic group including one or more heteroatoms selected from N, Oand S, optionally substituted by one or more groups selected fromhalogen, C₁-C₆ alkyl and C(O)C₁-C₆ alkyl; wherein the alkyl groups areoptionally substituted by one or more halogen atoms, C₁-C₄ alkoxy,C(O)NH₂, C(O)NHC₁-C₆ alkyl or C(O)N(C₁-C₆ alkyl)₂; or R¹⁹ and R²⁰together with the nitrogen atom to which they attached form a 5- to10-membered heterocyclic group, the heterocyclic group including one ormore further heteroatoms selected from N, O and S, the heterocyclicgroup being optionally substituted by one or more substituents selectedfrom OH; halogen; aryl; 5- to 10-membered heterocyclic group includingone or more heteroatoms selected from N, O and S; S(O)₂-aryl;S(O)₂—C₁-C₆ alkyl; C₁-C₆ alkyl optionally substituted by one or morehalogen atoms; C₁-C₆ alkoxy optionally substituted by one or more OHgroups or C₁-C₄ alkoxy; and C(O)OC₁-C₆ alkyl, wherein the aryl andheterocyclic substituent groups are themselves optionally substituted byC₁-C₆ alkyl, C₁-C₆ haloalkyl or C₁-C₆ alkoxy; or a pharmaceuticallyacceptable salt thereof.
 23. The compound according to claim 22 whereinR¹⁸, R¹⁹ and R²⁰ are each independently selected from H and C₁-C₆ alkyl;and R²¹ is selected from C₁-C₈ alkyl, aryl and a 3- to 14-memberedheterocyclic group; or a pharmaceutically acceptable salt thereof. 24.The compound according to claim 22 selected from the group consistingof:

or a pharmaceutically acceptable salt thereof.
 25. A pharmaceuticalcomposition comprising a compound according claim 22, together with oneor more pharmaceutical excipients.
 26. A method for the treatment of adisease mediated by the blockade of an epithelial sodium channelcomprising administration of a compound according to claim 22 or apharmaceutically acceptable salt thereof.
 27. The method according toclaim 26 wherein the disease is an inflammatory or allergic condition orobstructive airways disease.
 28. The method according to claim 27wherein the inflammatory or allergic condition is selected from cysticfibrosis, primary ciliary dyskinesia, chronic bronchitis, chronicobstructive pulmonary disease, asthma, respiratory tract infections,lung carcinoma, xerostomia, and keratoconjunctivitis sire.
 29. Apharmaceutical combination of a compound according to claim 22 with ananti-inflammatory, bronchodilatory, antihistamine or anti-tussive drugsubstance.